

1. 고창권, Matsuda M, 예상규, 민본홍, 이광호, Jong Gu Park. 배양 Monocytes에서 세포농도에 따른 Fc $\gamma$  Receptors의 선택적 표현. 대한면역학회지. 1998;20(3):277-83.  
배제사유 : 동물실험 또는 전임상시험연구
2. 김광수, 박경순. XRP44X Enhances the Cytotoxic Activity of Natural Killer Cells by Activating the c-JUN N-Terminal Kinase Signaling Pathway. 발생과생식. 2020;24(1):53-61.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
3. 김광중, 박성희, 이유신. 원저 : 인체 흑색종 세포주 A - 137 에 대한 감마 인터페론의 세포 살해능, 증식 억제능, HLA항원 표현에 관한 연구. 대한피부과학회지. 1990;28(2):147-58.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
4. 김광중, 박성희, 이유신. 인체 흑색종 세포주 A - 137 에 대한 감마 인터페론의 세포 살해능, 증식 억제능, HLA항원 표현에 관한 연구. 大韓皮膚科學會誌. 1990;28(2):147-58.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
5. 김대원, 이의섭, 최윤표, 강승우, 정재준, 서보승. 게르마늄 수경재배 미나리 추출물 처리에 의한 In Vitro, In Vivo에서의 사이토카인 감소 및 면역 활성화에 대한 효과. 한국식품영양과학회지. 2020;49(1):101-10.  
배제사유 : 동물실험 또는 전임상시험연구
6. 김영진, 노홍규, 박은신, 김호, 유순희, 박수정, et al. 갑상선 세포에서 전사보조활성인자인 CBP와 CIITA는 인터페론-감마 활성 부위에 대하여 서로 다른 조절 작용을 나타낸다. Endocrinology and Metabolism(구 대한내분비학회지). 1999;14(3):493-504.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
7. 김용석, 김홍식. 진행 내장암환자에서 5-Fluorouracil 및 재조합 감마 인터페론(인터맥스(r)) 병용요법의 제2상 임상시험. 계명의대논문집. 1994;13(2):131-45.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
8. 김재화, 유익동. 젿버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon-gamma 생성에 미치는 영향. 大韓化粧品學會誌 = Journal of the society of cosmetic scientists of Korea. 2010;36(2):151-6.  
배제사유 : 동물실험 또는 전임상시험연구
9. 김재화, 유익동. 젿버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon- $\gamma$ 생성에 미치는 영향. 대한화장품학회지(J. Soc. Cosmet. Scientists Korea). 2010;36(2):151-6.  
배제사유 : 동물실험 또는 전임상시험연구
10. 김창욱, 신주엽, 윤승규, 허원희, 남순우, 장우임, et al. 구연 : 라미부딘을 사용하고 있는 만성 B형 간

염에서 숙주의 HBV 특이 T세포 면역반응을 반영하는 ELISPOT Assay의 유용성. *Clinical and Molecular Hepatology*(대한간학회지). 2003;9(3s):50.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

11. 김홍식, 송홍석. 진행 대장암환자에서 5-Fluorouracil 및 재조합 감마 인터페론(인터맥스) 병용요법의 제2상 임상시험. *啓明醫大論文集*. 1994;13(2):131-45.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

12. 맹선희, 이지수, 박창환, 조영주. 알레르기성 기관지천식환자의 말초 혈액 T세포, NK세포 TNK세포의 Der p 2 항원의 자극에 의한 interferon gamma의 생산. *천식및알레르기*. 2003;23(2):341-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

13. 박설희, 문영철, 성주명, 허희진, 허정원. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. *Laboratory Medicine Online*. 2018;8(2):41-51.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

14. 박재경, 심우영, 허충림, 이춘봉. Retinoids가각질형성세포에서 감마인터페론에 의한 HLA - DR , ICAM - 1 발현에 미치는 영향. *大韓皮膚科學會誌*. 1995;33(1):33-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

15. 변진석, 정원일. Involvement of Hepatic Innate Immunity in Alcoholic Liver Disease. *Immune Network*. 2010;10(6):181-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

16. 성혜란, 김지연, 박민경, 김일희, 이동욱, 한상배, et al. 결장암에 대한 활성 자연살해세포의 항암효능. *약학회지*. 2010;54(3):192-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

17. 안규대, 김경희, 임현호, 김민찬, 이상엽. 건강인에서 NK세포 자극 후와 T세포 자극 후 분비된 Interferon-gamma 농도의 비교. *Laboratory Medicine Online*. 2018;8(1):15-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

18. 유수연, 박원봉. 섬오가피 추출물의 항암관련 사이토카인 분비활성. *약학회지*. 2010;54(4):232-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

19. 윤도희, 이은경, 김정원. The effect of histamine on the production of interferongamma and interleukin-12 in peripheral blood mononuclear cells from patients with atopic dermatitis. *천식및알레르기*. 1999;19(3):459-67.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

20. 이춘봉, 심우영, 박재경, 허충림. 원저 : Retinoids가각질형성세포에서 감마인터페론에 의한 HLA - DR , ICAM - 1 발현에 미치는 영향. *대한피부과학회지*. 1995;33(1):33-43.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

21. 이해리, 전준호, 이기은. The Poly- $\gamma$ -D-Glutamic Acid Capsule of Bacillus licheniformis, a Surrogate of Bacillus anthracis Capsule Induces Interferon-Gamma Production in NK Cells through Interactions with Macrophages. *Journal of Microbiology and Biotechnology*. 2017;27(5):1032-7.

배제사유 : 동물실험 또는 전임상시험연구

22. 임영애, 김순선, 조성원, 정재연. 만성B형간염 환자에서의 NK Vue Gold Kit 시약의 유효성 평가. 임

- 상검사와정도관리. 2016;38(3):151-8.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
23. 전준호, 이해리, 이기은. 탄저균 poly- $\gamma$ -d-glutamic acid 캡슐에 의한 자연살해세포의 인터페론 감마 생산 기전. 주간 건강과 질병. 2018;11(5):128-32.  
배제사유 : 동물실험 또는 전임상시험연구
24. 정다운, 변정수, 구나연, 정문희, 김은희, 김형석, et al. 개 유선종양세포에 대한 자연살해세포 독성. 대한수의학회지. 2020;60(1):25-32.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
25. 정원일. 실험적 항섬유화 치료법의 임상적용. Clinical and Molecular Hepatology(대한간학회지). 2011;17(1s):48-54.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
26. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 임상연구 : 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):378-86.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
27. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):17.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
28. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):378-86.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
29. 정인배, 한혜경, 김나옥, 하정식, 박현숙, 박주영. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. 대한산부인과학회지. 2003;46(2):378-86.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
30. 정인배. 태반 영양모세포주의 class I 인체백혈구 항원 발현에 미치는 감마 인터페론의 역할. Obstetrics & Gynecology Science. 2003;46(2):17-.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
31. 천은미, 김미선, 장윤희, 박성숙, 조영주. 중증 기관지천식 환자의 말초단핵구에서 자연살해세포의 비율과 자연살해세포에서 interferon gamma의 생산. 천식및알레르기. 2000;20(3):535-44.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
32. 최영희, 이진희, 윤종현. S-689 콜라겐 유도 관절염 마우스 모델에서 편백나무추출오일의 치료 효과. 대한내과학회 추계학술대회. 2016;2016(1):394.  
배제사유 : 동물실험 또는 전임상시험연구
33. 최영희, 이진희, 윤종현. S-689 콜라겐 유도 관절염 마우스 모델에서 편백나무추출오일의 치료 효과. 대한내과학회 추계학술발표논문집. 2016;2016(1):394.  
배제사유 : 동물실험 또는 전임상시험연구
34. Abdel-Wahab M E-SF, Agha S, Ragab E, Fathi O, Sultan A, Elghawalby N, et al. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2). Hepato-Gastroenterology. 1999;46(SUPPL. 1):1293-6.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

35. Abe K UT, Haruki K, Takano Y, Onda S, Sakamoto T, Gocho T, et al. Effects of omega-3 fatty acid supplementation in patients with bile duct or pancreatic cancer undergoing chemotherapy. *Anticancer Research*. 2018;38(4):2369-75.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
36. Abe Y MM, Miyazaki T, Horiuchi A, Kimura S. The endogenous induction of tumor necrosis factor serum (TNS) for the adjuvant postoperative immunotherapy of cancer--changes in immunological markers of the blood. *Japanese Journal of Surgery*. 1990;20(1):19-26.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
37. Abken H HA, Reinhard G, Marten A, Schlimper C, Glasmacher A, Bieber T, et al. Cellular immunotherapy after autologous hematopoietic stem cell transplantation: Experimental strategies and clinical experiences. *Leukemia and Lymphoma*. 2003;44(4):583-92.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
38. Abraham M MI, Harel Y, Klein S, Pereg Y, Oberkovitz G, Wald H, et al. Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents. *Journal of Clinical Oncology*. Conference. 2017;35(15 Supplement 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
39. Acoba J D, Rock A, Wong H, C. Phase Ib/II study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. *Journal of Clinical Oncology*. Conference. 2017;35(4 Supplement 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
40. Adcock D M, Fink L, M, Marlar R, A, Cavallo F, Zangari M. The hemostatic system and malignancy. *Clinical Lymphoma and Myeloma*. 2008;8(4):230-6.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
41. Ademmer K EM, Muller-Ostermeyer F, Friess H, Buchler M, W, Schubert W, Malfertheiner P. Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+CD18+ cells and CD8+CD103+ cells by multi-epitope imaging. *Clinical & Experimental Immunology*. 1998;112(1):21-6.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
42. Adotevi O GY, Galaine J, Lakkis Z, Idirene I, Certoux J, M, Jary M, et al. In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial. *OncoImmunology*. 2018;7 (5) (e1424673).  
배제사유 : NK 세포 활성도를 다루지 않는 연구
43. Adotevi O KS, Lakkis Z, Fein F, Jary M, Dobi E, Idirene I, et al. NK-EGFR01: Feasibility of allogenic natural killer cell (NK) adoptive transfer by intra-arterial injection in combination to cetuximab - A phase i clinical trial in EGFR+ gastrointestinal adenocarcinoma. *European Journal of Cancer*. 2013;2):S556.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

44. Agaugue S HA, De Sousa P, De Waele P, Gilham D. The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer. *Annals of Oncology*. 2018;29 (Supplement 8):viii420.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
45. Ahmed J YM, Li Y, Chu Y, Shi H, Chard L, Alusi G, et al. A novel tumour selective oncolytic vaccinia virus lacking the N1L gene enhances the anti-tumour immune response when used as an anticancer therapeutic. *Molecular Therapy*. 2014;1):S248-S9.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
46. Ahmed J YM, Li Y, Chu Y, Zhang Z, Gao D, Chard L, S, et al. A promising neo-adjuvant immuno-therapeutic agent for preventing cancer recurrence and metastasis after surgery. *Molecular Therapy*. 2015;1):S166.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
47. Ajaikumar B S, Swamy K, Radheshyam N, Patil S, Shashidhara H, P, Vishweshwara M, S, A, et al. An investigator initiated, open label, randomized, controlled, multicentric study, to assess the safety and efficacy of nimotuzumab (BIOMAb-EGFR) concurrent with cisplatin and radiotherapy (RT) in histologically documented squamous cell carcinoma of the cervix. *Annals of oncology*. 2017;28:v334?v5.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
48. Alanio C BB, Gies J, R, Henrickson S, Weng N, P, Ritz-Romeo J, A, O'Hara M, et al. Skewed CD4 and CD8 T-cell differentiation in pancreatic cancer patients. *Cancer Immunology Research*. Conference: 4th CRI CIMT EATI AACR International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2019;7(2).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
49. Albeituni S H, Ding C, Yan J. Hampering immune suppressors: Therapeutic targeting of myeloid-derived suppressor cells in cancer. *Cancer Journal (United States)*. 2013;19(6):490-501.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
50. Aldrich J F, Lowe D, B, Shearer M, H, Winn R, E, Jumper C, A, Kennedy R, C. Vaccines and immunotherapeutics for the treatment of malignant disease. *Clinical and Developmental Immunology*. 2010;2010 (697158).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
51. Algarra I GJ, J, Cabrera T, Collado A, Garrido F. The biological consequences of altered MHC class I expression in tumours. *Journal of Biological Regulators and Homeostatic Agents*. 1999;13(2):90-6.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
52. Alizadeh D TM, Hanke N, T, Larmonier C, B, Janikashvili N, Bonnotte B, Katsanis E, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. *Cancer Research*. 2014;74(1):104-18.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

53. Aloysius M M, Robins R, A, Eremin J, M, Eremin O. Vaccination therapy in malignant disease. *Surgeon*. 2006;4(5):309-20.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
54. Amedei A NE, Prisco D. Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. *Human Vaccines and Immunotherapeutics*. 2014;10(11):3354-68.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
55. Ames E CR, J, Grossenbacher S, K, Mac S, Chen M, Smith R, C, Hagino T, et al. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. *Journal of Immunology*. 2015;195(8):4010-9.  
배제사유 : 동물실험 또는 전임상시험연구
56. An GD, Kim KH, Lim HH, Kim MC, Lee SY. Comparison of Interferon-gamma Secretion by Stimulated NK Cells and T cells from Healthy Subjects. *Laboratory Medicine Online*. 2018;8(1):15.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
57. An Y LF, Chen Y, Yang Q. Crosstalk between cancer-associated fibroblasts and immune cells in cancer. *Journal of Cellular and Molecular Medicine*. 2020;24(1):13-24.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
58. Angelova A RJ. Immune system stimulation by oncolytic rodent protoparvoviruses. *Viruses*. 2019;11 (5) (415).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
59. Anonymous. 51th Annual Meeting of the European Pancreatic Club 2019. *Pancreatology*. 2019;19 (Supplement 1):S1-S180.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
60. Anonymous. AACR Special Conference: The Function of Tumor Microenvironment in Cancer Progression. *Cancer Research. Conference: AACR Special Conference on The Function of Tumor Microenvironment in Cancer Progression*. 2016;76(15 Supplement).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
61. Anonymous. Abstract Book of ESMO Asia Congress 2016. *Annals of Oncology. Conference: ESMO Asia Congress*. 2016;27(Supplement 9).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
62. Anonymous. Abstracts from 83rd Annual Meeting of the American Thyroid Association. *Thyroid. Conference: 83rd Annual Meeting of the American Thyroid Association. San Juan Puerto Rico. Conference Publication:.* 2013;23(SUPPL. 1).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
63. Anonymous. CD137 Activation augments the efficacy of EGFR-Targeted therapy. *Cancer Discovery*. 2014;4(7):758.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
64. Anonymous. Discussion. *Surgery (United States)*. 2019;166(4):507-8.

- 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
65. Anonymous. Research Highlights. *Molecular Therapy*. 2020;28(4):991-4.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
66. Aparicio-Pages M N, Verspaget H, W, Pena A, S, Jansen J, B, Lamers C, B. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract: relation with circulating gastrointestinal hormones. *Neuropeptides*. 1991;20(1):1-7.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
67. Aparicio-Pages M N, Verspaget H, W, Pena A, S, Lamers C, B. Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract. *Journal of Clinical & Laboratory Immunology*. 1991;35(1):27-32.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
68. Arafar A. Cytokine induced killer cell immunotherapy in cancer treatment: from bench to bedside. *Biomedical Research and Therapy*. 2014;1 (2) (12).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
69. Aranda F VE, Eggermont A, Galon J, Fridman W, H, Zitvogel L, Kroemer G, et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. *OncImmunity*. 2014;3 (2) (e27297).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
70. Argiles J M, Toledo M, Lopez-Soriano F, J, Busquets S. Pro-inflammatory cytokines and their actions on the metabolic disturbances associated with cancer: Implications in cachexia. *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry*. 2011;10(4):275-80.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
71. Asano H KM, Yusa T, Kawakami K, Matsuno S. [Effect of LAK cells and BRM on the growth of pancreatic cancer cells injected into nude mice]. *Nippon Geka Gakkai Zasshi. Journal of Japan Surgical Society*. 1994;95(9):678-88.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
72. Ash A ME, Courtney N, Stiff A, Atwal L, Carson E, W. Using a novel interleukin-15 construct (ALT-803) to enhance natural killer cell activity against cetuximab-treated head and neck cancer cells. *Annals of Surgical Oncology*. 2017;24 (1 Supplement 1):S150-S1.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
73. Ashour A E, Turnquist H, R, Burns N, Wang X, Lin X, Tremayne J, et al. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. *Cancer Biotherapy & Radiopharmaceuticals*. 2007;22(2):235-8.  
배제사유 : 동물실험 또는 전임상시험연구
74. Axelrod R S, Havas H, F, Murasko D, M, Bushnell B, Guan C, F. Effect of the mixed bacterial vaccine on the immune response of patients with non-small cell lung cancer and refractory malignancies. *Cancer*. 1988;61(11):2219-30.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

75. Baciu C GR, He H, Ahmed M, Denroche R, E, Timms L, Jang G, H, et al. Prognostic biomarkers for pancreatic cancer. *Cancer Research*. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR. 2016;76(14 Supplement).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
76. Bae J HT, Tai Y, T, Munshi N, C, Anderson K, C. Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1). *Journal of Clinical Oncology*. Conference. 2019;37(Supplement 15).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
77. Bai X YM, Jiao Y, Chu Q, Wu K. Blocking tgf-beta signaling to enhance the efficacy of immune checkpoint inhibitor. *OncoTargets and Therapy*. 2019;12:9527-38.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
78. Baine M J, Chakraborty S, Smith L, M, Mallya K, Sasson A, R, Brand R, E, et al. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. *PLoS ONE [Electronic Resource]*. 2011;6(2):e17014.  
배제사유 : 동물실험 또는 전임상시험연구
79. Bang S KH, S, Choo Y, S, Park S, W, Chung J, B, Song S, Y. Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer. *Pancreas*. 2006;32(1):29-36.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
80. Baskar S DV, D, Terunuma H, Manjunath S, R, Senthilkumar R, Sivaraman G, Pandian A, et al. Prolonged survival of a patient with inoperable, locally advanced adenocarcinoma of pancreas after autologous immune enhancement therapy with chemotherapy. *Indian Journal of Cancer*. 2015;52(3):395-6.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
81. Batchu R B, Gruzdyn O, V, Tavva P, S, Kolli B, K, Dachevall R, Weaver D, W, et al. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. *Surgery*. 2019;166(4):503-8.  
배제사유 : 동물실험 또는 전임상시험연구
82. Batista I A, Melo S, A. Exosomes and the future of immunotherapy in pancreatic cancer. *International Journal of Molecular Sciences*. 2019;20 (3) (567).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
83. Bazhin A KS, Werner J. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. *European Surgical Research*. 2015;55 (1-2):92.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
84. Beauchemin N AA. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. *Cancer and Metastasis Reviews*.



2013;32(3-4):643-71.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

85. Beck B BC. Unravelling cancer stem cell potential. *Nature Reviews Cancer*. 2013;13(10):727-38.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

86. Bekaii-Saab T S, Roda J, M, Guenterberg K, D, Ramaswamy B, Young D, C, Ferketich A, K, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. *Molecular Cancer Therapeutics*. 2009;8(11):2983-91.

배제사유 : NK 세포 활성도를 다루지 않는 연구

87. Bellone G NA, Vizio B, Brondino G, Addeo A, Prati A, Giacobino A, et al. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. *International Journal of Oncology*. 2009;34(6):1701-15.

배제사유 : NK 세포 활성도를 다루지 않는 연구

88. Bellone G TA, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. *American Journal of Pathology*. 1999;155(2):537-47.

배제사유 : 동물실험 또는 전임상시험연구

89. Benatar T CM, Y, Lee Y, Li H, Feng N, Gu X, Lee V, et al. Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. *Cancer Immunology, Immunotherapy*. 2008;57(12):1757-69.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

90. Bendell J C, Manji G, A, Pant S, Lai D, W, Colabella J, Berry W, et al. A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies. *Journal of Clinical Oncology*. Conference. 2020;38(4 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

91. Berman D KA, Peck R, Feltquate D, Lonberg N, Canetta R. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. *Pharmacology and Therapeutics*. 2015;148:132-53.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

92. Beswick E J. NK cells set sights on cancer stem cells. *Science Translational Medicine*. 2015;7(306).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

93. Beyer K BA, Stoyanova A, Kamphues C, Sattler A, Kotsch K. Interactions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with the immune system: Implications for inflammation and cancer. *Cancers*. 2019;11 (8) (1161).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

94. Beyer K NL, Sendler M, Kading A, Heidecke C, D, Partecke L, I, von Bernstorff W. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response. *Pancreas*. 2016;45(3):401-8.  
배제사유 : 동물실험 또는 전임상시험연구
95. Bhat J DS, Dananberg A, Quabius E, S, Fritsch J, Marie Dowds C, Saxena A, et al. Histone deacetylase inhibitor modulates NKG2D receptor expression and memory phenotype of human gamma/delta T cells upon interaction with tumor cells. *Frontiers in Immunology*. 2019;10 (MAR) (569).  
배제사유 : 동물실험 또는 전임상시험연구
96. Bhat R DS, Dinsart C, Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. *International Journal of Cancer*. 2011;128(4):908-19.  
배제사유 : 동물실험 또는 전임상시험연구
97. Bhoopathi P QB, A, Gui Q, Shen X, N, Grossman S, R, Das S, K, Sarkar D, et al. Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. *Cancer Research*. 2014;74(21):6224-35.  
배제사유 : 동물실험 또는 전임상시험연구
98. Bierie B MH, L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. *Cytokine and Growth Factor Reviews*. 2010;21(1):49-59.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
99. Biran A PM, Gal H, Burton D, G, A, Ovadya Y, Vadai E, Geiger T, et al. Senescent cells communicate via intercellular protein transfer. *Genes and Development*. 2015;29(8):791-802.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
100. Birtolo C GV, L, W, Ptasznik A, Eibl G, Pandol S, J. Phosphatidylinositol 3-Kinase: A Link between Inflammation and Pancreatic Cancer. *Pancreas*. 2016;45(1):21-31.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
101. Blackham A U, Northrup S, A, Stewart J, H. Sensitivity of pancreatic adenocarcinoma to oncolytic vesicular stomatitis virus. *Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR*. 2012;72(8 SUPPL. 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
102. Blair B G, Bardelli A, Park B, H. Somatic alterations as the basis for resistance to targeted therapies. *Journal of Pathology*. 2014;232(2):244-54.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
103. Bloushtain N QU, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, Korc M, et al. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. *Journal of Immunology*. 2004;173(4):2392-401.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
104. Blumenthal R D. Technology evaluation: Onyvax-105, Onyvax. *Current Opinion in Molecular Therapeutics*. 2003;5(6):668-72.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

105. Bodey B BJB, Siegel S, E, Kaiser H, E. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? *In Vivo*. 1999;13(4):357-73.

배제사유 : 동물실험 또는 전임상시험연구

106. Boettcher A N, Loving C, L, Cunnick J, E, Tuggle C, K. Development of severe combined immunodeficient (SCID) pig models for translational cancer modeling: Future insights on how humanized SCID pigs can improve preclinical cancer research. *Frontiers in Oncology*. 2018;8 (NOV) (559).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

107. Bonavita E GM, R, Jaillon S, Mantovani A. Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. *Advances in Cancer Research*. 2015;128:141-71.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

108. Bondarenko G UA, Rohan S, Kulesza P, Dubrovskiy O, Gursel D, Mathews J, et al. Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. *Neoplasia*. 2015;17(9):735-41.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

109. Bono P HM, Jaakkola P, Shetty S, Thibault A, de Jonge M, J, A, Minchom A, R, et al. Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours. *Annals of Oncology*. 2019;30 (Supplement 5):v865-v6.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

110. Booth L RJ, L, Poklepovic A, Dent P. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. *Cancer Biology & Therapy*. 2019;20(1):109-21.

배제사유 : 동물실험 또는 전임상시험연구

111. Borden E C. Interferons alpha and beta in cancer: therapeutic opportunities from new insights. *Nature Reviews Drug Discovery*. 2019;18(3):219-34.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

112. Boudreau J E, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. *Molecular Therapy*. 2011;19(5):841-53.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

113. Bracci L SG, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death and Differentiation*. 2014;21(1):15-25.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

114. Bregni M UN, T, Childs R. The second international meeting on allogeneic transplantation in solid tumors. *Bone Marrow Transplantation*. 2006;38(8):527-37.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

115. Brenner E SK, Braumuller H, Dierstein M, Wieder T, Rocken M. RIP1-Tag2xSTAT1.ko mice as a tool to characterize IFN-gamma dependent cancer therapy. *Experimental Dermatology*. 2011;20 (2):199.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
116. Brooks J F-MB, Woller N, Manns M, P, Kubicka S, Gurlevik E, Kuhnel F. Combined inhibition of PD1 and CD96 checkpoints improves survival in a resectable murine model of pancreatic cancer. *European Journal of Cancer*. 2016;61 (1):S189.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
117. Brooks J F-MB, Woller N, Niemann J, Ribback S, Peters K, Demir I, E, et al. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. *Cancer Research*. 2018;78(2):475-88.  
배제사유 : 동물실험 또는 전임상시험연구
118. Bryson G J, Lear D, Williamson R, Wong R, C, W. Detection of the CD56+/CD45-immunophenotype by flow cytometry in neuroendocrine malignancies. *Journal of Clinical Pathology*. 2002;55(7):535-7.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
119. Buchser W J, Laskow T, C, Pavlik P, J, Lin H, M, Lotze M, T. Cell-mediated autophagy promotes cancer cell survival. *Cancer Research*. 2012;72(12):2970-9.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
120. Buijs J T, Juarez P, Guise T, A. Therapeutic strategies to target TGF-beta in the treatment of bone metastases. *Current Pharmaceutical Biotechnology*. 2011;12(12):2121-37.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
121. Bullis C HS, Davare M. Multiplexed immunohistochemistry and the immune microenvironment of primary central nervous system tumors. *Neuro-Oncology*. 2019;21 (Supplement 6):vi147-vi8.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
122. Buonaguro L PA, Tornesello M, L, Buonaguro F, M. Translating tumor antigens into cancer vaccines. *Clinical and Vaccine Immunology*. 2011;18(1):23-34.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
123. Bustos M DJ, Martinez-Anso E, Larequi E, Castano D, Palazon A, Belza I, et al. Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism. *Oncoimmunology*. 2012;1(9):1527-36.  
배제사유 : 동물실험 또는 전임상시험연구
124. Byrne K LK, J, Buggy D, J. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis? *Canadian Journal of Anesthesia*. 2016;63(2):184-92.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
125. Byrne K T, Vonderheide R, H. CD40 therapy and surgery: A potential immunologic

partnership. *Journal of Immunotherapy*. 2013;36(7):359-61.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

126. Byun JS, Jeong WI. Involvement of hepatic innate immunity in alcoholic liver disease. *Immune Netw*. 2010;10(6):181-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

127. Cai L MT, Fernandez-Del Castillo C, Mino-Kenudson M, Warshaw A, L, Lillemoe K, D, Ferrone S, et al. Association of high HLA class I antigen expression with poor prognosis in intraductal papillary mucinous neoplasms (IPMN). *Pancreas*. 2016;45 (10):1499.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

128. Cai L MT, Fernandez-Del Castillo C, Warshaw A, L, Lillemoe K, D, Ferrone S, Mino-Kenudson M, et al. Potential role of nk cells in progression of intraductal papillary mucinous neoplasms (IPMN). *Journal of the American College of Surgeons*. 2016;223 (4 Supplement 1):e142-e3.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

129. Caldeira J C, Perrine M, Pericle F, Cavallo F. Virus-like particles as an immunogenic platform for cancer vaccines. *Viruses*. 2020;12 (5) (488).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

130. Camussi G DM, C, Tetta C. Tumor-derived microvesicles and the cancer microenvironment. *Current Molecular Medicine*. 2013;13(1):58-67.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

131. Cannon A TC, M, Atri P, Bhatia R, Kumar S, Batra S. Analysis of associations of CXCR3 ligands with immune microenvironment and aggressiveness in murine and human pancreatic ductal adenocarcinoma. *Journal of Clinical Oncology. Conference*. 2020;38(4 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

132. Caparosa E M, Stem J, Snook A, E, Waldman S, A. Biomarker targeting of colorectal cancer stem cells. *Biomarkers in Medicine*. 2018;13(11):891-4.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

133. Carpenter E SN, Kemp S, Sirihorachai V, The S, Delrosario L, Gunchick V, et al. Using Endoscopic Fine Needle Biopsies to Map the Immune Landscape in Human Pancreatic Cancer. *Gastrointestinal Endoscopy*. 2020;91 (6 Supplement):AB182.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

134. Carrere N VF, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, et al. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. *Human Gene Therapy*. 2005;16(10):1175-93.

배제사유 : 동물실험 또는 전임상시험연구

135. Castiello L AE, D'Agostino G, Santodonato L, Belardelli F. In situ vaccination by direct dendritic cell inoculation: The coming of age of an old idea? *Frontiers in Immunology*. 2019;10 (SEP) (2303).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

136. Cata J P, Ramirez M, F, Velasquez J, F, Di A, Popat K, U, Gottumukkala V, et al. Lidocaine stimulates the function of natural killer cells in different experimental settings. *Anticancer Research*. 2017;37(9):4727-32.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
137. Cerullo V PS, Diaconu I, Escutenaire S, Arstila P, T, Ugolini M, Nokisalmi P, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. *Cancer Research*. 2010;70(11):4297-309.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
138. Chames P BD. Bispecific antibodies for cancer therapy. *Current Opinion in Drug Discovery and Development*. 2009;12(2):276-83.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
139. Chang C L, Wu T, C, Hung C, F. Control of human mesothelin-expressing tumors by DNA vaccines. *Gene Therapy*. 2007;14(16):1189-98.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
140. Chang J H, Jiang Y, Pillarisetty V, G. Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. *Medicine*. 2016;95(49):e5541.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
141. Chang W A, Tsai M, J, Kuo P, L, Hung J, Y. Role of galectins in lung cancer (Review). *Oncology Letters*. 2017;14(5):5077-84.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
142. Chard L S, Maniati E, Wang P, Hughes J, Wang J, Denes B, et al. A vaccinia virus armed with interleukin-10 that dampens host immunity to the vector but not to tumor is a promising therapeutic agent for pancreatic cancer. *Molecular Therapy*. 2013;1:S196.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
143. Chard L S, Maniati E, Wang P, Zhang Z, Gao D, Wang J, et al. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. *Clinical Cancer Research*. 2015;21(2):405-16.  
 배제사유 : 동물실험 또는 전임상시험연구
144. Check J H. The importance of the immunomodulatory protein, progesterone-induced blocking factor, in allowing cancer cells to escape immune surveillance and therapeutic considerations. *Anticancer Research*. 2014;34 (10):5860-2.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
145. Chen J XH, Zhu X, X, Zhao Y, Fang H, Z, Zhao J, Q. [DNT cell inhibits the growth of pancreatic carcinoma via NKG2D and MICA pathway in vivo]. *Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]*. 2017;97(16):1265-9.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
146. Chen J XH, Zhu X, X. Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer. *Therapeutics and Clinical Risk Management*. 2016;12:11-8.

배제사유 : NK 세포 활성도를 다루지 않는 연구

147. Chen J Y, Yuan M, Lu S, B. A new strategy to prevent cancer recurrence and metastasis after operation: Research and application of heat shock protein/peptides complex vaccine. Chinese Journal of Clinical Rehabilitation. 2002;6(6):913-4.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
148. Chen J. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro. Journal of Digestive Diseases. 2017;18 (Supplement 1):78.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
149. Chen L ZX. Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer. Immunotherapy. 2016;8(2):223-34.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
150. Chen Q K, Yuan S, Z. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology]. 1994;16(5):353-5.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
151. Chen R M, Gong F, S, Ying M, G, Xie Y, Q, Zheng Q, H. Cytolytic activity of NK cell stimulated with HSP70 peptide TKD against pancreatic carcinoma cell. [Chinese]. Chinese Journal of Cancer Prevention and Treatment. 2013;20(3):181-4.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
152. Chen S WD, A, Wu J, D, Wan Y, Matei D, E, Zhang Y, Zhang B. CD73: An emerging checkpoint for cancer immunotherapy. Immunotherapy. 2019;11(11):983-97.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
153. Chen X DY, Lin X, Qian Y, Zhou T, Huang Z. CD4 + CD25 + regulatory T cells in tumor immunity. International Immunopharmacology. 2016;34:244-9.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
154. Chen Y WC, He M, Zhang H, Chen X. Effect of low dose heavy ion irradiation on subset percentage and cytokines expression of peripheral blood lymphocytes in patients with pancreatic cancer. [Chinese]. Chinese Journal of Oncology. 2014;36(6):435-9.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
155. Chen Z WL, Xu T, Wang Q, Kang L, Zhao Q. Generation of bispecific antibodies by Fc heterodimerization and their application. Current Pharmaceutical Biotechnology. 2016;17(15):1324-32.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
156. Chirletti FIAPBBMMSLSARGDGPRCSMFMP. Study of Lymphocyte Subpopulations and Cytotoxic Activity in the Blood of Patients Undergoing Surgery for Pancreatic Cancer. Journal of the Pancreas. Conference: 37th National Congress of the "Italian Association for the Study of the Pancreas", AISP. 2013;14(5 Supplement).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

157. Chitadze G LM, Bhat J, Wesch D, Steinle A, Furst D, Mytilneos J, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. *International Journal of Cancer*. 2013;133(7):1557-66.  
배제사유 : 동물실험 또는 전임상시험연구
158. Chmielewski M AH. CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. *Cell Reports*. 2017;21(11):3205-19.  
배제사유 : 동물실험 또는 전임상시험연구
159. Chopra N CS, Bhargava S, Wajid S, Ganguly N, K. Potentials of "stem cell-therapy" in pancreatic cancer: An update. *Pancreatology*. 2019;19(8):1034-42.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
160. Chu H DF, Jiang L, Wang Z, Gong Z, Lian P, Li P, et al. The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors. *Technology in Cancer Research and Treatment*. 2017;16(5):577-85.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
161. Chung H W, Jang S, Lim J, B. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma. *Cancer*. 2013;119(1):233-44.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
162. Chung H W, Lim J, B. Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma. *Cancer Science*. 2011;102(9):1673-9.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
163. Chung IB HH, Kim NO, Ha JS, Park HS, Park JY. The role of Interferon-gamma on the Expression of Class I Human Leukocyte Antigens in a Human First Trimester Trophoblast Cell Line. *Korean J Obstet Gynecol*. 2003;Feb 46(2):378-386.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
164. Chung J F, Lee S, J, Sood A, K. Immunological and pleiotropic effects of individual beta-blockers and their relevance in cancer therapies. *Expert Opinion on Investigational Drugs*. 2016;25(5):501-5.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
165. Chung Y S, Kondo Y, Sawada T, Nakata B, Tanaka H, Inui A, et al. Comparison between a newly established pancreatic cystadenocarcinoma cell line, OCUP-1 and cells derived from pancreatic ductal carcinoma. *International Journal of Oncology*. 1994;4(6):1333-9.  
배제사유 : 동물실험 또는 전임상시험연구
166. Cieza Rubio N E, Heimark R, Jie T. Role of myeloid derived suppressor cells in the



inflammatory response of pancreatitis and pancreatic cancer. *Annals of Surgical Oncology*. 2016;1):S155.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

167. Cieza-Rubio N JT, Heimark R, L. Mechanistic studies in the inflammatory response of pancreatitis and pancreatic cancer: Role of myeloid derived suppressor cells. *Pancreas*. 2015;44 (8):1367.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

168. Citro A CE, Maffi P, Nano R, Melzi R, Mercalli A, Dugnani E, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. *Journal of clinical investigation*. 2012;122(10):3647-51.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

169. Clift R TB, J, Taverna D, Blouw B, Lee J, Thompson C, B, Maneval D, C. Rationale for evaluating PEGylated recombinant human hyaluronidase PH20 (pegvorhyaluronidase alfa; PEGPH20) in patients with hyaluronan (HA)- accumulating colorectal cancer. *Cancer Research. Conference*. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

170. Clive K S, Tyler J, A, Clifton G, T, Holmes J, P, Mittendorf E, A, Ponniah S, et al. Use of GM-CSF as an adjuvant with cancer vaccines: Beneficial or detrimental? *Expert Review of Vaccines*. 2010;9(5):519-25.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

171. Collignon A SF, Robert S, Trad M, Germain S, Nigri J, Andre F, et al. Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. *OncoImmunology*. 2018;7 (12) (e1504727).

배제사유 : 동물실험 또는 전임상시험연구

172. Conlon K C, Dubois S, Lee C, C, R, Fleisher T, Hsu J, I, Waldmann T, A. Phase I trial of recombinant human Interleukin 15 (rhIL-15) administered as continuous intravenous infusion (CIV) for 10 days (240 hours) in patients with refractory metastatic cancers. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

173. Conlon K C, Lake Potter E, Pittaluga S, Lee C, C, R, Miljkovic M, D, Fleisher T, A, et al. IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion. *Clinical Cancer Research*. 2019;25(16):4945-54.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

174. Conroy M J, Dunne M, R, Donohoe C, L, Reynolds J, V. Obesity-associated cancer: An immunological perspective. *Proceedings of the Nutrition Society*. 2016;75(2):125-38.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

175. Coyne G O, S, Khan S, S, Conlon K, Streicher H, Bruns A, Piekarz R, et al. Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers. *Cancer Research. Conference: American Association*

for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

176. Cravatt B F, Wright A, T, Kozarich J, W. Activity-based protein profiling: From enzyme chemistry to proteomic chemistry. *Annual Review of Biochemistry*. 2008;77:383-414.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

177. Cubas R ZS, Li M, Chen C, Yao Q. Chimeric Trop2 virus-like particles: A potential immunotherapeutic approach against pancreatic cancer. *Journal of Immunotherapy*. 2011;34(3):251-63.

배제사유 : 동물실험 또는 전임상시험연구

178. Cui R YW, Lattime E, C, Stein M, N, Xu Q, Tan X, L. Targeting tumor-associated macrophages to combat pancreatic cancer. *Oncotarget*. 2016;7(31):50735-54.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

179. Curd L M, Favors S, E, Gregg R, K. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. *Clinical & Experimental Immunology*. 2012;168(2):192-9.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

180. Dai B RD, Kang Y, Gumin J, Perez M, V, R, Li X, Pratt M, et al. Preclinical evaluation of sequential combination of oncolytic adenovirus delta-24-RGD and phosphatidylserine-targeting antibody in pancreatic ductal adenocarcinoma. *Molecular Cancer Therapeutics*. 2017;16(4):662-70.

배제사유 : 동물실험 또는 전임상시험연구

181. Daikeler T MK, Weiss B, Hartmann J, Knobloch A, Arning M, Kanz L, et al. The influence of gemcitabine on the CD4/CD8 ratio in patients with solid tumours. *Oncology Reports*. 1997;4(3):561-4.

배제사유 : NK 세포 활성도를 다루지 않는 연구

182. Dalglish A G. Practical aspects in the use of biomarkers for the development of cancer vaccines. *Current Cancer Therapy Reviews*. 2008;4(2):161-5.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

183. D'Alincourt Salazar M ME, R, Tsai W, D'Apuzzo M, Goldstein L, Blazar B, R, Diamond D, J. Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. *Oncoimmunology*. 2016;5(6):e1160184.

배제사유 : 동물실험 또는 전임상시험연구

184. Dambrauskas Z SH, Joshi M, Hyltander A, Naredi P, Iresjo B, M. Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma. *International Journal of Oncology*. 2014;44(1):99-104.

배제사유 : NK 세포 활성도를 다루지 않는 연구

185. Damia G TG, Allavena P, D'Incalci M. Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells. *Cancer Immunology, Immunotherapy*. 1990;32(4):241-4.

배제사유 : 동물실험 또는 전임상시험연구

186. Dankner M G-OS, D, Huang Y, H, Blumberg R, S, Beauchemin N. CEACAM1 as a multi-purpose target for cancer immunotherapy. *OncoImmunology*. 2017;6 (7) (e1328336).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
187. Das M S-VE, Bayry J. Regulatory T cells do not suppress rather activate human basophils by IL-3 and STAT5-dependent mechanisms. *OncoImmunology*. 2020;9 (1) (1773193).  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
188. Datta R RC, L, Dodi I, A, Rees R, C. NK cell, monocyte and non T cell biomarkers as prognostic indicators in cancer immunotherapy. *Current Cancer Therapy Reviews*. 2008;4(2):120-4.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
189. Davidsen K W-LK, Du W, Blo M, Engelsen A, Terry S, Dmello S, et al. BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy. *Cancer Research. Conference*. 2018;78(13 Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
190. Davis M CK, Bohac G, C, Barcnas J, Leslie W, Watkins L, Lamzabi I, et al. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. *Journal of Immunotherapy*. 2012;35(8):629-40.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
191. Davis M CK, C, Bohac G, Barcnas J, Leslie W, T, Deng Y, Li Y, et al. The effects of pemetrexed on innate and adaptive immune cells in subjects with adenocarcinoma of the pancreas. *Cancer Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR*. 2012;72(8 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
192. Dawson D W, Fernandez-Zapico M, E. Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence. *Gastroenterology*. 2016;151(2):234-7.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
193. de Groot P F, Nikolic T, Imangaliyev S, Bekkering S, Duinkerken G, Keij F, M, et al. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. *Diabetologia*. 2020;63(3):597-610.  
 배제사유 : 동물실험 또는 전임상시험연구
194. De Jong G BL, Kedde M, Verdegaal E, Yasuda E, Van Helden P, Wagner K, et al. At1413 antibody derived from a cured AML patient recognises a unique sialylated CD43 epitope shared by AML, MDS and melanoma cells. *ESMO Open*. 2018;3 (Supplement 2):A192.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
195. Dedeepiya V RG, Munirathnam D, Sumana P, Terunuma H, Senthilkumar R, Srinivasan T, et al. Hurdles overcome in technology transfer for AIET and positive outcome in

Indian patients. *Journal of Stem Cells and Regenerative Medicine*. 2012;8(3):207-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

196. Degrade L NC, Franciosi C, Caprotti R, Brivio F, Romano F, Leone B, E, et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. *Langenbecks Archives of Surgery*. 2009;394(1):115-21.

배제사유 : NK 세포 활성도를 다루지 않는 연구

197. Demoulin B CW, J, Murad J, Graber D, J, Sentman M, L, Lonz C, Gilham D, E, et al. Exploiting natural killer group 2D receptors for CAR T-cell therapy. *Future Oncology*. 2017;13(18):1593-605.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

198. Dempe S LM, Struyf S, Bhat R, Verbeke H, Paschek S, Berghmans N, et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. *Cancer Immunology, Immunotherapy*. 2012;61(11):2113-23.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

199. DeSelm C J, Tano Z, E, Varghese A, M, Adusumilli P, S. CAR T-cell therapy for pancreatic cancer. *Journal of Surgical Oncology*. 2017;116(1):63-74.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

200. Dhimolea E RJ, M. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. *mAbs*. 2012;4(1):4-13.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

201. Di Mitri D TA, Alimonti A. Molecular pathways: Targeting Tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. *Clinical Cancer Research*. 2015;21(14):3108-12.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

202. Dintinjana R D, Redovic A. Personalised therapy of hepato-pancreato-biliary malignancies. *Libri Oncologici*. 2018;45 (Supplement 2):9.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

203. Djeu J GD, Trinh T, L, Tu N, Coppola D. Expression of MICA/b, a ligand for natural killer (NK) cell recognition, on human pancreatic adenocarcinoma and potential for NK intervention. *Journal of Clinical Oncology*. 2017;35 (7 Supplement 1):129.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

204. Dong Xda E IN, Lotze M, T, Demarco R, A, Popovic P, Shand S, H, Watkins S, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. *Journal of Immunotherapy*. 2007;30(6):596-606.

배제사유 : NK 세포 활성도를 다루지 않는 연구

205. Dotti G GS, Savoldo B, Brenner M, K. Design and development of therapies using chimeric antigen receptor-expressing T cells. *Immunological Reviews*.

2014;257(1):107-26.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

206. Dou J GN. Emerging strategies for the identification and targeting of cancer stem cells. *Tumor Biology*. 2010;31(4):243-53.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

207. Downs-Kelly E SA, E, Hansel D, E. The role of HLA-G in gastrointestinal inflammatory disease and malignancy. *Seminars in Cancer Biology*. 2007;17(6):451-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

208. Dredge K BT, V, Hammond E, Lickliter J, D, Lin L, Bampton D, Handley P, et al. A Phase i study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. *British Journal of Cancer*. 2018;118(8):1035-41.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

209. Drucker B J, Marincola F, M, Siao D, Y, Donlon T, A, Bangs C, D, Holder W, D, Jr. A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. *In Vitro Cellular & Developmental Biology*. 1988;24(12):1179-87.

배제사유 : 동물실험 또는 전임상시험연구

210. Duan Q LH, Gao C, Zhao H, Wu S, Wu H, Wang C, et al. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. *Journal of Experimental & Clinical Cancer Research*. 2019;38(1):192.

배제사유 : 동물실험 또는 전임상시험연구

211. Duan X DL, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, et al. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. *Medical Oncology*. 2011;28(2):466-74.

배제사유 : NK 세포 활성도를 다루지 않는 연구

212. Duewell P KU, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli A, B, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. *Journal of Immunology*. 2011;187(1):55-63.

배제사유 : 동물실험 또는 전임상시험연구

213. Eibl G. Obesity, inflammation, and pancreatic cancer. *Cancer Research*. Conference: AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment. 2014;75(13 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

214. Eisold S AD, Schmidt J, Wiessner R, Klar E, von Knebel-Doerberitz M, Linnebacher M. Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model. *European Surgical Research*. 2006;38(6):513-21.

배제사유 : 동물실험 또는 전임상시험연구

215. Eisold S SJ, Ryschich E, Gock M, Klar E, von Knebel Doeberitz M, Linnebacher M. Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma. *Pancreas*. 2007;35(1):63-72.  
 배제사유 : 동물실험 또는 전임상시험연구
216. Eissa I R, Naoe Y, Bustos-Villalobos I, Ichinose T, Tanaka M, Zhiwen W, et al. Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. *Frontiers in Oncology*. 2017;7:149.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
217. Elaskalani O BM, C, Falasca M, Metharom P. Targeting platelets for the treatment of cancer. *Cancers*. 2017;9 (7) (94).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
218. Elia A LL, Brunet L, R, Hagemann T. Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2013;1(SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
219. Ellermeier J WJ, Duewell P, Hoves S, Stieg M, R, Adunka T, Noerenberg D, et al. Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer. *Cancer Research*. 2013;73(6):1709-20.  
 배제사유 : 동물실험 또는 전임상시험연구
220. Ellis R WA. Letter from the editor. *Human Vaccines and Immunotherapeutics*. 2016;12(3):557.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
221. Elyada E BM, Laise P, Flynn W, F, Courtois E, T, Burkhart R, A, Teinor J, A, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. *Cancer Discovery*. 2019;9(8):1102-23.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
222. Enesel M B, Acalovschi I, Grosu V, Sbarcea A, Rusu C, Dobre A, et al. Perioperative application of the *Viscum album* extract Isorel in digestive tract cancer patients. *Anticancer Research*. 2005;25(6 C):4583-90.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
223. Epardaud M EK, G, Rubinstein M, P, Yonekura A, R, Bellemare-Pelletier A, Bronson R, Hamerman J, A, et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. *Cancer Research*. 2008;68(8):2972-83.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
224. Eriksson E MI, Wenthe J, Stahle M, Jarblad-Leja J, Ullenhag G, Dimberg A, et al. A novel oncolytic adenovirus expressing immunostimulatory genes that promotes an anti-tumor response. *Journal for ImmunoTherapy of Cancer*. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC.

2016;4(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

225. Eriksson E MI, Wenthe J, Stahle M, Leja-Jarblad J, Ullenhag G, Dimberg A, et al. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus. *Clinical Cancer Research*. 2017;23(19):5846-57.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

226. Eriksson E WJ, Naseri S, Hellstrom A, C, Loskog A. CD40 and 4-1BB pathway activation using oncolytic viruses kills tumor cells by oncolysis and CD40-mediated apoptosis while activating immune cells. *Cancer Research. Conference*. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

227. Fabris L PM, J, Mertens J, Bjorkstrom N, K, Cramer T, Lleo A, Solinas A, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. *Liver International*. 2019;39 Suppl 1:63-78.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

228. Fahrig R QD, Heinrich J, C, Heinemann V, Boeck S, Schmid R, M, Praha C, et al. RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients. *Anti-Cancer Drugs*. 2006;17(9):1045-56.

배제사유 : 동물실험 또는 전임상시험연구

229. Fan G WZ, Hao M, Li J. Bispecific antibodies and their applications. *Journal of Hematology and Oncology*. 2015;8 (1) (130).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

230. Fedele V MD. Permissive State of EMT: The Role of Immune Cell Compartment. *Frontiers in Oncology*. 2020;10 (587).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

231. Ferrarelli L K. Active life, active antitumor defense. *Science Signaling*. 2017;10 (476) (eaan4822).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

232. Fiala M. Curcumin and omega-3 fatty acids enhance NK cell-induced apoptosis of pancreatic cancer cells but curcumin inhibits interferon-gamma production: benefits of omega-3 with curcumin against cancer. *Molecules*. 2015;20(2):3020-6.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

233. Fitas A L, Martins C, Nunes G, Lopes L, Lenzen S, Borrego L, M, et al. Higher C-peptide, higher neutrophil and lower natural killer peripheral counts at type 1 diabetes onset-biomarkers for a longer remission phase? *Pediatric diabetes. Conference: 42nd annual meeting of the international society for pediatric and adolescent diabetes, ISPAD 2016. Spain. Conference start: 20161026. Conference end: 20161029*. 2016;17:143?4.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

234. Fokas E ONE, Gordon-Weeks A, Mukherjee S, McKenna W, G, Muschel R, J. Pancreatic

ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2015;1855(1):61-82.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

235. Formenti S C, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. *Journal of the National Cancer Institute*. 2013;105(4):256-65.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

236. Foucher E D, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic ductal adenocarcinoma: A strong imbalance of good and bad immunological cops in the tumor microenvironment. *Frontiers in Immunology*. 2018;9 (MAY) (1044).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

237. Foy T M, Lynch R, G, Waldschmidt T, J. Ontogeny and distribution of the murine B cell FcγRII. *Journal of Immunology*. 1992;149(5):1516-23.

배제사유 : 동물실험 또는 전임상시험연구

238. Francescone R A, Wagner J, Barbosa Vendramini Costa D, Franco-Barraza J, Gabitova L, Rollins D, et al. Desmoplastic expression of NetrinG1 fuels pancreatic cancer growth and promotes metastasis through nutritional supply and immunosuppression. *Molecular Biology of the Cell. Conference*. 2017;28(26).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

239. Francescone R V-CD, B, Franco-Barraza J, Wagner J, Muir A, Gabitova L, Pazina T, et al. NG1/NGL1 engagement supports PDAC development via CAF to PDAC nutrition and CAFregulated immunosuppression. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

240. Frankel T L, Burns W, Riley J, Morgan R, A, Davis J, L, Hanada K, et al. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines. *Cancer Immunology, Immunotherapy*. 2010;59(12):1757-69.

배제사유 : 동물실험 또는 전임상시험연구

241. Frost F G, Cherukuri P, F, Milanovich S, Boerkoel C, F. Pan-cancer RNA-seq data stratifies tumours by some hallmarks of cancer. *Journal of Cellular and Molecular Medicine*. 2020;24(1):418-30.

배제사유 : 동물실험 또는 전임상시험연구

242. Fuenmayor J MR, F. Novel antibody-based proteins for cancer immunotherapy. *Cancers*. 2011;3(3):3370-93.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

243. Fujihira A ST, Chang M, O, Moriyama T, Kitajima M, Takaku H. Antitumor effects of baculovirus-infected dendritic cells against human pancreatic carcinoma. *Gene Therapy*. 2014;21(9):849-54.

배제사유 : 동물실험 또는 전임상시험연구



244. Funa K NB, Jacobsson G, Alm G, V. Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas. *British Journal of Cancer*. 1984;50(2):231-3.  
 배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구
245. Furugaki K CL, Kunisawa Y, Osada K, Shinkai K, Tanaka M, Kataoka K, et al. Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models. *PLoS ONE*. 2014;9 (7) (e101854).  
 배제사유 : 동물실험 또는 전임상시험연구
246. Gaborit N A-HA, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, et al. Examination of HER3 targeting in cancer using monoclonal antibodies. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112(3):839-44.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
247. Gajewski T F, Schreiber H, Fu Y, X. Innate and adaptive immune cells in the tumor microenvironment. *Nature Immunology*. 2013;14(10):1014-22.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
248. Gallo-Hendrikx E CJ, Percy D, Croy B, A, Wildeman A, G. Enhancement of pancreatic tumor metastasis in transgenic immunodeficient mice. *Oncogene*. 1994;9(10):2983-90.  
 배제사유 : 동물실험 또는 전임상시험연구
249. Gallo-Hendrikx E PD, Capps J, McKeown B, Quinton M, McMillan I, Croy B, A, et al. Evaluation of three lines of immunodeficient mice for the study of spontaneous metastatic tumors. *APMIS*. 1999;107(2):245-56.  
 배제사유 : 동물실험 또는 전임상시험연구
250. Galluzzi L CT, A, Kroemer G, Wolchok J, D, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. *Science Translational Medicine*. 2018;10 (459) (eaat7807).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
251. Galluzzi L SL, Zitvogel L, Kroemer G. The secret ally: Immunostimulation by anticancer drugs. *Nature Reviews Drug Discovery*. 2012;11(3):215-33.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
252. Gao Y SJ, Feng J, Tao M. The effect of high intensity focused ultrasound on immune cells in the peripheral blood of patients with pancreatic carcinoma. [Chinese]. *Tumor*. 2009;29(5):490-2.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
253. Gardian K DM. Inflammatory cells and pancreatic tumor progression. *Przegląd Gastroenterologiczny*. 2013;8(2):133-7.  
 배제사유 : 동물실험 또는 전임상시험연구
254. Garrido F. MHC/HLA class I loss in cancer cells. *Advances in Experimental Medicine and Biology*. 2019;1151:15-78.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

255. Gasteiger S SS, Primavesi F, Oberhuber G, Gobel G, Ofner D, Stattner S. Changes of the immunophenotype in pancreatic cancer. *European Journal of Surgical Oncology*. 2019;45(2):e66-e7.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
256. Gastpar R GM, Bausero M, A, Asea A, Gross C, Schroeder J, A, Multhoff G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. *Cancer Research*. 2005;65(12):5238-47.  
 배제사유 : 동물실험 또는 전임상시험연구
257. GC J. Natural killer T cell and pathophysiology of asthma. *Korean J Pediatr*. 2010;2010 Feb 53(2):136-145.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
258. Gehrman M MJ, Eichholtz-Wirth H, Fritz E, Ellwart J, Jaattela M, Zilch T, et al. Dual function of membrane-bound heat shock protein 70 (Hsp70), Bag-4, and Hsp40: Protection against radiation-induced effects and target structure for natural killer cells. *Cell Death and Differentiation*. 2005;12(1):38-51.  
 배제사유 : 동물실험 또는 전임상시험연구
259. Gerdes C A, Nicolini V, G, Herter S, Van Puijenbroek E, Lang S, Roemmele M, et al. GA201 (RG7160): A novel, humanized, glycoengineered anti - EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. *Clinical Cancer Research*. 2013;19(5):1126-38.  
 배제사유 : 동물실험 또는 전임상시험연구
260. Ghiringhelli F RC, Hichami A, Delmas D. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. *Anti-Cancer Agents in Medicinal Chemistry*. 2012;12(8):852-73.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
261. Gil M KK, E. Interleukin-18 is a prognostic biomarker correlated with CD8+ T cell and natural killer cell infiltration in skin cutaneous melanoma. *Journal of Clinical Medicine*. 2019;8 (11) (1993).  
 배제사유 : 동물실험 또는 전임상시험연구
262. Gil-Bernabe A M, Lucotti S, Muschel R, J. Coagulation And Metastasis: What Does The Experimental Literature Tell Us? *British Journal of Haematology*. 2013;162(4):433-41.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
263. Gilham D E, Maher J. 'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors. *Immunotherapy*. 2017;9(9):723-33.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
264. Giraud L GL, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: Current evidence and perspectives. *Immunotherapy*. 2015;7(9):999-1010.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

265. Gitto S B, Beardsley J, M, Nakkina S, P, Oyer J, L, Cline K, A, Litherland S, A, et al. Identification of a novel IL-5 signaling pathway in chronic pancreatitis and crosstalk with pancreatic tumor cells. *Cell communication and signaling : CCS*. 2020;18(1):95.  
배제사유 : 동물실험 또는 전임상시험연구
266. Gong Y. Proportion of peripheral lymphocyte subsets correlates with the progression-free survival and metastatic status of pancreatic neuroendocrine tumour patients. *Annals of Oncology*. 2019;30 (Supplement 5):v195.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
267. Gough N R. Immune regulatory functions of mutant p53. *Science Signaling*. 2014;7 (357) (ec354).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
268. Grevers F LD, De Koning W, Van Eijck C, H, J, Mustafa D, A. The complex immune-microenvironment heterogeneity in pancreatic cancer. *Cancer Research. Conference: AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care. United States*. 2019;79(24 Supplement).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
269. Grierson P LK, H, Amin M. Immunotherapy in gastrointestinal cancers. *Journal of Gastrointestinal Oncology*. 2017;8(3):474-84.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
270. Grigoriadis I G. An in silico designed dosimetric autologous living vaccine consisting of with multiple wilms' tumor 1 WT1-consynthetic-restricted peptide mimotopic epitopes rmfpnapylp pulsed dendritic cells on a personalized active network analysis for asymptomatic or minimally symptomatic metastatic pancreatic cancer. *Cytotherapy*. 2017;19 (5 Supplement 1):S37.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
271. Grisendi G SC, Rossignoli F, D'Souza N, Golinelli G, Fiori A, Horwitz E, M, et al. Tumor Stroma manipulation by MSC. *Current Drug Targets*. 2016;17(10):1111-26.  
배제사유 : 동물실험 또는 전임상시험연구
272. Gritzapis A DD, Paraskevas E, Baxevas C, Papamichail M. Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. *Cancer Immunology, Immunotherapy*. 2002;51(8):440-8.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
273. Grossenbacher S K, Ames E, Mac S, Masoud R, Canter R, J, Monjazebe A, M, et al. Enhanced natural killer cell targeting of cancer stem cells using Cetuximab. *Journal for ImmunoTherapy of Cancer. Conference: 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC*. 2014;2(SUPPL. 3).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
274. Grossenbacher S K, Canter R, J, Murphy W, J. Natural killer cell immunotherapy to target stem-like tumor cells. *Journal for ImmunoTherapy of Cancer*. 2016;4 (1) (19).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

275. Guang Hua X, Jae Wha K, Gao L, Ick Dong Y. Modulatory Effect of Four Azulene Derivatives from the Fruiting Bodies of *Lactarius hatsudake* on Interferon- $\gamma$  Production. *대한화장품학회지*. 2010;36(2):151-6.  
배제사유 : 동물실험 또는 전임상시험연구
276. Guang Hua X, 김재화, Gao L, 유익동. 젓버섯아재비 자실체로부터 분리한 Azulene계 화합물이 Interferon- $\gamma$  생성에 미치는 영향. *대한화장품학회지*. 2010;36(2):151-6.  
배제사유 : 동물실험 또는 전임상시험연구
277. Gudipaty L RN, K, Fuller C, S, Gallop R, Schutta M, H, Rickels M, R. Effect of exenatide, sitagliptin, or glimepiride on beta-cell secretory capacity in early type 2 diabetes. *Diabetes care*. 2014;37(9):2451-8.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
278. Guerlevik E F-MB, Brooks J, Woller N, Manns M, Kubicka S, Kuehnel F. Proffered Paper: Establishment of resectable transgenic mouse models of pancreatic ductal adenocarcinoma for investigations on adjuvant therapies. *European Journal of Cancer*. 2016;61 (1):S8.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
279. Guo X ZL, Jiang J, Zhao Y, Wang X, Shen M, Zhu F, et al. Blocking NF-kappaB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. *Clinical Cancer Research*. 2016;22(23):5939-50.  
배제사유 : 동물실험 또는 전임상시험연구
280. Gurlevik E F-MB, Brooks J, Demir I, E, Steiger K, Ribback S, Yevsa T, et al. Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. *Gastroenterology*. 2016;151(2):338-50.e7.  
배제사유 : 동물실험 또는 전임상시험연구
281. Gurlevik E F-MB, Brooks J, Demir I, E, Steiger K, Woller N, Wirth T, C, et al. Transgenic tumormodels of resectable pancreatic cancer for evaluation of adjuvant therapies. *Pancreatology*. 2015;1):S39-S40.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
282. Gurwitz D. Cancer therapeutics: Reflections on natural killer cells. *Drug Development Research*. 2008;69(6):285-8.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
283. Gutkin D W, Shurin M, R. Clinical evaluation of systemic and local immune responses in cancer: Time for integration. *Cancer Immunology, Immunotherapy*. 2014;63(1):45-57.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
284. Guzhova I V, Margulis B, A. HSP70-based anti-cancer immunotherapy. *Human Vaccines and Immunotherapeutics*. 2016;12(10):2529-35.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
285. Haga Y SC, L, Woo D, Tempero M, A. Dose-related comparison of antibody-dependent

- cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A: Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. *International Journal of Pancreatology*. 1994;15(1):43-50.  
 배제사유 : 동물실험 또는 전임상시험연구
286. Halder R C, Almasi A, Sagong B, Leung J, Jewett A, Fiala M. Curcuminoids and omega-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon gamma production. *Frontiers in Physiology*. 2015;6:129.  
 배제사유 : 동물실험 또는 전임상시험연구
287. Haller M J, Gitelman S, E, Gottlieb P, A, Michels A, W, Perry D, J, Schultz A, R, et al. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. *Diabetes*. 2016;65(12):3765-75.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
288. Hammond E HN, M, Cullinane C, Brennan T, V, Bampton D, Handley P, Karoli T, et al. Immunomodulatory activities of pixatimod: Emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. *Journal for ImmunoTherapy of Cancer*. 2018;6 (1) (54).  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
289. Hammond E HN, M, Cullinane C, Brennan T, V, Bampton D, Handley P, Karoli T, et al. Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. *Journal for Immunotherapy of Cancer*. 2018;6(1):54.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
290. Hamzah J AJ, G, Herringson T, Parish C, R, Hammerling G, J, O'Donoghue H, Ganss R. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. *Journal of Immunology*. 2009;183(2):1091-8.  
 배제사유 : 동물실험 또는 전임상시험연구
291. Hamzaoui M EA, Sahli S, Ben Salah M, Boussen H, Ben Attia M, Houissa T. [Nasal angiocentric T cell-natural killer cell lymphoma with pancreatic localisation in a child]. *Archives de Pediatrie*. 2003;10(11):979-82.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
292. Han W DZ. Roles of exosomes in liver metastases: Novel diagnosis and treatment choices. *Journal of Cellular Physiology*. 2019;234(12):21588-600.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
293. Hancock W W, Wang L, Aishwarya V. Cancer immunotherapy by use of FANA ASO therapy to silence Foxp3, impair Treg function and promote anti-tumor immunity. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
294. Hantschel M PK, Jordan A, Scholz R, Andreesen R, Schmitz G, Schmetzer H, et al.

Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. *Cell Stress & Chaperones*. 2000;5(5):438-42.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

295. Hao Y B, Yi S, Y, Ruan J, Zhao L, Nan K, J. New insights into metronomic chemotherapy-induced immunoregulation. *Cancer Letters*. 2014;354(2):220-6.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

296. Haque I SA, Banerjee S, Banerjee S, K. Current and emerging perspectives on immunotherapy for pancreatic cancer. *Translational Cancer Research*. 2017;6(Supplement2):S331-S6.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

297. Hara H KA, Yoshida K, Ohashi M, Ohnami S, Uchida E, Higashihara E, et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. *Cancer Science*. 2007;98(3):455-63.

배제사유 : 동물실험 또는 전임상시험연구

298. Harizi H CJ, B, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. *Trends in Molecular Medicine*. 2008;14(10):461-9.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

299. Harrer D C, Dorrie J, Schaft N. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. *Human Gene Therapy*. 2018;29(5):547-58.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

300. Harrison J CJ, E, Piquet M, Dimitrieva S, Gabriel M, Hank T, P, Lillemoe K, et al. 797 Single-Cell Rna Sequencing Analysis of Pancreatic Ductal Adenocarcinoma Reveals Intertumoral Transcriptomic Heterogeneity. *Gastroenterology*. 2020;158 (6 Supplement 1):S-1528.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

301. Harvey J B, Phan L, H, Villarreal O, E, Bowser J, L. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. *Frontiers in Immunology*. 2020;11 (508).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

302. He C WJ, Sun S, Zhang Y, Li S. Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. *Journal of Oncology Print*. 2019;2019:9346017.

배제사유 : NK 세포 활성화 측정 시 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

303. Hernandez-Alcoceba R SB, Berraondo P, Gonzalez-Aseguinolaza G, Prieto J. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives. *Expert Opinion on Investigational Drugs*. 2013;22(7):827-41.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

304. Hershkovitz O JS, Bloushtain N, Zilka A, Landau G, Bar-Ilan A, Lichtenstein R, G, et al. Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. *Biochemistry*. 2007;46(25):7426-36.

배제사유 : 동물실험 또는 전임상시험연구

305. Herskind C FK, Lohr J, Li C, Y, Wenz F, Lohr F. Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: Radiobiological and immunologic strategies. [German]. *Strahlentherapie und Onkologie*. 2004;180(6):331-9.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
306. Hirooka Y IA, Kawashima H, Hara K, Nonogaki K, Kasugai T, Ohno E, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. *Pancreas*. 2009;38(3):e69-74.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
307. Hisamatsu T, Mikami Y, Matsuoka K, Kanai T, Hibi T. Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease. *Intestinal Research*. 2012;10(4):317.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
308. Hochnadel I K-BU, Jedicke N, Lenzen H, Manns M, P, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. *Human Vaccines and Immunotherapeutics*. 2017;13(12):2931-52.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
309. Holt C YF, Timms L, Sam M, Begley K, Hudson T, McPherson J, D, et al. Whole-genome mutation landscape in pancreatic ductal adenocarcinoma. *Cancer Research. Conference: AACR Special Conference on Pancreatic Cancer: Progress and Challenges*. 2012;72(14 SUPPL. 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
310. Hombach A TT, Jensen M, Heuser C, Sircar R, Diehl V, Kruis W, et al. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. *Clinical & Experimental Immunology*. 1997;108(2):352-7.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
311. Homma Y TK, Nakazawa M, Matsuyama R, Mori R, Takeda K, Ichikawa Y, et al. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. *Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies & of the National Cancer Institute of Mexico*. 2014;16(3):330-5.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
312. Hong J T, Son D, J, Lee C, K, Yoon D, Y, Lee D, H, Park M, H. Interleukin 32, inflammation and cancer. *Pharmacology & Therapeutics*. 2017;174:127-37.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
313. Horiuchi H TU, Uchida S, Hayashi K, Kinoshita H, Yamana H, Aoyagi S, et al. [Intra-arterial cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2004;31(11):1752-4.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

314. Horton B SS. Tissue site of tumor growth dictates anti-tumor immunity and response to checkpoint blockade. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
315. Hoseini S S, Cheung N, K, V. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. *Cancer Letters*. 2017;399:44-52.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
316. Hoshikawa M AT, Matsushita H, Karasaki T, Hosoi A, Odaira K, Fujieda N, et al. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. *Biochemical & Biophysical Research Communications*. 2018;495(2):2058-65.  
 배제사유 : 동물실험 또는 전임상시험연구
317. Hu S YJ, Shanguan J, Eresen A, Li Y, Ma Q, Yaghmai V, et al. Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12D p53LSL-R172H Pdx1-Cre mouse model. *American Journal of Cancer Research*. 2019;9(8):1757-65.  
 배제사유 : 동물실험 또는 전임상시험연구
318. Hu W LJ, Sun D, S, Liu H, R, Liu X, L, Li Y. Anti-CD3 monoclonal antibody activated autologous killer cells in treatment of advanced malignant tumor: An observation of short-term effectiveness. [Chinese]. *Chinese Journal of Cancer Biotherapy*. 2008;15(2):155-8.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
319. Hu Y L, Fu Y, H, Tabata Y, Gao J, Q. Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy. *Journal of Controlled Release*. 2010;147(2):154-62.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
320. Hu Z I, Bendell J, C, Bullock A, LoConte N, K, Hatoum H, Ritch P, et al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. *Cancer medicine*. 2019;8(11):5148-57.  
 배제사유 : 동물실험 또는 전임상시험연구
321. Hua L C, Du W, D, Ni Q, X, Zhang Q, H, Fu D, L. Effect of intra-tumor embedding of slow-release 5-fluorouracil on serum tumor biomarkers and cellular immunity of patients with pancreatic carcinoma. [Chinese]. *Fudan University Journal of Medical Sciences*. 2004;31(3):299-302.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
322. Huang H HM, Du W, Zhang Y, Driscoll K, E, Brekken R, A. Targeted inhibition of Tgfbetar2 reduces IL-6 production from cancerassociated fibroblasts, suppresses Stat3 activation in pancreatic cancer cells and reverses immunosuppression. *Cancer Immunology Research*. Conference. 2017;6(9 Supplement).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)



323. Huang H ZY, Gallegos V, Sorrelle N, Zaid M, M, Toombs J, Du W, et al. Targeting TGFbetaR2-mutant tumors exposes vulnerabilities to stromal TGFbeta blockade in pancreatic cancer. *EMBO Molecular Medicine*. 2019;11 (11) (e10515).  
배제사유 : 동물실험 또는 전임상시험연구
324. Huang L QG, Morse M, A, Wang X, Zhou X, Wu J, Hobeika A, et al. Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. *Oncology Letters*. 2019;18(6):5717-24.  
배제사유 : 동물실험 또는 전임상시험연구
325. Huang Q HM, Meng F, Sun R. Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment. *Cellular & Molecular Immunology*. 2019;16(1):87-9.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
326. Husain Z HY, Seth P, Sukhatme V, P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. *Journal of Immunology*. 2013;191(3):1486-95.  
배제사유 : 동물실험 또는 전임상시험연구
327. Hussain M JA, Ashraf M, Al-Zaubai N, Stewart A, Mukhtar M, M. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. *Pharmacological Research*. 2012;66(1):7-18.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
328. Iannone F PA, Birarelli P, Milana B, Santilli M, Sacco L, Ripanti A, et al. Study of lymphocyte subpopulations and cytotoxic activity in the blood of patients undergoing surgery for pancreatic cancer. *Journal of the Pancreas*. 2013;1):576.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
329. Iannone F PA, Peruzzi G, Birarelli P, Milana B, Sacco L, Dinatale G, et al. Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function. *Pancreas*. 2015;44(3):386-93.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
330. Iguchi-Manaka A OG, Kojima H, Cho Y, Hirochika R, Bando H, Sato T, et al. Increased soluble CD155 in the serum of cancer patients. *PLoS ONE*. 2016;11 (4) (e0152982).  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
331. Ikemoto T SM, Iwahashi S, Saito Y, Kanamoto M, Mori H, Morine Y, et al. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. *International Journal of Clinical Oncology*. 2014;19(1):81-6.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
332. Ilic D. Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1-30 June, 2017. *Regenerative Medicine*. 2017;12(7):887-92.

배제사유 : 동물실험 또는 전임상시험연구

333. Ior CC. Suanzaoren Decoction for the treatment of malignant tumor with insomnia (liver-blood deficiency): a randomized, double-blind, placebo-controlled clinical research. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-IOR-16008392>. 2016.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
334. Ireland L LT, Schmid M, C, Mielgo A. Blockade of Stromal Gas6 Alters Cancer Cell Plasticity, Activates NK Cells, and Inhibits Pancreatic Cancer Metastasis. *Frontiers in Immunology*. 2020;11:297.  
배제사유 : 동물실험 또는 전임상시험연구
335. Ishigaki Y YK, Hashimoto N, Nikaido H, Nikaido O, Hayakawa J, I. Enhanced human tumor cell transplantability in a new congenic immunodeficient mouse; KSN-BNX. *Folia Microbiologica*. 1998;43(5):493-4.  
배제사유 : 동물실험 또는 전임상시험연구
336. Ishikawa H ST, Otani T, Suzuki T, Shimozuma K, Nishino H, Fukuda S, et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. *Journal of Nutrition*. 2006;136(3 Suppl):816S-20S.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
337. Itoh K SK, Ebina N, Anzai R, Ouchi A, Matsuno S. Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2. [Japanesel. *Nippon Geka Gakkai zasshi*. 1993;94(8):781-90.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
338. Iwamoto C OK, Okumura T, Koikawa K, Takesue S, Nakayama H, Endo S, et al. BM-derived cells are involved in the tumor microenvironment and promote invasion of pancreatic cancer. *Pancreas*. 2017;46 (10):1408.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
339. Iwamoto C OK, Okumura T, Koikawa K, Takesue S, Nakayama H, Endo S, et al. BM-Derived Cells Recruited to the Pancreas Constitute the Tumor Microenvironment and Promote Invasion of Pancreatic Cancer. *Gastroenterology*. 2018;154 (6 Supplement 1):S-74-S-5.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
340. Iwamoto C OK, Takesue S, Koikawa K, Okumura T, Endo S, Nakata K, et al. BM-derived cells recruited to the pancreas compose the tumor microenvironment and promote invasion of pancreatic cancer. *Cancer Science*. 2018;109 (Supplement 2):715.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
341. Jackson H J, Rafiq S, Brentjens R, J. Driving CAR T-cells forward. *Nature Reviews Clinical Oncology*. 2016;13(6):370-83.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
342. Jakel C E, Vogt A, Gonzalez-Carmona M, A, Schmidt-Wolf I, G. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. *Journal of*

Immunological Research. 2014;2014:897214.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

343. Jan C I, Huang S, W, Canoll P, Lin Y, C, Lu H, M, Chio S, C, et al. Human leukocyte antigen G as a novel target for switch-based chimeric antigen receptor natural killer cell therapy of solid cancers. *Cancer Immunology Research*. Conference: AACR Special Conference on Tumor Immunology and Immunotherapy. United States. 2020;8(3 SUPPL).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

344. Jan M S, Hsu F, R, Lin Y, C, Chuang S, H, Lin J, W, Chuang M, H, et al. Oral administration of a traditional herbal remedy, JC001, suppresses pancreatic tumorigenesis in mice via regulating immune cell functions. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

345. Janakiram M SU, A, Liu W, Zhao A, Schoenberg M, P, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. *Immunological Reviews*. 2017;276(1):26-39.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

346. Janakiram N B, Mohammed A, Bryant T, Ritchie R, Pathuri G, Lightfoot S, et al. Enhanced pancreatic tumor progression in p48Cre-KrasG12D mice is regulated by natural killer T (NKT) cells dependent on mPGES-1 in tumor-associated macrophages. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

347. Janakiram N B, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, et al. Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice. *Immunology*. 2017;152(1):36-51.

배제사유 : 동물실험 또는 전임상시험연구

348. Jarahian M WC, Issa Y, Altevogt P, Momburg F. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. *International Journal of Cancer*. 2007;120(12):2625-34.

배제사유 : NK 세포 활성도를 다루지 않는 연구

349. Javeed N GM, P, Dutta S, K, Lin Y, Bamlet W, R, Oberg A, L, Petersen G, M, et al. Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes. *OncoImmunology*. 2017;6 (1) (e1252013).

배제사유 : 동물실험 또는 전임상시험연구

350. Jeon S LS, A, Kim J, Shin M, H, Kwon J, Lee K, M. Multiple defects in NK cells of surgically resectable pancreatic cancer patients can be reversed by ex-vivo stimulation. *Journal of Immunology*. Conference: 105th Annual Meeting of the American Association of Immunologists, IMMUNOLOGY. 2018;200(1 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

351. Jewett A KJ, Fong Y, Ko M, W, Safaei T, Perisic Nanut M, Kaur K. NK cells shape

pancreatic and oral tumor microenvironments: role in inhibition of tumor growth and metastasis. *Seminars in Cancer Biology*. 2018;53:178-88.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

352. Jewett A KJ, Kaur K, Safaei T, Sutanto C, Chen W, Wong P, et al. Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis. *Molecular Therapy Oncolytics*. 2020;16:41-52.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

353. Jiang X SK, Labadie K, Daniel S, K, Seo D, Abbasi A, Kim T, et al. Combination immunotherapy with PD-1 and CXCR4 blockade activates antitumor immunity against pancreatic neuroendocrine tumors. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

354. Jing W CY, Lu L, Hu X, Shao C, Zhang Y, Zhou X, et al. Human umbilical cord blood-derived mesenchymal stem cells producing IL15 eradicate established pancreatic tumor in syngeneic mice. *Molecular Cancer Therapeutics*. 2014;13(8):2127-37.

배제사유 : 동물실험 또는 전임상시험연구

355. Jo DS HJ, Kim SY, Kim MS, Yi HK, Lee DY, Hwang PH. Changes in the expression of cytokines and apoptosis-related genes in children with infectious mononucleosis. *Korean J Pediatr*. 2009;Dec 52(12):1348-1357.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

356. Johnson P CR, Chowdhury F, Gao Y, Harvey M, Geldart T, Kerr P, et al. Clinical and biological effects of an agonist anti-CD40 antibody a cancer research UK phase I study. *Clinical Cancer Research*. 2015;21(6):1321-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

357. Jonescheit H OH, H, Gonnermann D, Hermes M, Sulaj V, Peters C, Kabelitz D, et al. Influence of indoleamine-2,3-dioxygenase and its metabolite kynurenine on gammadelta t cell cytotoxicity against ductal pancreatic adenocarcinoma cells. *Cells*. 2020;9 (5) (1140).

배제사유 : 동물실험 또는 전임상시험연구

358. Juhl H SM, Baltzer K, Helmig F, Wolf H, Brenner W, Kalthoff H. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. *Cancer Research*. 1995;55(23 Suppl):5749s-55s.

배제사유 : 동물실험 또는 전임상시험연구

359. Jun E SA, Y, Choi J, W, Lee H, H, Kim M, Y, Ko D, H, Kang H, J, et al. Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-beta1 Deregulation and Disease Progression in Pancreatic Cancer. *Frontiers in Immunology*. 2019;10:1354.

배제사유 : 동물실험 또는 전임상시험연구

360. Kabelitz D WD, He W. Perspectives of gammadelta T cells in tumor immunology. *Cancer Research*. 2007;67(1):5-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

361. Kabelitz D WD, Pitters E, Zoller M. Potential of human gammadelta t lymphocytes for immunotherapy of cancer. *International Journal of Cancer*. 2004;112(5):727-32.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

362. Kailayangiri S AB, Wiebel M, Jamitzky S, Rossig C. Overcoming heterogeneity of antigen expression for effective car t cell targeting of cancers. *Cancers*. 2020;12 (5) (1075).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

363. Kamigaki T IH, Okada S, Matsuda E, Tanaka M, Oguma E, Kinoshita Y, et al. Improvement of impaired immunological status of patients with various types of advanced cancers by autologous immune cell therapy. *Anticancer Research*. 2015;35(8):4535-44.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

364. Kandasamy P DJ, E, Miknis G, Lang J, Chauca-Diaz A, Johnson C, Hudson C, et al. Characterization of MP1115? a new natural killer cell activator. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

365. Kang H J, Bae K, Kim J, H, Cho C, K, Yoo H, S. Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy. *Integrative Cancer Therapies*. 2018;17(2):322-31.

배제사유 : 사전에 정의한 연구 설계에 해당되지 않은 연구

366. Kannagi R SK, Miyazaki K, Lim K, T, Yusa A, Yin J, Izawa M. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers. *Cancer Science*. 2010;101(3):586-93.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

367. Karacsonyi S MY, Farkas G, Toth M, Beladi I. Role of the NK reaction in the diagnostics of liver and pancreas tumours. *Acta Chirurgica Hungarica*. 1985;26(1):51-8.

배제사유 : 동물실험 또는 전임상시험연구

368. Karakhanova S MB, Harig S, von Ahn K, Fritz J, Schmidt J, Jager D, et al. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. *International Journal of Molecular Sciences*. 2014;15(3):4104-25.

배제사유 : 동물실험 또는 전임상시험연구

369. Karakhanova S RE, Mosl B, Harig S, Jager D, Schmidt J, Hartwig W, et al. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. *British Journal of Cancer*. 2015;112(6):1027-36.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

370. Karlitepe A EG, Vatansever S, Kabadayi H, Gunduz C, Avci C. Differentiation of adipose tissue derived stem cells to natural killer cells having anti-tumor activities in vitro in

pancreatic cancer. FEBS Journal. 2016;283 (Supplement 1):92.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

371. Karlitepe A KH, Vatansever S, Gurdal M, Gunduz C, Ercan G. Anti-cancer efficiency of natural killer cells differentiated from human adipose tissue-derived mesenchymal stem cells and transfected with miRNA150. *Experimental Oncology*. 2017;39(3):212-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

372. Kataoka H UH, Iwamura T, Seiki M, Nabeshima K, Koono M. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. *American Journal of Pathology*. 1999;154(2):457-68.

배제사유 : 동물실험 또는 전임상시험연구

373. Kato S MT, Hippo Y, Nakajima A. Natural killer T cells regulate tumor immunity in mouse pancreatic cancer organoid orthotropic model. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

374. Katoh H WM. Myeloid-derived suppressor cells and therapeutic strategies in cancer. *Mediators of Inflammation*. 2015;2015 (159269).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

375. Katoh M KM. Identification and characterization of human FMNL1, FMNL2 and FMNL3 genes in silico. *International Journal of Oncology*. 2003;22(5):1161-8.

배제사유 : 동물실험 또는 전임상시험연구

376. Katsiogiannis S CD, Kim Y, Singh R, P, Wong D, T. Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitumor cytotoxicity. *FASEB Journal*. 2017;31(3):998-1010.

배제사유 : 동물실험 또는 전임상시험연구

377. Katsuta E DM, G, Olex A, L, Fernandez L, J, Hochwald S, Takabe K. Pancreatic adenocarcinoma with high expression of CD31 have better prognosis. *Annals of Surgical Oncology*. 2017;24 (1 Supplement 1):S128.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

378. Kaur K CH, H, Cook J, Eibl G, Jewett A. Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice. *Frontiers in Immunology*. 2017;8:1606.

배제사유 : 동물실험 또는 전임상시험연구

379. Kaur K CH, H, Topchyan P, Cook J, M, Barkhordarian A, Eibl G, Jewett A. Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice. *Frontiers in Immunology*. 2018;9:1229.

배제사유 : 동물실험 또는 전임상시험연구

380. Kaur K KA, K, Topchyan P, Ko M, W, Ohanian N, Chiang J, Cook J, et al. Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated

Pancreatic Tumors in Hu-BLT Mice. *Cancers*. 2019;12(1):24.

배제사유 : 동물실험 또는 전임상시험연구

381. Kawakami K KM, Husain S, R, Puri R, K. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo. *Gene Therapy*. 2003;10(13):1116-28.

배제사유 : 동물실험 또는 전임상시험연구

382. Kawaoka T OM, Takashima M, Ueno T, Yamamoto K, Yahara N, Yoshino S, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. *Oncology Reports*. 2008;20(1):155-63.

배제사유 : 동물실험 또는 전임상시험연구

383. Kawasaki B T, Farrar W, L. Cancer stem cells, CD200 and immunoevasion. *Trends in Immunology*. 2008;29(10):464-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

384. Keenan B P, Jaffee E, M. Whole cell vaccines - Past progress and future strategies. *Seminars in Oncology*. 2012;39(3):276-86.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

385. Kegasawa T TT, Yoshioka T, Suda T, Ikezawa K, Nakabori T, Yamada R, et al. Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. *Biochemical & Biophysical Research Communications*. 2019;517(1):84-8.

배제사유 : 동물실험 또는 전임상시험연구

386. Khallouf H MA, Serba S, Teichgraber V, Buchler M, W, Jager D, Schmidt J. 5-Fluorouracil and interferon-alpha immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. *Journal of Immunotherapy*. 2012;35(3):245-53.

배제사유 : 동물실험 또는 전임상시험연구

387. Khallouf H SS, Jager D, Schmidt J. Immunochemotherapy with 5-fluorouracil and interferon-enhances innate and adoptive immune responses against pancreatic cancer in vivo. *Clinical Cancer Research. Conference: AACR International Conference on Translational Cancer Medicine*. 2010;16(7 MEETING ABSTRACTS).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

388. Khallouf H SS, Marten A, Jager D, Schmidt J. Immunochemotherapy with 5-fluorouracil and interferon-alpha enhances innate and adoptive immune responses against pancreatic cancer. *Pancreas*. 2010;39 (8):1327.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

389. Khallouf H SS, Marten A, Jager D, Schmidt J. Immunochemotherapy with 5-Fluorouracil and Interferon-alpha enhances the recognition of pancreatic cancer cells by NK and CD8+ T cells via increasing the expression of NKG2D ligands and MHC Class-I. *Cancer Research. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR*. 2011;71(8 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

390. Khallouf H SS, Marten A, Jager D, Schmidt J. NK cells and CD8+ T cells in orthotopic pancreatic cancer model: Mediation of anti-cancer immune response by 5-fluorouracil and interferon. *Cancer Research. Conference: 101st Annual Meeting of the American Association for Cancer Research, AACR. 2010;70(8 SUPPL. 1).*  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
391. Khodabandeh Shahraki P ZY, Azarpira N, Hosseinzadeh M, Farjadian S. Prognostic Value of HLA-G in Malignant Liver and Pancreas Lesions. *Iranian Journal Of Immunology: IJI. 2018;15(1):28-37.*  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
392. Khong A ND, J, Nowak A, K, Lake R, A, Robinson B, W, S. The use of agonistic anti-CD40 therapy in treatments for cancer. *International Reviews of Immunology. 2012;31(4):246-66.*  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
393. Kidane D CW, J, Czochor J, Eckert K, A, Glazer P, M, Bothwell A, L, M, Sweasy J, B. Interplay between DNA repair and inflammation, and the link to cancer. *Critical Reviews in Biochemistry and Molecular Biology. 2014;49(2):116-39.*  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
394. Kienle G S, Kiene H. Complementary cancer therapy: A systematic review of prospective clinical trials on anthroposophic mistletoe extracts. *European Journal of Medical Research. 2007;12(3):103-19.*  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
395. Kim DH KM, Cho JH, Lim NK, Park JI, Jeong SH, Lee HW, et al. Aging Effects on Dendritic Cells after Total Body Irradiation in Mice. *Korean J Hematol. 2007;Sep 42(3):224-232.*  
 배제사유 : 동물실험 또는 전임상시험연구
396. Kim H KD, W, Cho J, Y. Exploring the key communicator role of exosomes in cancer microenvironment through proteomics. *Proteome Science. 2019;17 (1) (5).*  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
397. Kim JY, Huh K, Lee KY, Yang JM, Kim TJ. Nickel induces secretion of IFN-gamma by splenic natural killer cells. *Exp Mol Med. 2009;41(4):288-95.*  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
398. Kim KJ PS, Lee YS. Immunologic Effect of Gamma Interferon on Human Melanoma Cell Line A - 375 - With Special Emphasis on Cytolytic Activity , Antiproliferative Activity and HLA Antigen Expression. *Korean J Dermatol. 1990;Apr 28(2):147-158.*  
 배제사유 : 동물실험 또는 전임상시험연구
399. Kim Y D, Park S, M, Ha H, C, Lee A, R, Won H, Cha H, et al. HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. *Journal of Cancer. 2020;11(14):4059-72.*  
 배제사유 : 동물실험 또는 전임상시험연구



400. Kim Y S, Kaidina A, M, Chiang J, H, Yarygin K, N, Lupatov A, Y. Cancer stem cell molecular markers verified in vivo. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry*. 2017;11(1):43-54.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
401. Kimura M YY, Narita M, Takenaga K, Takenouchi T, Yamaguchi T, Saisho H, et al. Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by in vivo gene transfer using retrovirus. *International Journal of Cancer*. 1999;82(4):549-55.  
 배제사유 : 동물실험 또는 전임상시험연구
402. Kimura Y KM, Yusa T, Sunamura M, Kimura M, Shimamura H, Matsuno S. Establishment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1). *International Journal of Pancreatology*. 1996;20(1):43-50.  
 배제사유 : 동물실험 또는 전임상시험연구
403. Kimura Y TJ, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. *Pancreas*. 2012;41(2):195-205.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
404. Kishi A TY, Ogawa K, Takano S, Tomita S, Tanigawa M, Niman M, et al. Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer. *Cancer Immunology, Immunotherapy*. 2002;50(11):604-14.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
405. Kishimoto T IH, Kimura C, Takahashi T, Kato H, Yoshiki T. Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. *International Journal of Cancer*. 1996;69(4):290-4.  
 배제사유 : 동물실험 또는 전임상시험연구
406. Klausz K K-TA, Buck M, Krohn S, Otte A, K, Kellner C, Croci G, A, et al. Targeting the glyco-antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B cell lymphoma and plasma cell tumors. *Blood. Conference: 60th Annual Meeting of the American Society of Hematology, ASH*. 2018;132(Suppl. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
407. Knorr D NZ, Bendzick L, Bock A, Kaufman D, S. Development of natural killer cells from human pluripotent stem cells in a feeder free system amenable to clinical translation. *Journal of Investigative Medicine*. 2012;60 (4):733.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
408. Kobari M ES, Shibuya K, Sunamura M, Saitoh K, Matsuno S. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. *British Journal of Surgery*. 2000;87(1):43-8.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구

409. Koevary S B. In vitro natural killer cell activity in the spontaneously diabetic BB/Wor rat: effects of serum on lysis of insulinoma cells. *Diabetes Research*. 1988;8(2):77-84.  
배제사유 : 동물실험 또는 전임상시험연구
410. Kontos F KT, Vallera D, A, Ferrone S, Ferrone C, R. IL-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma. *Journal of the American College of Surgeons*. 2019;229 (4 Supplement 1):S176.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
411. Kopecky J SZ, Knizek J, Priester P, Filip S, Slovacek L, Kopecky O. Depression as an alteration factor of immunocompetent cells in patients with pancreatic cancer. *Supportive Care in Cancer*. 2012;1):S30.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
412. Kopecky J SZ, Knizek J, Priester P, Slovacek L, Filip S, Kopecky O. Immune alteration (NK and T cells) in patient with pancreatic carcinoma with or without chemotherapy. *Supportive Care in Cancer*. 2012;1):S28.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
413. Korbecki J SD, Kojder K, Grochans S, Gutowska I, Chlubek D, Baranowska-Bosiacka I. Fractalkine/CX3CL1 in Neoplastic Processes. *International Journal of Molecular Sciences*. 2020;21(10):25.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
414. Koski A KL, Escutenaire S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. *Molecular Therapy*. 2010;18(10):1874-84.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
415. Kovach N L, Lindgren C, G, Fefer A, Thompson J, A, Yednock T, Harlan J, M. Pentoxifylline inhibits integrin-mediated adherence of interleukin-2- activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components, and cultured tumor cells. *Blood*. 1994;84(7):2234-42.  
배제사유 : 동물실험 또는 전임상시험연구
416. Krampera M. Extracellular vesicles. *Haematologica*. 2017;102 (Supplement 3):187-8.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
417. Krasnick B A, Gao Q, Goedegebuure P, Ding L, Fields R, C. Dissecting the single cell profile of pancreatic ductal adenocarcinoma. *Hpb*. 2019;21 (Supplement 1):S42-S3.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
418. Kruger C GT, F, Korangy F. Immune based therapies in cancer. *Histology and Histopathology*. 2007;22(4-6):687-96.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
419. Kuhl J S, Klapdor R, Bahlo M, Arps H, Dietel M, Mohr M. [Effects of interleukin-2 and lymphokine-activated killer cells on cell cultures and on transplanted tumors (nude mouse) of human pancreatic carcinomas]. *Beitrag Zu Infusionstherapie und Klinische*

Ernahrung. 1987;18:261-5.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

420. Kuhl J S, Klapdor R, Mohr H, Arps H, Dietel M. Cytokines and pancreatic cancer. The effect of rIFN-gamma, HuLeIFN, rTNF-alpha, and LAK-cells on pancreatic and other gastrointestinal tumors in vitro. *International Journal of Pancreatology*. 1989;4(2):207-19.  
배제사유 : 동물실험 또는 전임상시험연구
421. Kumar V SA, K, Makkar H, P, S, Becker K. Dietary roles of phytate and phytase in human nutrition: A review. *Food Chemistry*. 2010;120(4):945-59.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
422. Kunk P R, Bauer T, W, Slingluff C, L, Rahma O, E. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. *Journal for ImmunoTherapy of Cancer*. 2016;4 (1) (14).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
423. Kunkel G T, MacEyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. *Nature Reviews Drug Discovery*. 2013;12(9):688-702.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
424. Kvarnhammar A M, Veitonmaki N, Hagerbrand K, Dahlman A, Smith K, E, Fritzell S, et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. *Journal for ImmunoTherapy of Cancer*. 2019;7 (1) (103).  
배제사유 : 동물실험 또는 전임상시험연구
425. Kwok H F, Buick R, J, Kuehn D, Gormley J, A, Doherty D, Jaquin T, J, et al. Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. *Molecular Cancer*. 2011;10:147.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
426. Lachmann G vHC, Kurth J, Yuerek F, Spies C. Innate immunity recovers earlier than acquired immunity during severe postoperative immunosuppression. *International journal of medical sciences*. 2018;15(1):179.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
427. Lafreniere R RS, A. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. *Journal of the National Cancer Institute*. 1986;76(2):309-22.  
배제사유 : 동물실험 또는 전임상시험연구
428. Laprevotte E DA, Bastid J, Dejou C, Lapierre M, Alberici G, Bensussan A, et al. Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

429. Larsen S K, Svane I, M, Straten P, T, Andersen M, H. Therapeutic cancer vaccines. *Current Cancer Therapy Reviews*. 2010;6(2):163-74.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
430. Lazarova M SA. Impairment of NKG2D-Mediated Tumor Immunity by TGF-beta. *Frontiers in Immunology*. 2019;10 (2689).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
431. Le D T, Brockstedt D, G, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, et al. A live-attenuated *Listeria* vaccine (ANZ-100) and a live-attenuated *Listeria* vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. *Clinical Cancer Research*. 2012;18(3):858-68.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
432. Le D T, Crocenzi T, S, Uram J, N, Lutz E, R, Laheru D, A, Sugar E, A, et al. Randomized phase 2 study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). *Journal of Clinical Oncology. Conference*. 2016;34(Supplement 15).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
433. Le D T, Crocenzi T, S, Uram J, N, Lutz E, R, Laheru D, A, Sugar E, A, et al. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). *Journal of Clinical Oncology. Conference*. 2015;33(15 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
434. Le D T, Crocenzi T, S, Uram J, N, Lutz E, R, Laheru D, A, Sugar E, A, et al. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). *Journal for ImmunoTherapy of Cancer. Conference: 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC*. 2015;3(SUPPL. 2).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
435. Le D T, Picozzi V, J, Ko A, H, Wainberg Z, A, Kindler H, Wang-Gillam A, et al. A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study). *Clinical cancer research*. 2019.  
 배제사유 : 동물실험 또는 전임상시험연구
436. Le D T, Wang-Gillam A, Picozzi V, J, Crocenzi T, S, Morse M, Zeh H, et al. A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). *Journal of Clinical Oncology. Conference*. 2014;32(15 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

437. Le D T, Wang-Gillam A, Picozzi V, J, Crocenzi T, S, Morse M, Zeh H, et al. A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). *Journal of Clinical Oncology. Conference.* 2015;33(3 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
438. Le Q T, Shirato H, Giaccia A, J, Koong A, C. Emerging treatment paradigms in radiation oncology. *Clinical Cancer Research.* 2015;21(15):3393-401.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
439. Lee CB SW, Park JK, Haw CR. Effects of REtinoids on Keratinocytes HLA - DR and ICAM - 1 Expression Induced by Interferon - gamma. *Korean J Dermatol.* 1995;Feb 33(1):33-43.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
440. Lee H LJ, E, Moon H, S, Hwang H, K, Lee S, M, Kang C, M. Oral nutritional supplement enriched with purple perilla extract might enhance NK-cell activity after pancreaticobiliary cancer surgery. *Hpb.* 2019;21 (Supplement 2):S423.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
441. Lee J KT, H, Yoo W, Choi H, Jo S, Kong K, Lee S, R, et al. An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model. *Cancer Immunology Research.* 2019;7(2):219-29.  
 배제사유 : 동물실험 또는 전임상시험연구
442. Lee JS YC, Lyu CJ, Park SM, Cho HS, Kim KY. T Cell Function before, during and after Chemotherapy in Children with Acute Lymphoblastic Leukemia. *Korean J Pediatr Hematol Oncol.* 1997;Oct 4(2):350-362.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
443. Lee JT PS, Lee JH, Kim BK, Kim NK. Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. *J Korean Med Sci.* 1996;Feb 11(1):26-32.  
 배제사유 : 동물실험 또는 전임상시험연구
444. Lee K ZJ, Norris M, K, Chow C, Dieli-Conwright C, M. Prehabilitative Exercise for the Enhancement of Physical, Psychosocial, and Biological Outcomes Among Patients Diagnosed with Cancer. *Current Oncology Reports.* 2020;22 (7) (71).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
445. Lee S S, Kim J, C, Lee S, Dolan J, Baird A. Automated mapping and analysis of stromal cells in tumor microenvironment in pancreatic adenocarcinoma and cholangiocarcinoma using deep learning. *Journal of Investigative Medicine.* 2018;66 (4):843-4.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
446. Lee S S, Kim J, C, Lee S, Dolan J, Baird A. Automated mapping and analysis of stromal cells in tumor microenvironment in pancreatic adenocarcinoma andcholangiocarcinoma using deep learning. *Cancer Research. Conference.* 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

447. Lennon F E, Moss J, Singleton P, A. The mu-opioid receptor in cancer progression: Is there a direct effect? *Anesthesiology*. 2012;116(4):940-5.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

448. Lersch C ZM, Bauer A, Hart R, Wagner F, Siebenrock K, Fink U, et al. Palliative chemoimmunotherapy with low doses of cyclophosphamide (LDCY), echinacea purpurea extracts (echinacin) and thymostimulin in outpatients with far advanced pancreatic malignancies. A preliminary report. *Journal of Experimental and Clinical Cancer Research*. 1990;9(4):247-50.

배제사유 : NK 세포 활성도를 다루지 않는 연구

449. Levi I AH, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, Rachmilewitz J. Characterization of tumor infiltrating Natural Killer cell subset. *Oncotarget*. 2015;6(15):1-9.

배제사유 : 동물실험 또는 전임상시험연구

450. Li C CL, Yang L, Wang B, Zhuo Y, Zhang L, Wang X, et al. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer. *Pancreas*. 2020;49(1):120-7.

배제사유 : 동물실험 또는 전임상시험연구

451. Li C YN, Li H, Wang Z. Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis. *Journal of Cancer Research and Therapeutics*. 2020;16(2):393-6.

배제사유 : NK 세포 활성도를 다루지 않는 연구

452. Li H CM, Y, Lee Y, Benatar T, Lee V, Feng N, Gu X, et al. Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo. *International Immunopharmacology*. 2007;7(10):1350-9.

배제사유 : 동물실험 또는 전임상시험연구

453. Li H CM, Y, Lee Y, Lee V, Feng N, Benatar T, Jin H, et al. Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. *Cancer Immunology, Immunotherapy*. 2005;54(11):1115-26.

배제사유 : 동물실험 또는 전임상시험연구

454. Li H W-EM, C, M, Nemenoff R. Anti- and protumorigenic effects of PPARgamma in lung cancer progression: A double-edged sword. *PPAR Research*. 2012;(362085).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

455. Li H XS, T, Zhang S, X, Liu S, B, Zou P, N, Xiang J, P. Altered lymphocyte subsets and natural killer cells of patients with obstructive jaundice in perioperative period. *Journal of Tongji Medical University*. 1991;11(3):145-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

456. Li J YS, Norgard R, J, Yan F, Yamazoe T, Blanco A, Stanger B, Z. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer. *Cancer Immunology Research*. 2020;8(3):282-91.

배제사유 : 동물실험 또는 전임상시험연구

457. Li Q BA, E, DeSilva M, G, Wasserfall C, Maclaren N, K, Notkins A, L, Lan M, S. Autoantigens in insulin-dependent diabetes mellitus: molecular cloning and characterization of human IA-2 beta. *Proceedings of the Association of American Physicians*. 1997;109(4):429-39.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

458. Li Q WY, Lin M, Xia L, Bao Y, Sun X, Yang L. Phase I clinical trial with PD-1/MUC1 CAR-pNK92 immunotherapy. *Cancer Immunology Research*. Conference: 4th CRI CIMT EATI AACR International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2019;7(2).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

459. Li X NR, Chen J, Liu Z, Xiao M, Jiang F, Lu C. The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms. *Pancreas*. 2011;40(5):753-61.

배제사유 : 동물실험 또는 전임상시험연구

460. Li X XJ, X. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy. *Journal of Theoretical Biology*. 2016;406:42-51.

배제사유 : NK 세포 활성화 측정 시 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구

461. Li Z FJ, Mandeli J, Wetmur J, Woo S, L. A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. *Journal of the National Cancer Institute*. 2008;100(19):1389-400.

배제사유 : 동물실험 또는 전임상시험연구

462. Li Z YX, Werner J, Bazhin A, V, D'Haese J, G. The role of interleukin-18 in pancreatitis and pancreatic cancer. *Cytokine & Growth Factor Reviews*. 2019;50:1-12.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

463. Liang W WH, Sun T, M, Yao W, Q, Chen L, L, Jin Y, Li C, L, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. *World Journal of Gastroenterology*. 2003;9(3):495-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

464. Lim S A, Kim J, Jeon S, Shin M, H, Kwon J, Kim T, J, et al. Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients. *European Journal of Immunology*. 2019;49 (Supplement 3):1860.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

465. Lim S A, Kim J, Jeon S, Shin M, H, Kwon J, Kim T, J, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. *Frontiers in Immunology*. 2019;10:496.

배제사유 : 동물실험 또는 전임상시험연구

466. Lim YA, Kim SS, Cho SW, Cheong JY. Evaluation of the Effectiveness of NK Vue Gold Kit in Patients with Chronic Hepatitis B. *Journal of Laboratory Medicine and Quality Assurance*. 2016;38(3):151-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

467. Lima L G, Monteiro R, Q. Activation of blood coagulation in cancer: Implications for tumour progression. *Bioscience Reports*. 2013;33(5):701-10.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

468. Lin M AM, Liang S, Wang X, Liang Y, Zhang M, Chen J, et al. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. *Oncotarget*. 2017;8(60):101795-807.

배제사유 : NK 세포 활성도를 다루지 않는 연구

469. Lin M LS, Wang X, Liang Y, Zhang M, Chen J, Niu L, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. *Journal of Cancer Research & Clinical Oncology*. 2017;143(12):2607-18.

배제사유 : NK 세포 활성도를 다루지 않는 연구

470. Lin M LS, Wang X, Liang Y, Zhang M, Chen J, Niu L, et al. Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. *Immunology Letters*. 2017;186:20-7.

배제사유 : NK 세포 활성도를 다루지 않는 연구

471. Lin M YY, Y, Liu S, P, Shi J, J, Long X, A, Niu L, Z, Chen J, B, et al. Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. *Journal of Cancer Research and Clinical Oncology*. 2015;141(10):1827-33.

배제사유 : NK 세포 활성도를 다루지 않는 연구

472. Lin Q LM, Guo Y, Gan T. The human immune system reconstituted B-NDG mouse models are ideal tools for CAR-T and therapeutic antibody preclinical efficacy evaluation. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

473. Lin X HM, Xie F, Zhou H, Yang J, Huang Q. Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein. *Oncotarget*. 2016;7(43):70092-9.

배제사유 : 동물실험 또는 전임상시험연구

474. Linnebacher M MC, Emmrich J, Kreikemeyer B. Lysates of *S. pyogenes* serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. *Journal of Immunotherapy*. 2008;31(8):704-13.

배제사유 : 동물실험 또는 전임상시험연구

475. Liu G GM, Liu X, Huang N, Li D, Jiang Z, Yang W, et al. Effective modulation of CD4(+)/CD25(+)/high regulatory T and NK cells in malignant patients by combination of interferon-alpha and interleukin-2. *Cancer Immunology, Immunotherapy*. 2012;61(12):2357-66.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

476. Liu H PM, Incio J, Lee H, Ho W, Crain J, Naxerova K, et al. Use of angiotensin system



inhibitors is associated with longer overall survival in pancreatic ductal adenocarcinoma patients who underwent pancreatectomy. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

477. Liu S LM, Xu J, Ceng J, Chen J, Xu M, Niu L. Percutaneous irreversible electroporation ablation combined with NK-cells transfusion for the treatment of pancreatic cancer: Analysis of its safety and short-term efficacy. [Chinese]. *Journal of Interventional Radiology (China)*. 2019;28(1):42-8.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

478. Liu S ZW, Liu K, Wang Y. CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer. *Cancer Immunology, Immunotherapy*. 2020;69(5):789-97.

배제사유 : 동물실험 또는 전임상시험연구

479. Liu S, Lin M, Xu J, Ceng J, Chen J, Xu M, et al. Percutaneous irreversible electroporation ablation combined with NK-cells transfusion for the treatment of pancreatic cancer: analysis of its safety and short-term efficacy. *Journal of interventional radiology (china)*. 2019;28(1):42?8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

480. Liu Y FM, Chen H, Yang G, Qiu J, Zhao F, Cao Z, et al. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. *Cancer Letters*. 2020;485:1-13.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

481. Liu Y GJ, Huang L. Modulation of tumor microenvironment for immunotherapy: Focus on nanomaterial-based strategies. *Theranostics*. 2020;10(7):3099-117.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

482. Liu Y ZC. The role of human gammadelta t cells in anti-tumor immunity and their potential for cancer immunotherapy. *Cells*. 2020;9 (5) (1206).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

483. Liu Z ZQ, Peng H, Zhang W, Z. Animal lectins: Potential antitumor therapeutic targets in apoptosis. *Applied Biochemistry and Biotechnology*. 2012;168(3):629-37.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

484. Lobene A J, Kindler J, M, Jenkins N, T, Pollock N, K, Laing E, M, Grider A, et al. Zinc Supplementation Does Not Alter Indicators of Insulin Secretion and Sensitivity in Black and White Female Adolescents. *Journal of nutrition*. 2017;147(7):1296?300.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

485. Lobene A J, Kindler J, M, Pollock N, K, Laing E, M, Lewis R, D. Zinc supplementation, beta cell function, insulin secretion, and insulin resistance in black and white female adolescents. *FASEB journal*. Conference: experimental biology 2016, EB. San diego, CA united states. Conference start: 20160402. Conference end: 20160406. Conference publication: (var.pagings). 2016:30.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

486. Loi M DI, Greto D, Mangoni M, Sottili M, Meattini I, Becherini C, et al. Radiotherapy in the age of cancer immunology: Current concepts and future developments. *Critical Reviews in Oncology/Hematology*. 2017;112:1-10.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
487. Lollini P L, Nicoletti G, Landuzzi L, Cavallo F, Forni G, de Giovanni C, et al. Vaccines and other immunological approaches for cancer immunoprevention. *Current Drug Targets*. 2011;12(13):1957-73.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
488. Loney C HA, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels J, P, H, et al. Celyad's novel CAR T-cell therapy for solid malignancies. *Current Research in Translational Medicine*. 2018;66(2):53-6.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
489. Long Y SQ, Wu J, Wang Y, Jiao S. Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. *Oncology Letters*. 2014;7(5):1594-8.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
490. Loskog A EE, Milenova I, Moreno R, Alemany R. A novel oncolytic adenovirus expressing tumor microenvironment modulators that activates myeloid cells, lymphocytes and endothelial cells. *Cancer Research. Conference: 107th Annual Meeting of the American Association for Cancer Research, AACR*. 2016;76(14 Supplement).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
491. Lu Y HJ, Sun W, Duan X, Chen X. Hypoxia-mediated immune evasion of pancreatic carcinoma cells. *Molecular Medicine Reports*. 2015;11(5):3666-72.  
 배제사유 : 동물실험 또는 전임상시험연구
492. Lu Z YL, Wang G, Peng Y, Miao Y. Comprehensive analysis of links between diabetes and pancreatic cancer: A bioinformatical approach. *Pancreatology*. 2018;18 (4 Supplement 1):S127.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
493. Luedke E J-RA, C, Bhave N, Carson Iii W, E. Monoclonal antibody therapy of pancreatic cancer with cetuximab: Potential for immune modulation. *Journal of Immunotherapy*. 2012;35(5):367-73.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
494. Luna J I, Grossenbacher S, K, Murphy W, J, Canter R, J. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy. *Expert Opinion on Biological Therapy*. 2017;17(3):313-24.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
495. Luna J I, Grossenbacher S, K, Sturgill I, R, Ames E, Judge S, J, Bouzid L, A, et al. Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells. *Cancers*. 2019;11(1):14.  
 배제사유 : 동물실험 또는 전임상시험연구

496. Lundgren S EJ, Heby M, Nodin B, Eberhard J, Jirstrom K. Prognostic significance of tumor infiltrating natural killer cells in periampullary adenocarcinoma. *Journal of Clinical Oncology. Conference.* 2016;34(4 SUPPL. 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
497. Lundgren S WC, F, Elebro J, Heby M, Nodin B, Krzyzanowska A, Bjartell A, et al. The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. *PLoS ONE [Electronic Resource].* 2016;11(6):e0156497.  
배제사유 : NK 세포 활성화도 측정 시 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
498. Lutz V HA, Nasiri E, Student M, Picard F, Buchholz M, Gress T, M, et al. Role of Il-18r and Il-1r Signaling on Phenotypical and Functional Plasticity of Cytotoxic T Cells in Pancreatic Cancer. *Gastroenterology.* 2019;156 (6 S1):S-754.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
499. Lygidakis N J, Stringaris K. Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. *Hepato-Gastroenterology.* 1996;43(8):440-7.  
배제사유 : 원자가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
500. Madsen C B, Lavrsen K, Steentoft C, Vester-Christensen M, B, Clausen H, Wandall H, H, et al. Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing. *PLoS ONE [Electronic Resource].* 2013;8(9):e72413.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
501. Madsen C B, Lavrsen K, Steentoft C, Vester-Christensen M, B, Clausen H, Wandall H, H, Pedersen A, E. Glycan elongation beyond the mucin associated TN antigen protects tumor cells from immune-mediated kill. *Scandinavian Journal of Immunology.* 2013;77 (4):291.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
502. Maeng SH LJ, Park CW, Cho YJ. The effect of Der p 2 antigen on the production of interferon gamma by CD3+T, CD56+NK and CD3+CD56+TNK cells from patients with mild persistent allergic asthma. *J Asthma Allergy Clin Immunol.* 2003;Jun 23(2):341-348.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
503. Mahoney D. Immunotherapy prolonged survival in stage IV cancers. *Oncology Report.* 2012(MAY):6.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
504. Maia A LJ, De Oliveira C, Martin-Fernandez J, Paraschoudi G, Rao M, Ligeiro D, et al. Natural Killer and TCR gamma-delta T-cells are present in the tumor microenvironment and can be expanded for adoptive immunotherapy for epithelial cancer. *Journal for ImmunoTherapy of Cancer. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC.* 2018;6(Supplement 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
505. Maitra R GM, H, Goel S. Reovirus: A targeted therapeutic - Progress and potential. *Molecular Cancer Research.* 2012;10(12):1514-25.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

506. Maletzki C OW, Bodammer P, Klier U, Kreikemeyer B, Emmrich J. Antitumoral and immunostimulatory effects of a bacterial vaccine - Coleys Toxin. *Pancreas*. 2009;38(8):1024-5.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

507. Mandi Y FG, Karacsonyi S, Toth M, Beladi I. The role of NK cells in the diagnosis of liver and pancreatic diseases. [Hungarian]. *Orvosi hetilap*. 1984;125(18):1061-4.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

508. Manohar M KH, K, Verma A, K, Mishra A. IL-15 regulates fibrosis and inflammation in a mouse model of chronic pancreatitis. *American Journal of Physiology - Gastrointestinal & Liver Physiology*. 2018;315(6):G954-G65.

배제사유 : 동물실험 또는 전임상시험연구

509. Mantovani A SB, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. *Cytokine and Growth Factor Reviews*. 2010;21(1):27-39.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

510. Marchesi F LM, Solinas G, Erreni M, Allavena P, Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. *Journal of Neuroimmunology*. 2010;224(1-2):39-44.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

511. Marchini A BS, Scott E, M, Angelova A, L, Rommelaere J. Oncolytic parvoviruses: From basic virology to clinical applications. *Virology Journal*. 2015;12 (1) (6).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

512. Marchini A DL, Pozdeev V, I, Angelova A, Rommelaere J. Immune conversion of tumor microenvironment by oncolytic viruses: The protoparvovirus H-1PV case study. *Frontiers in Immunology*. 2019;10 (AUG) (1848).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

513. Marincola F M, Da Pozzo L, F, Drucker B, J, Holder W, D, Jr. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. *Surgery*. 1990;108(5):919-29.

배제사유 : 동물실험 또는 전임상시험연구

514. Marincola F M, Da Pozzo L, F, Howick J, C, Drucker B, J, Hough K, L, Holder W, D, Jr. Prolonged survival of nude mice bearing human pancreatic cancer and treated with lymphokine-activated killer cells and interleukin-2. *Current Surgery*. 1989;46(4):304-7.

배제사유 : 동물실험 또는 전임상시험연구

515. Marincola F M, Drucker B, J, Keeling C, A, Siao D, Y, Starnes H, F, Jr, Goodwin D, A, et al. The in vivo distribution of human peripheral blood lymphocytes and lymphokine-activated killer cells adoptively transferred in human pancreatic cancer-bearing nude mice. *Surgery*. 1989;105(1):79-85.

배제사유 : 동물실험 또는 전임상시험연구

516. Marincola F M, Siao D, Y, Drucker B, J, Holder W, D, Jr. Lymphokine-activated killer cell activity in patients with cancer of the pancreas. *Current Surgery*. 1988;45(4):298-301.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
517. Marten A BM, W. Immunotherapy of pancreatic carcinoma. *Current Opinion in Investigational Drugs*. 2008;9(6):565-9.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
518. Marten A SB, Ziske C, Weineck S, Buttgerit P, Huhn D, Sauerbruch T, et al. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein. *Journal of Immunotherapy*. 2000;23(4):464-72.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
519. Marten A SJ, Debus J, Harig S, Lindel K, Klein J, Bartsch D, K, et al. CapRI: Final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-alpha2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). *Journal of Clinical Oncology*. Conference. 2010;28(18 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
520. Marten A vL-TM, Buchler M, W, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. *International Journal of Cancer*. 2006;119(10):2359-65.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
521. Marten A. Immunotherapy of pancreatic carcinoma. *Reviews on Recent Clinical Trials*. 2008;3(2):121-5.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
522. Martin C K-MC, Pelegrin A, Watier H, Viaud-Massuard M, C, Joubert N. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France. *mAbs*. 2018;10(2):210-21.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
523. Martinez Martinez J. An 84% survival of stage C colorectal carcinoma [2]. [Spanish]. *Oncologia*. 2003;26(8):62-3.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
524. Masu T AM, Nakatsuka K, Shimizu M, Miura D, Arai T, Harimoto H, et al. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. *PLoS ONE [Electronic Resource]*. 2018;13(12):e0200664.  
 배제사유 : 동물실험 또는 전임상시험연구
525. Masugi Y AT, Kitago M, Shinoda M, Sakamoto M. CD8(+) cell density in the tumor center relates to pancreatic cancer survival differentially by the abundance of CD8(+) cell infiltrates in the tumor margin. *Pancreas*. 2019;48 (10):1486.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

526. Masuyama J MT, Iwamoto S, Fujita S. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies. *Cytotherapy*. 2016;18(1):80-90.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

527. Matsuoka H YK, Seo Y, Saito T, Tomoda H, Tsurumoto S. Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan. *Anticancer Research*. 1995;15(5 B):2291-6.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

528. Matyszewski A CA, M, Solarek W, Korzen P, Safir I, J, Kukwa W, Szczylik C. Molecular basis of carcinogenesis in diabetic patients (Review). *International Journal of Oncology*. 2015;46(4):1435-43.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

529. Maus M V, Fraietta J, A, Levine B, L, Kalos M, Zhao Y, June C, H. Adoptive immunotherapy for cancer or viruses. *Annual Review of Immunology*. 2014;32:189-225.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

530. Mayfosh A J, Baschuk N, Hulett M, D. Leukocyte heparanase: A double-edged sword in tumor progression. *Frontiers in Oncology*. 2019;9 (APR) (331).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

531. Mazzolini G AC, Sangro B, Feijoo E, Ruiz J, Benito A, Tirapu I, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. *Journal of Clinical Oncology*. 2005;23(5):999-1010.

배제사유 : NK 세포 활성도를 다루지 않는 연구

532. McCarthy N. Immunotherapy: Put your coat on! *Nature Reviews Cancer*. 2015;15(6):p319.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

533. McMichael E L, Jaime-Ramirez A, C, Guenterberg K, D, Luedke E, Atwal L, S, Campbell A, R, et al. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. *Clinical Cancer Research*. 2017;23(2):489-502.

배제사유 : 동물실험 또는 전임상시험연구

534. McMichael E L, Jaime-Ramirez A, C, Guenterberg K, Luedke E, Atwal L, Carson W, E. Interleukin-21 activates natural killer cell activity against cetuximabcoated pancreatic tumor cells. *Journal for ImmunoTherapy of Cancer*. Conference: 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2015;3(SUPPL. 2).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

535. Mehla K MR, Nicodemus C, Caffrey T, Hollingsworth M, O'Connell K. IgE-based therapeutic strategy against pancreatic cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2019;7(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

536. Melichar B TM, Tosner J, Kopecky O. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. *Onkologie*. 2001;24(2):156-60.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
537. Melzer M K, Arnold F, Stifter K, Zengerling F, Azoitei N, Seufferlein T, et al. An immunological glance on pancreatic ductal adenocarcinoma. *International Journal of Molecular Sciences*. 2020;21 (9) (3345).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
538. Meng Y EE, V, Hamzeh K, W, Darga T, E, Mauceri H, J, Fu Y, X, Kron S, J, et al. Radiation-inducible immunotherapy for cancer: Senescent tumor cells as a cancer vaccine. *Molecular Therapy*. 2012;20(5):1046-55.  
배제사유 : 동물실험 또는 전임상시험연구
539. Mesiano G TM, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. *Expert Opinion on Biological Therapy*. 2012;12(6):673-84.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
540. Meulendijks D JW, Martinez-Garcia M, Taus A, Lolkema M, P, Voest E, E, Langenberg M, H, G, et al. First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors. *Clinical Cancer Research*. 2016;22(4):877-85.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
541. Michaels A D, Newhook T, E, Lindberg J, M, Adair S, J, Nagdas S, Mullen M, G, et al. The role of resident liver macrophages in suppressing the progression of hepatic micrometastases from pancreatic ductal adenocarcinoma. *Cancer Research. Conference: AACR Special Conference on The Function of Tumor Microenvironment in Cancer Progression*. 2016;76(15 Supplement).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
542. Miller A L-MC, Blackwell S, Tomanek-Chalkley A, Shrader H, Coleman K, Weiner G, et al. Intraperitoneal CMP-001: A novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreatic cancer. *Annals of Surgical Oncology*. 2020;27 (Supplement 1):S36-S7.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
543. Miller A M, Lemke-Miltner C, Blackwell S, Tomanek-Chalkley A, Coleman K, Weiner G, et al. CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatment of peritoneal carcinomatosis of gastrointestinal and pancreatic cancers. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2019;79(13 Supplement).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
544. Miller A M, Lemke-Miltner C, D, Blackwell S, Tomanek-Chalkley A, Gibson-Corely K, N, Coleman K, L, et al. Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer. *Annals of*

Surgical Oncology. 2020;14:14.

배제사유 : 동물실험 또는 전임상시험연구

545. Mir M A, Agrewala J, N. Signaling through CD80: An approach for treating lymphomas. Expert Opinion on Therapeutic Targets. 2008;12(8):969-79.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

546. Mittal R WM, Breed E, R, Liang Z, Yoseph B, P, Burd E, M, Farris Iii A, B, et al. Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy. PLoS ONE. 2014;9 (5) (e93523).

배제사유 : 동물실험 또는 전임상시험연구

547. Mittal R WM, Breed E, R, Liang Z, Yoseph B, P, Coopersmith C, Ford M. Pre-existing malignancy alters innate and adaptive immune responses in a murine model of infection. Shock. 2013;2):46.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

548. Miya K SS, Furuta T, Azuma S, Umemoto T, Takao H, Katou M, et al. [Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 1992;19(10 Suppl):1453-6.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

549. Miyashita T MK, Harmon J, W, Ahmed A, K, Tajima H, Fushida S, Ohta T. Gemcitabine induces major histocompatibility complex class I-related Chain A/B expression, activating gammadelta T cell function in pancreatic cancer. Gastroenterology. 2015;1):S1172.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

550. Miyashita T MK, Kamigaki T, Makino I, Nakagawara H, Tajima H, Takamura H, et al. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer. Clinical & Experimental Medicine. 2017;17(1):19-31.

배제사유 : 동물실험 또는 전임상시험연구

551. Miyashita T TH, Shoji M, Nakanuma S, Sakai S, Makino I, Hayashi H, et al. [Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]. 2013;40(12):1600-2.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

552. Miyazawa M KM, Maguchi H, Ishii H, Yamao K, Kawai M, Hirono S, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Journal of Hepato-Biliary-Pancreatic Sciences. 2017;24 (Supplement 1):A269.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

553. Miyazawa M KM, Maguchi H, Katanuma A, Ishii H, Ozaka M, Yamao K, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. International journal of cancer.



2017;140(4):973-82.

배제사유 : NK 세포 활성도를 다루지 않는 연구

554. Miyoshi E MK, Terao N, Tan C, C, Terao M, Nakagawa T, Matsumoto H, et al. Fucosylation is a promising target for cancer diagnosis and therapy. *Biomolecules*. 2012;2(1):34-45.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

555. Mocellin S RC, R, Lise M, Marincola F, M. Adjuvant immunotherapy for solid tumors: From promise to clinical application. *Cancer Immunology, Immunotherapy*. 2002;51(11-12):583-95.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

556. Mondragon L KG, Galluzzi L. Immunosuppressive gammadelta T cells foster pancreatic carcinogenesis. *OncoImmunology*. 2016;5 (11) (e1237328).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

557. Monjazeb A M, Ames E, Murphy W, J, Canter R. Radiation enhances innate immune recognition of cancer stem cells in solid tumors. *International Journal of Radiation Oncology Biology Physics*. 2014;1):S808.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

558. Morisaki T HT, Koya N, Kiyota A, Tanaka H, Umabayashi M, Onishi H, et al. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. *Anticancer Research*. 2014;34(8):4529-38.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

559. Morisaki T. Combinatorial treatments including vaccines, immune cell transfer therapy, and chemotherapy for far-advanced cancer: rationale and practice. [Japanese]. *Biotherapy*. 2009;23(4):295-301.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

560. Morokuma A SY, Nakamura A, Sakuma H, Ishihara Y, Abe M. Assessing antitumor and T cell immune responses by cytokine assay in cancer patients treated with immunotherapy - A pilot study. *Personalized Medicine Universe*. 2018;7:28-33.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

561. Morris Z S, Guy E, Francis D, Gressett M, Yang R, Rakhmievich A, et al. In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model. *Journal for ImmunoTherapy of Cancer. Conference: 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC*. 2014;2(SUPPL. 3).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

562. Mosely S I, S, Prime J, E, Sainson R, C, A, Koopmann J, O, Wang D, Y, Q, Greenawalt D, M, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. *Cancer Immunology Research*. 2017;5(1):29-41.

배제사유 : 동물실험 또는 전임상시험연구

563. Mota C DI, E, Konukiewitz B, Muckenhuber A, Teller S, Weichert W, Friess H, et al. The histopathological effect of neoadjuvant therapy on human pancreatic cancer. *Pancreatology*. 2017;17 (3 Supplement 1):S78.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
564. Mota Reyes C TS, Muckenhuber A, Konukiewitz B, Safak O, Weichert W, Friess H, et al. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. *Clinical Cancer Research*. 2020;26(1):220-31.  
 배제사유 : 동물실험 또는 전임상시험연구
565. Mota-Reyes C DI, E, Mundt B, Brooks J, Konukiewitz B, Muckenhuber A, Teller S, et al. An R0-resectable, genetically engineered mouse model of pancreatic cancer mimics the response to neoadjuvant chemotherapy in human pancreatic cancer. *Pancreatology*. 2018;18 (4 Supplement 1):S146.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
566. Mota-Reyes C MB, Brooks J, Konukiewitz B, Kuhnle F, Friess H, Ceyhan G, O, et al. An R0-resectable, genetically engineered mouse model of pancreatic cancer mimics the response to neoadjuvant chemotherapy in human pancreatic cancer. *United European Gastroenterology Journal*. 2018;6 (8 Supplement):A82.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
567. Mpekris F BJ, W, Stylianopoulos T, Jain R, K. Role of vascular normalization in benefit from metronomic chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America*. 2017;114(8):1994-9.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
568. Mu W WZ, Zoller M. Ping-Pong-Tumor and Host in Pancreatic Cancer Progression. *Frontiers in Oncology*. 2019;9:1359.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
569. Muenst S LH, Soysal S, D, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: Therapeutic concepts. *Journal of Internal Medicine*. 2016;279(6):541-62.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
570. Mukherjee S LS, Cox C, Thapa A, Hughes S, Bangs F, Willenbrock F, et al. Translational analysis from SCALOP trial: CCL5 as a prognostic biomarker and a potentially actionable target in locally advanced pancreatic cancer (LAPC). *Journal of Clinical Oncology. Conference*. 2020;38(4 Supplement).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
571. Muller-Hubenthal B AM, Lorenzen D, Huber M, Freudenberg M, A, Galanos C, Unger C, et al. Tumour biology: Tumour-associated inflammation versus antitumor immunity. *Anticancer Research*. 2009;29(11):4795-805.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
572. Multhoff G PA, G, Streffer C, Gaipl U, S. Dual role of heat shock proteins (HSPs) in anti-tumor immunity. *Current Molecular Medicine*. 2012;12(9):1174-82.

- 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
573. Munoz M CR. Involvement of substance P and the NK-1 receptor in pancreatic cancer. *World Journal of Gastroenterology*. 2014;20(9):2321-34.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
574. Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. *Cancer Science*. 2005;96(9):543-52.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
575. Murthy D AK, S, Singh P, K. Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics. *Frontiers in Physiology*. 2018;9 (APR) (335).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
576. Muthalagu N MT, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, Laing S, et al. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. *Cancer Discovery*. 2020;10(6):872-87.  
배제사유 : 동물실험 또는 전임상시험연구
577. Muthana M MG, Pockley A, G. Tumour infiltrating host cells and their significance for hyperthermia. *International Journal of Hyperthermia*. 2010;26(3):247-55.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
578. Nabavinia M S, Gholoobi A, Charbgoon F, Nabavinia M, Ramezani M, Abnous K. Anti-MUC1 aptamer: A potential opportunity for cancer treatment. *Medicinal Research Reviews*. 2017;37(6):1518-39.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
579. Naden J. Cell line xenograft growth in the B6:129-Rag2tm1Fwa IL2rgtm1Rsky/DwlHsd (R2G2) mouse model. *FASEB Journal*. 2019;33(S1):lb1-872.4.  
배제사유 : 동물실험 또는 전임상시험연구
580. Naden J. Cell line xenograft growth in the B6:129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd (R2G2) mouse model. *Journal of the American Association for Laboratory Animal Science*. 2019;58 (5):675.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
581. Nagaraj S ZC, Strehl J, Messmer D, Sauerbruch T, Schmidt-Wolf I, G. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. *International Immunology*. 2006;18(8):1279-83.  
배제사유 : 동물실험 또는 전임상시험연구
582. Nair P, Mukherjee M, Lim HF, Huang C, Radford K, Boulet LP, et al. Benralizumab attenuates airway eosinophilopoietic processes in prednisone-dependent asthma. *European respiratory journal*. 2017;50.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
583. Nakamura M WJ, Suzuki H, Tanaka M, Katano M, Morisaki T. Long-term outcome of

immunotherapy for patients with refractory pancreatic cancer. *Anticancer Research*. 2009;29(3):831-6.

배제사유 : NK 세포 활성도를 다루지 않는 연구

584. Nakao A KH, Sahin T, T, Nomura N, Kanzaki A, Misawa M, Shirota T, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. *Cancer Gene Therapy*. 2011;18(3):167-75.

배제사유 : NK 세포 활성도를 다루지 않는 연구

585. Nan K J, Wei Y, C, Zhou F, L, Li C, L, Sui C, G, Hui L, Y, et al. Effects of depression on parameters of cell-mediated immunity in patients with digestive tract cancers. *World Journal of Gastroenterology*. 2004;10(2):268-72.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

586. Nanba H. Immunotherapy for cancer with polysaccharide of Maitake mushroom. *Journal of Cachexia, Sarcopenia and Muscle*. 2011;2 (4):258.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

587. Narumi K FS, Masuyama J. A retrospective study of 83 pancreatic cancer patients treated by combining chemotherapy with NK cell-enriched immunotherapy. *Journal of Clinical Oncology*. Conference. 2018;36(15 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

588. Narumi K MR, Ueda R, Hashimoto H, Yamamoto Y, Aoki K. S100A8/A9 protein activates an antitumor effect of NK cells through rage. *Molecular Therapy*. 2014;1):S244-S5.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

589. Narumi K MR, Ueda R, Hashimoto H, Yamamoto Y, Yoshida T, Aoki K. Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE. *Journal of Immunology*. 2015;194(11):5539-48.

배제사유 : 동물실험 또는 전임상시험연구

590. Natoli C FB, Di Stefano P, Amatetti C, Tinari N, Iacobelli S. Combinations of biological response modifiers: Rationale and clinical responses. *Pharmacological Research*. 1992;26(SUPPL. 2):102-3.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

591. Nct. Analgesia and Pancreatic Cancer Surgery. <https://clinicaltrials.gov/show/NCT01929915>. 2013.

배제사유 : NK 세포 활성도를 다루지 않는 연구

592. Nct. Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer. <https://clinicaltrials.gov/show/NCT01116791>. 2010.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

593. Nelson D FS, Robinson B. The "trojan Horse" approach to tumor immunotherapy: Targeting the tumor microenvironment. *Journal of Immunology Research*. 2014;2014 (789069).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

594. Nemunaitis J M, Nemunaitis J. Potential of Advexin: A p53 gene-replacement therapy in Li-Fraumeni syndrome. *Future Oncology*. 2008;4(6):759-68.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

595. Nesselhut J MD, Lange H, Chang R, Y, Nesselhut T. Combination of PD-1/PD-L1 checkpoint blockade and dendritic cell therapy. *European Journal of Immunology*. 2018;48 (Supplement 1):95.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

596. Newhook T LJ, M, Adair S, J, Nagdas S, Parsons J, Bauer T, W. Resident liver macrophages suppress outgrowth of occult liver metastases and prolong survival in a preclinical mouse model of pancreatic cancer. *Annals of Surgical Oncology*. 2016;1):S163.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

597. Nishime C KK, Yamamoto T, Katano I, Monnai M, Goda N, Mizushima T, et al. Innate Response to Human Cancer Cells with or without IL-2 Receptor Common gamma-Chain Function in NOD Background Mice Lacking Adaptive Immunity. *Journal of Immunology*. 2015;195(4):1883-90.

배제사유 : 동물실험 또는 전임상시험연구

598. Noguchi A KT, Naitoh K, Saito M, Iwai K, Maekawa R, Kamigaki T, et al. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. *International Immunopharmacology*. 2014;18(1):90-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

599. Noonan A M, Farren M, R, Geyer S, M, Huang Y, Tahiri S, Ahn D, et al. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. *Molecular Therapy: the Journal of the American Society of Gene Therapy*. 2016;24(6):1150-8.

배제사유 : 동물실험 또는 전임상시험연구

600. Nordstrom J L, Huang L, Yang Y, Tuailon N, Stavenhagen J, B, Stewart S, et al. Preclinical antitumor activity of an Fc domain-optimized HER2 monoclonal antibody (mAb). *Journal of Clinical Oncology. Conference*. 2010;28(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

601. Obara W KT, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, et al. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. *Cancer immunology, immunotherapy*. 2017;66(1):17?24.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

602. Oberg H H, Grage-Griebenow E, Adam-Klages S, Jerg E, Peipp M, Kellner C, et al. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. *Pancreatology*. 2016;16(6):1069-79.

배제사유 : NK 세포 활성도를 다루지 않는 연구

603. Oberg H H, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M, et al. Tribody [(HER2) 2xCD16] Is More Effective Than Trastuzumab in Enhancing gammadelta T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. *Frontiers in Immunology*. 2018;9:814.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
604. Oberg H H, Wesch D, Kalyan S, Kabelitz D. Regulatory interactions between neutrophils, tumor cells and T Cells. *Frontiers in Immunology*. 2019;10 (JULY) (1690).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
605. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. *Digestion*. 2000;62 Suppl 1:92-7.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
606. Oberg K. The evolution of treatment in neuroendocrine tumors. *European Journal of Clinical Investigation*. 2009;1):18-9.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
607. O'Connell A WS, Weiner L, M. The potential role of fibroblast activation protein as a natural killer cell immune checkpoint. *Cancer Immunology Research*. Conference: 4th CRI CIMT EATI AACR International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2019;7(2).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
608. Oh E MB, Li Y, Lian C, Hong J, Park G, M, Yang B, et al. Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect). *Cancers*. 2019;11(7):09.  
배제사유 : 동물실험 또는 전임상시험연구
609. Ohashi M YK, Kushida M, Miura Y, Ohnami S, Ikarashi Y, Kitade Y, et al. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. *British Journal of Cancer*. 2005;93(4):441-9.  
배제사유 : 동물실험 또는 전임상시험연구
610. Ohashi T MY, Narimiya M, Yokoyama J, Ikeda Y, Isogai Y. Type 1 (insulin-dependent) diabetic patient with remarkable infiltration of lymphocytes to the islets. *Endocrine Journal*. 1993;40(6):633-9.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
611. Ohgidani M FK, Kentaro S, Kunisawa Y, Itaka K, Kataoka K, Nakano K. Block/homo polyplex micelle-based GM-CSF gene therapy via intraperitoneal administration elicits antitumor immunity against peritoneal dissemination and exhibits safety potentials in mice and monkeys. *Cancer Research*. Conference: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances. 2012;73(1 SUPPL. 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

612. Ohgidani M FK, Shinkai K, Kunisawa Y, Itaka K, Kataoka K, Nakano K. Block/homo polyplex micelle-based GM-CSF gene therapy via intraperitoneal administration elicits antitumor immunity against peritoneal dissemination and exhibits safety potentials in mice and cynomolgus monkeys. *Journal of Controlled Release*. 2013;167(3):238-47.  
 배제사유 : 동물실험 또는 전임상시험연구
613. Ohta T EA, Kitagawa H, Kayahara M, Takamura H, Fujimura T, Nishimura G, et al. Fas ligand expression in human pancreatic cancer. *Oncology Reports*. 2004;12(4):749-54.  
 배제사유 : 동물실험 또는 전임상시험연구
614. Okada H BL, H. Manipulation of dendritic cells for tumor immunity. *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry*. 2007;6(2):151-60.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
615. Okada H KG, Zhu X, Kastenhuber E, R, Hoji A, Ueda R, Fujita M. Immunotherapeutic approaches for glioma. *Critical Reviews in Immunology*. 2009;29(1):1-42.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
616. Onishi H FA, Oyama Y, Kawamoto M, Yamasaki A, Morisaki T. Hedgehog signaling augments PDL-1 expression in cancer cells under hypoxic condition to inhibit antitumor effects by activated lymphocytes. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2017;77(13 Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
617. Onrc CC. A controlled trial of Autologous and umbilical cord blood cytokine-induced killer cells (U-CIKs) infusion on influence of the immune function in Advanced Cancer after Radiotherapy. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002992>. 2013.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
618. Onrc CC. Multi-center clinical study of umbilical cord blood cytokine-induced killer cells (U-CIKs) infusion on influence of the immune function in Advanced Cancer after Chemotherapy. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-ONRC-13002983>. 2013.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
619. Onyeaghala G LJ, Pankratz N, Nelson H, H, Thyagarajan B, Walcheck B, Anderson K, E, et al. Association between MICA polymorphisms, s-MICA levels, and pancreatic cancer risk in a population-based case-control study. *PLoS ONE*. 2019;14 (6) (e0217868).  
 배제사유 : 동물실험 또는 전임상시험연구
620. Orhan A VR, P, Andersen M, B, Madsen M, T, Holmich E, R, Raskov H, Gogenur I. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. *European Journal of Cancer*. 2020;132:71-84.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
621. Ostapchuk E O, Kali A, Belyaev N, N. Transforming Growth Factor-beta and Tumor Necrosis Factor-alpha Reduce the Sensitivity of MiaPaCa2 Pancreatic Cancer Cells to Lysis by NK Cells. *Bulletin of Experimental Biology & Medicine*. 2018;165(2):259-63.

배제사유 : 동물실험 또는 전임상시험연구

622. Ostapoff K T, Cenik B, K, Wang M, Ye R, Xu X, Nugent D, et al. Neutralizing the activity of murine TGF-beta receptor 2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. *Cancer Research. Conference: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment*. 2014;75(1 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

623. Ou D MD, L, Wang X, Pozzilli P, Tingle A, J. beta-cell antigen-specific CD56(+) NKT cells from type 1 diabetic patients: Autoaggressive effector T cells damage human CD56(+) beta cells by HLA-restricted and non-HLA-restricted pathways. *Human Immunology*. 2002;63(4):256-70.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

624. Ou Z L, Luo Z, Wei W, Liang S, Gao T, L, Lu Y, B. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ\_0000977/miR-153 axis. *Rna Biology*. 2019;16(11):1592-603.

배제사유 : 동물실험 또는 전임상시험연구

625. Owen J L, Iragavarapu-Charyulu V, Lopez D, M. T cell-derived matrix metalloproteinase-9 in breast cancer: Friend or foe? *Breast Disease*. 2004;20:145-53.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

626. Palucka K BJ. Dendritic-Cell-Based Therapeutic Cancer Vaccines. *Immunity*. 2013;39(1):38-48.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

627. Pan P ZZ, Oshima K, Aldakkak M, Tsai S, Huang Y, W, Dong W, et al. Black raspberries suppress pancreatic cancer through modulation of NKp46+, CD8+, and CD11b+ immune cells. *Food Frontiers*. 2020;1(1):70-82.

배제사유 : 동물실험 또는 전임상시험연구

628. Pardali K MA. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2007;1775(1):21-62.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

629. Park AJ LM. Peripheral Th1 and Th2 Lymphocytes Values by Intracellular Cytokine Staining for Interferon-and Interleukin-4 in the Patients with Repeated Spontaneous Abortion. *Korean J Lab Med*. 2005;Apr 25(2):111-115.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

630. Park G YB, Kim E, Kim H, Kim Y, Cho S, Hwang Y, et al. Potent antitumor efficacy of ex vivo expanded and cryopreserved human natural killer cells against orthotopic pancreatic cancer. *Cytotherapy*. 2019;21 (5 Supplement):S35.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

631. Park S, Mun YC, Seong C-M, Huh HJ, Huh J. Variable Natural Killer Cell Activity in Hematological Malignancies at Diagnosis. *Laboratory Medicine Online*. 2018;8(2):41.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구



632. Pasto A CF, M, Sica A. Influence of innate immunity on cancer cell stemness. *International Journal of Molecular Sciences*. 2020;21 (9) (3352).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
633. Penafuerte C B-LN, Bouchentouf M, Birman E, Forner K, Galipeau J. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. *Journal of Immunology*. 2011;186(12):6933-44.  
 배제사유 : 동물실험 또는 전임상시험연구
634. Peng Y P, Xi C, H, Zhu Y, Yin L, D, Wei J, S, Zhang J, J, et al. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. *Oncotarget*. 2016;7(41):66586-94.  
 배제사유 : 동물실험 또는 전임상시험연구
635. Peng Y P, Zhang J, J, Liang W, B, Tu M, Lu Z, P, Wei J, S, et al. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. *BMC Cancer*. 2014;14(1):1-12.  
 배제사유 : 동물실험 또는 전임상시험연구
636. Peng Y P, Zhang J, J, Liang W, B, Tu M, Lu Z, P, Wei J, S, et al. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. *BMC Cancer*. 2014;14:738.  
 배제사유 : 동물실험 또는 전임상시험연구
637. Peng Y P, Zhu Y, Zhang J, J, Xu Z, K, Qian Z, Y, Dai C, C, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. *Journal of Translational Medicine*. 2013;11:262.  
 배제사유 : 동물실험 또는 전임상시험연구
638. Perfilyeva Y V, Ostapchuk Y, O, Abdolla N, Tleulieva R, Krasnoshtanov V, C, Belyaev N, N. Exogenous Melatonin Up-Regulates Expression of CD62L by Lymphocytes in Aged Mice under Inflammatory and Non-Inflammatory Conditions. *Immunological Investigations*. 2019;48(6):632-43.  
 배제사유 : 동물실험 또는 전임상시험연구
639. Perlow H K, Yang L, Zaharoff D. Pancreatic cancer immunotherapy with chitosan/IL-12. *Cancer Research. Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR*. 2014;74(19 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
640. Peron J M, Bureau C, Gourdy P, Lulka H, Souque A, Calippe B, et al. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity. *Gut*. 2007;56(1):107-14.  
 배제사유 : 동물실험 또는 전임상시험연구
641. Petrelli A GS. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. *Current Medicinal Chemistry*. 2008;15(5):422-32.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

642. Petroni D H, Mohan K, Coveler A, Torgerson T, R, Skoda-Smith S. Abnormal newborn SCID screen and lymphopenia in an infant exposed to in utero folfirinnox chemotherapy. *Journal of Allergy and Clinical Immunology*. 2016;1):AB23.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
643. Petty A J, Heyman B, Yang Y. Chimeric antigen receptor cell therapy: Overcoming obstacles to battle cancer. *Cancers*. 2020;12 (4) (842).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
644. Pezzilli R ED, Imbrogno A, Morselli A, M. Circulating lymphocyte subsets in pancreatic adenocarcinoma. *Pancreas*. 2011;40 (8):1348.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
645. Pezzilli R FD, Imbrogno A, Morselli-Labate A, M. Circulating lymphocyte subsets in pancreatic ductal adenocarcinoma. *Digestive and Liver Disease*. 2012;2):S146.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
646. Phan T G, Long G, V, Scolyer R, A. Multiple checkpoints on the long road towards cancer immunotherapy. *Immunology and Cell Biology*. 2015;93(4):323-5.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
647. Pillarisetty V G, Shibuya K, C, Li Y, Leahy A, Whiting S, H, Yee C. Neoadjuvant therapy of pancreatic cancer promotes an antitumor immune response. *Annals of Surgical Oncology*. 2012;1):S20-S1.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
648. Plate J M, Harris J, E. Immune cell functions in pancreatic cancer. *Critical Reviews in Immunology*. 2000;20(5):375-92.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
649. Plate J M, Plate A, E, Shott S, Bograd S, Harris J, E. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. *Cancer Immunology, Immunotherapy*. 2005;54(9):915-25.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
650. Poch B LE, Ramadani M, Gansauge S, Beger H, G, Gansauge F. Systemic immune dysfunction in pancreatic cancer patients. *Langenbecks Archives of Surgery*. 2007;392(3):353-8.  
 배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구
651. Poggi A VS, Zocchi M, R. How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive. *Frontiers in Immunology*. 2018;9 (FEB) (262).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
652. Pol J G, Marguerie M, Arulanandam R, Bell J, C, Lichty B, D. Panorama from the oncolytic virotherapy summit. *Molecular Therapy*. 2013;21(10):1814-8.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
653. Pottier C WA, Roncarati P, Longuespee R, Herfs M, Duray A, Delvenne P, et al. The

importance of the tumor microenvironment in the therapeutic management of cancer. *Expert Review of Anticancer Therapy*. 2015;15(8):943-54.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

654. Pradere J P, Dapito D, H, Schwabe R, F. The Yin and Yang of Toll-like receptors in cancer. *Oncogene*. 2014;33(27):3485-95.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

655. Prizment A E, Nelson H, H, Thyagarajan B, Linabery A, M, Anderson K, E. Plasma MICA and pancreatic cancer. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

656. Quail D F, Joyce J, A. Microenvironmental regulation of tumor progression and metastasis. *Nature Medicine*. 2013;19(11):1423-37.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

657. Quaranta V SM, C. Macrophage-mediated subversion of anti-tumour immunity. *Cells*. 2019;8 (7) (747).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

658. Rabinovich G A, Conejo-Garcia J, R. Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. *Journal of Molecular Biology*. 2016;428(16):3266-81.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

659. Raman K KB. Chemical tumor biology of heparan sulfate proteoglycans. *Current Chemical Biology*. 2010;4(1):20-31.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

660. Randhawa M A, Alghamdi M, S. Anticancer activity of *Nigella sativa* (Black Seed) - A review. *American Journal of Chinese Medicine*. 2011;39(6):1075-91.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

661. Rastelli L GS, Jagga Z, Charych D, H, Zalevsky J. Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors. *Journal of Clinical Oncology*. Conference. 2018;36(15 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

662. Rataj F JS, J, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha B, L, et al. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. *British Journal of Cancer*. 2019;120(1):79-87.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

663. Ravelli A RJ, M, Lanza F, Anfossi S, Cappelletti M, R, Zanotti L, Gobbi A, et al. Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity. *Expert Review of Anticancer Therapy*. 2015;15(6):689-702.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

664. Razumilava N GG, J. Classification, Diagnosis, and Management of Cholangiocarcinoma. *Clinical Gastroenterology and Hepatology*. 2013;11(1):13-21.el.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
665. Real L M, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, et al. Expression of HLA G in human tumors is not a frequent event. *International Journal of Cancer*. 1999;81(4):512-8.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
666. Reddy S P, Harwood R, M, Moore D, F, Grimm E, A, Murray J, L, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: A phase 1 study. *Journal of Immunotherapy*. 1997;20(1):79-87.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
667. Redzovic A LG, Dominovic M, Haller H, Rukavina D. Mucins help to avoid alloreactivity at the maternal fetal interface. *Clinical and Developmental Immunology*. 2013;2013(542152).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
668. Renner C CM, A, Kolibaba J, Liu Y, Petrusch U, Zippelius A, Stenner F, et al. Blocking LILRB and KIR receptors by B57 open conformers induces potent antitumor activity and acts synergistically with checkpoint blockade inhibition. *Journal of Clinical Oncology*. Conference. 2019;37(Supplement 15).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
669. Renner C PM. Tumor therapy by immune recruitment with bispecific antibodies. *Immunological Reviews*. 1995(145):179-209.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
670. Rescigno M AF, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2007;1776(1):108-23.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
671. Reticker-Flynn N E, Martins M, M, Basto P, A, Zhang W, Bejnood A, Gentles A, J, et al. Lymph node colonization promotes distant tumor metastasis through the induction of systemic immune tolerance. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
672. Reyes C M, Teller S, Muckenhuber A, Konukiewitz B, Safak O, Weichert W, et al. Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells. *Clinical Cancer Research*. 2020;26(1):220-31.  
 배제사유 : 동물실험 또는 전임상시험연구
673. Ringden O. Immunotherapy by allogeneic stem cell transplantation. *Advances in Cancer Research*. 2007;97:25-60.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

674. Robinson T O, Schluns K, S. The potential and promise of IL-15 in immuno-oncogenic therapies. *Immunology Letters*. 2017;190:159-68.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
675. Rolfo C GM, Reclusa P, Sirera R, Peeters M. Exosomes in lung cancer liquid biopsies: Two sides of the same coin? *Lung Cancer*. 2017;104:134-5.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
676. Roper J SX. Novel Three-Dimensional Cultures of Patient-Derived Cancer and Tumor Immune Cells. *Gastroenterology*. 2019;157(1):260-1.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
677. Rosental B HU, Brusilovsky M, Campbell K, S, Porgador A. A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. *OncoImmunology*. 2012;1(4):572-4.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
678. Rosewell Shaw A SM. Recent advances in oncolytic adenovirus therapies for cancer. *Current Opinion in Virology*. 2016;21:9-15.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
679. Rothhammer-Hampl T JF, Bauerlein V, Haarstrich C, Heinrichs H, Schneider A. Targeted suppression of TGF-beta2 by trabedersen (AP 12009) in an orthotopic xenograft melanoma mouse model. *Cancer Research*. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR. 2012;72(8 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
680. Roufas C CD, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A. The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: A comprehensive meta-analysis. *Frontiers in Oncology*. 2018;8 (FEB) (27).  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
681. Roy S BA, K, Dutta S, Polavaram N, S, Islam R, Schellenburg S, Banwait J, et al. Macrophage-derived neuropilin-2 exhibits novel tumor-promoting functions. *Cancer Research*. 2018;78(19):5600-17.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
682. Royal R E, Levy C, Turner K, Mathur A, Hughes M, Kammula U, S, et al. Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. *Journal of Immunotherapy*. 2010;33(8):828-33.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
683. Rubio-Patino C BJ, P, Chevet E, Ricci J, E. Reshaping the Immune Tumor Microenvironment Through IRE1 Signaling. *Trends in Molecular Medicine*. 2018;24(7):607-14.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
684. Rucki A A, Zheng L. Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. *World Journal of Gastroenterology*. 2014;20(9):2237-46.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

685. Ruhle P F, Fietkau R, Gaipf U, S, Frey B. Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry. *International Journal of Molecular Sciences*. 2016;17(8):11.

배제사유 : 동물실험 또는 전임상시험연구

686. Ryschich E HG, Wentzensen N, Schmidt E, Knaebel H, P, Encke J, Marten A, et al. Effect of Flt3 ligand gene transfer in experimental pancreatic cancer. *International Journal of Colorectal Disease*. 2007;22(2):215-23.

배제사유 : 동물실험 또는 전임상시험연구

687. Ryschich E JR, Ringel J, Harms W, Fabian O, V, Saller R, Schrewe M, et al. Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation. *International Journal of Cancer*. 2005;113(4):649-53.

배제사유 : NK 세포 활성도를 다루지 않는 연구

688. Saadat N AS, Gill A, Razalli N, Vemuri S, Goja A, Geamanu A, et al. Anticancer effects of garcinol in pancreatic cancer transgenic mouse model. *FASEB Journal. Conference: Experimental Biology*. 2013;27(Meeting Abstracts).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

689. Saadat N AS, Goja A, Razalli N, H, Geamanu A, David D, Shen Y, et al. Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model. *Nutrition and Cancer*. 2018;70(7):1075-87.

배제사유 : 동물실험 또는 전임상시험연구

690. Sachet M LG, Hayden H, Hassler M, Loibner H, Triozzi P, Friedl J. Treatment of a cancer patient by an adoptive cell therapy protocol combining DC vaccination with cbl-b ex vivo silencing. *Journal for ImmunoTherapy of Cancer. Conference: 30th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC*. 2015;3(SUPPL. 2).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

691. Sagnella S M, Yang L, Stubbs G, E, Boslem E, Martino-Echarri E, Smolarczyk K, et al. Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. *Cancer Cell*. 2020;37(3):354-70.e7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

692. Sakai Y MM, Komura T, Yamada T, Nasti A, Yoshida K, Takabatake H, et al. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. *Cancer Science*. 2019;110(3):903-12.

배제사유 : 동물실험 또는 전임상시험연구

693. Sakurai N KT, Suzuki M, Tsumoto K, Takemura S, Kodama H, Ebara S, et al. SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis. *Biochemical & Biophysical Research Communications*. 1999;256(1):223-30.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

694. Salazar M D, Manuel E, Tsai W, D'Apuzzo M, Goldstein L, Blazar B, R, et al. Blockade of checkpoint programmed death 1 (PD1) delays tumor growth and induces early transferable protective immunity in a murine orthotopic pancreatic ductal adenocarcinoma model. *Cancer Immunology Research*. Conference: CRI CIMT EATI AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival. United States. 2016;4(1 Supplement).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
695. Salina D ZT, Katz R, L. Quantitative assessment of tumor infiltrating neutrophils in primary renal cell carcinoma correlates with presence of metastases. *Cancer Research*. Conference: 104th Annual Meeting of the American Association for Cancer Research, AACR. 2013;73(8 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
696. Sallman D A, Brayer J, B, Poire X, Kerre T, Lewalle P, Wang E, S, et al. The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia. *Cancer Research*. Conference. 2018;78(13 Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
697. Salzberg M O, Triozzi P, Kooshki M, Alistar A, T, Bitting R, L, Fenstermaker J, et al. Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors. *Journal of Clinical Oncology*. Conference. 2016;34(Supplement 15).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
698. Sanders K L, Fox B, A, Bzik D, J. Attenuated *Toxoplasma gondii* Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations. *Cancer Immunology Research*. 2015;3(8):891-901.  
 배제사유 : 동물실험 또는 전임상시험연구
699. Sanders K L, Fox B, A, Bzik D, J. Intracellular immunotherapy of disseminated pancreatic cancer activates potent IFN $\gamma$  and CD8 $^{+}$  T cell dependent anti-tumor responses. *Cancer Research*. Conference: AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment. 2014;75(13 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
700. Sarhan D DAP, Lundqvist A. Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system. *International Journal of Molecular Sciences*. 2014;15(10):18557-73.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
701. Sarhan D DC, Sohn S, Nania S, Heuchel R, Lohr M, Karlsson M. Remodeling the tumor microenvironment-targeting scavenger receptors. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
702. Sarhan D. Antibody targeting of tumor associated macrophages in pancreatic cancer and

melanoma remodel the tumor microenvironment and revives immune targeting of tumor cells. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

703. Sarkar C CD, Basu S. Neurotransmitters as regulators of tumor angiogenesis and immunity: The role of catecholamines. *Journal of Neuroimmune Pharmacology*. 2013;8(1):7-14.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

704. Sato T YN, Sasaki H, Takahashi M, Okamoto T, Sakamaki S, Watanabe N, et al. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. *Cancer Research*. 1998;58(8):1677-83.

배제사유 : NK 세포 활성도를 다루었으나 인터페론 감마를 보고하지 않은 연구

705. Sato Y KY, Hirayama M, Matuyama T, Wakimoto H, Hamada H, Nitsu Y. Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients. *Human Gene Therapy*. 1996;7(15):1895-905.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

706. Sayitoglu E C, Georgoudaki A, M, Chrobok M, Ozkazanc D, Josey B, J, Arif M, et al. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. *Frontiers in Immunology*. 2020;11 (40).

배제사유 : 동물실험 또는 전임상시험연구

707. Scheid C YR, McDermott R, Fitzsimmons L, Scarffe J, H, Stern P, L. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. *Cancer Immunology, Immunotherapy*. 1994;38(2):119-26.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

708. Schettini J KA, Besmer D, M, Tinder T, L, Roy L, D, Lustgarten J, Gendler S, J, et al. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. *Cancer Immunology, Immunotherapy*. 2012;61(11):2055-65.

배제사유 : 동물실험 또는 전임상시험연구

709. Schirmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. *Cancer Immunology, Immunotherapy*. 2005;54(6):587-98.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

710. Schlingensiepen K H, Jaschinski F, Lang S, A, Moser C, Geissler E, K, Schlitt H, J, et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. *Cancer Science*. 2011;102(6):1193-200.

배제사유 : 동물실험 또는 전임상시험연구



711. Schmidt J ES, Buchler M, W, Marten A. Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. *Cancer Immunology, Immunotherapy*. 2004;53(11):1018-26.  
배제사유 : 동물실험 또는 전임상시험연구
712. Schmidt J JD, Hoffmann K, Buchler M, W, Marten A. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. *Journal of Immunotherapy*. 2007;30(1):108-15.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
713. Schmidt J PE, M, Ma J, Jager D, Knaebel H, P, Buchler M, W, Marten A. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). *Cancer Immunology, Immunotherapy*. 2006;55(11):1396-405.  
배제사유 : 동물실험 또는 전임상시험연구
714. Schmidt J WT, Jager D, Muhlrad P, F, Buchler M, W, Marten A. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. *British Journal of Cancer*. 2007;97(5):598-604.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
715. Schmidt T WB, Jonat W, Maass N, Wesch D, Keller L, Rocken C, et al. Influence of strength and endurance training on the immune system in breast cancer patients during chemotherapy. *Oncology research and treatment*. 2017;40:226?.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
716. Schmidt T ZC, Marten A, Endres S, Tiemann K, Schmitz V, Gorschluter M, et al. Intratumoral Immunization with Tumor RNA-Pulsed Dendritic Cells Confers Antitumor Immunity in a C57BL/6 Pancreatic Murine Tumor Model. *Cancer Research*. 2003;63(24):8962-7.  
배제사유 : 동물실험 또는 전임상시험연구
717. Schmitz M BM, Ockert D, Rieber E, P. Cancer immunotherapy: Novel strategies and clinical experiences. *Trends in Immunology*. 2002;23(9):428-9.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
718. Schneider C ST, Ziske C, Tiemann K, Lee K, M, Uhlinsky V, Behrens P, et al. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. *Gut*. 2004;53(3):355-61.  
배제사유 : 동물실험 또는 전임상시험연구
719. Schnurr M SC, Rothenfusser S, Galambos P, Dauer M, Robe J, Endres S, et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. *Cancer Research*. 2002;62(8):2347-52.  
배제사유 : 동물실험 또는 전임상시험연구
720. Schoenhals J E, Skrepnik T, Selek U, Cortez M, A, Li A, Welsh J, W. Optimizing

radiotherapy with immunotherapeutic approaches. *Advances in Experimental Medicine and Biology*. 2017;995:53-71.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

721. Scholch S RC, Tietz A, Rahbari N, N, Bork U, Schmidt T, Kahlert C, et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. *Oncotarget*. 2015;6(7):4663-76.

배제사유 : 동물실험 또는 전임상시험연구

722. Schwaiger T KM, R, Grund C, Roemer-Oberdoerfer A, Kapp J, F, Lerch M, M, Mettenleiter T, C, et al. Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity. *International Journal of Cancer*. 2017;141(12):2505-16.

배제사유 : 동물실험 또는 전임상시험연구

723. Schwaiger T KM, Sendler M, Grund C, Romer-Oberdrfer A, Mettenleiter T, C, Lerch M, M, et al. Newcastle disease virus mediated tumor lysis of murine pancreatic adenocarcinoma. *Pancreas*. 2014;43 (8):1406.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

724. Scott K E, N, Cleveland J, L. Lactate Wreaks Havoc on Tumor-Infiltrating T and NK Cells. *Cell Metabolism*. 2016;24(5):649-50.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

725. Seery T E, Kistler M, Sender L, S, Lee J, H, Shinde A, M, Annamalai A, et al. Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer. *Journal of Clinical Oncology*. Conference. 2019;37(Supplement 15).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

726. Segler A TA, M. Lenalidomide in solid tumors. *Cancer Chemotherapy and Pharmacology*. 2012;69(6):1393-406.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

727. Selvan R S, Pappas T, N, Ward F, E. Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells. *British Journal of Cancer*. 2000;82(3):691-701.

배제사유 : NK 세포 활성도를 다루지 않는 연구

728. Selvan S R, Dowling J, P, Kelly W, K, Lin J. Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies. *Current Cancer Drug Targets*. 2016;16(9):755-64.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

729. Semeraro M VE, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. *OncoImmunology*. 2013;2 (11) (e26494).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

730. Sephton S SD. Circadian disruption in cancer: A neuroendocrine-immune pathway from stress to disease? *Brain, Behavior, and Immunity*. 2003;17(5):321-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

731. Sevilla D W, Emmons F, N, Colovai A, I, Beaubier N, T, Baker C, Bhatia M, et al. Hematogones are markedly reduced in pediatric acquired aplastic anemia: Multiparametric flow cytometric analysis. *Leukemia and Lymphoma*. 2009;50(12):1951-7.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

732. Shahid A BM. The connection between the Th17 cell related cytokines and cancer stem cells in cancer: Novel therapeutic targets. *Immunology Letters*. 2019;213:9-20.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

733. Shanker A TM, C, Mishra M, K, Dikov M, M. Innate-adaptive immune crosstalk 2016. *Journal of Immunology Research*. 2017;2017 (3503207).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

734. Sharma S MK, Mettu N, Garrido-Laguna I, Ulahannan S, Khemka V, Kapoun A, et al. Initial results from a phase 1a/b study of etigilimab (OMP- 313M32), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

735. Sheen Y Y, Kim M, J, Park S, A, Park S, Y, Nam J, S. Targeting the transforming growth factor-beta signaling in cancer therapy. *Biomolecules and Therapeutics*. 2013;21(5):323-31.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

736. Shen L LJ, Liu Q, Song W, Zhang X, Tiruthani K, Hu H, et al. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. *Acs Nano*. 2018;12(10):9830-41.

배제사유 : 동물실험 또는 전임상시험연구

737. Shepard H M. Breaching the castle walls: Hyaluronan depletion as a therapeutic approach to cancer therapy. *Frontiers in Oncology*. 2015;5 (Aug) (192).

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

738. Shi P YT, Zhou F, Cui P, Gou S, Wang C. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. *BMC Cancer*. 2014;14:370.

배제사유 : 동물실험 또는 전임상시험연구

739. Shi Z LY, Zhang Y. Anti-cancer efficacy of systemic and intratumoral ys-on-001 as monotherapy or in combination with checkpoint inhibitor in syngeneic cancer models. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

740. Shima K MM, Hayashi H, Nakagawa K, Okada T, Sakata N, Omura N, et al. Potential utility of eGFP-expressing NOG mice (NOG-EGFP) as a high purity cancer sampling

system. Journal of Experimental and Clinical Cancer Research. 2012;31 (1) (55).

배제사유 : 동물실험 또는 전임상시험연구

741. Shimura T TS, Hosouchi Y, Kojima T, Kon Y, Yonezu M, Kuwano H. Clinical significance of soluble form of HLA class I molecule in japanese patients with pancreatic cancer. Human Immunology. 2001;62(6):615-9.

배제사유 : NK 세포 활성도를 다루지 않는 연구

742. Shinohara T MJ, Tada K, Sato Y, Uyama S, Takaue Y, Heike Y. Feasibility study of NK cell therapy against cancer. European Journal of Cancer. 2016;55 (Supplement 1):S21-S2.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

743. Sideras K BH, Kwekkeboom J, van Eijck C, H, Peppelenbosch M, P, Sleijfer S, Bruno M. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treatment Reviews. 2014;40(4):513-22.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

744. Sideras K KJ. Cancer inflammation and inflammatory biomarkers: Can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system? Transplant International. 2014;27(1):28-31.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

745. Sierro S RP, Speiser D, E. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opinion on Therapeutic Targets. 2011;15(1):91-101.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

746. Sierzega M LM, Rutkowska M, Surman M, Mytar B, Matyja A, Siedlar M, et al. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer. Annals of Surgical Oncology. 2017;24(3):808-15.

배제사유 : NK 세포 활성도를 다루지 않는 연구

747. Sievers E NJ, Starkmuth M, Frank S, Strehl J, Schmidt-Wolf I, G, H. Cytotoxicity of a CD94-enriched cell fraction from cytokine-induced killer (CIK) cells against tumor cells. Current Trends in Immunology. 2009;10:41-8.

배제사유 : 동물실험 또는 전임상시험연구

748. Silverman D A, Ashkin E, Whitfield B, Punt S, Manrique S, Z, Wang Y, et al. Tumoral p53 mutations differentially mediate poor T-cell infiltration and autologous T-cell killing in preclinical models. Cancer Research. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

749. Sima P RJ, Vetricka V. Glucans as new anticancer agents. Anticancer Research. 2019;39(7):3373-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

750. Simonson W T, N, Allison K, H. Tumour-infiltrating lymphocytes in cancer: Implications for the diagnostic pathologist. Diagnostic Histopathology. 2011;17(2):80-90.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

751. Sinclair A HR, Giblin P, Huber-Ruano I, Anido J, Pandya N, Hoffman K, et al. MSC-1 is a first-in-class humanized monoclonal antibody that modulates the tumor microenvironment by inhibiting a novel cancer immunotherapy target, LIF. *Cancer Research. Conference.* 2018;78(13 Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
752. Singha N C, Nekoroski T, Zhao C, Symons R, Jiang P, Frost G, et al. Hyaluronan (HA) depletion sensitizes HAhigh tumors to antibody-dependent cell-mediated cytotoxicity. *Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium.* San Antonio, TX United States. Conference Publication: 2015;75(9 SUPPL. 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
753. Sinkovics J G. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). *International Journal of Oncology.* 2012;40(2):305-49.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
754. Siu L L, Burris H, Le D, T, Hollebecque A, Steeghs N, Delord J, P, et al. Preliminary phase 1 profile of BMS- 986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. *Cancer Research. Conference.* 2018;78(13 Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
755. Skvortsova I. Special Issue "Cancer Stem Cells: Impact on Treatment". *Seminars in Cancer Biology.* 2018;53:iii-iv.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
756. Smith R A, Dzugan S, A, Rafique S, Fumagalli L, Lissoni P. Peripheral blood natural killer cell increase as a predictor of survival in metastatic cancer patients treated by neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus melatonin. *International Journal of Immunotherapy.* 1999;15(3-4):131-5.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
757. Soeda A M-HY, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. *Japanese Journal of Clinical Oncology.* 2009;39(12):797-806.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
758. Solinas C PG, Demurtas L, Puzzone M, Mascia R, Morgan G, Giampieri R, et al. Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. *Critical Reviews in Oncology/Hematology.* 2017;110:106-16.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
759. Solis L M, Uraoka N, Parra E, R, Shen Y, Wei W, Jiang M, et al. Characterization of immune profiling of pancreatic intraductal papillary mucinous neoplasm using multiplex immunofluorescence and image analysis approaches. *Cancer Research. Conference.*

2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

760. Song S Y, Kim H, S. Strategies to improve dendritic cell-based immunotherapy against cancer. *Yonsei Medical Journal*. 2004;45 Suppl:48-52.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

761. Song Y GY, Wang Q, Meng Z, Li G, Shen Y, Wu Y, et al. Enriching the Housing Environment for Mice Enhances Their NK Cell Antitumor Immunity via Sympathetic Nerve-Dependent Regulation of NKG2D and CCR5. *Cancer Research*. 2017;77(7):1611-22.

배제사유 : 동물실험 또는 전임상시험연구

762. Soon-Shiong P LJ, Seery T, Kistler M, Shinde A, Annamalai A, Sender L, et al. NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 2).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

763. Soulas C LA, Bonnafous C, Hoffman C, Bonnet E, Dujardin A, Bresó V, et al. NKG2A immune checkpoint blockade potentiates cetuximab induced ADCC in head and neck cancer preclinical model. *Cancer Research*. Conference. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

764. Soulas C RR, Brezar V, Lopez J, Bonnet E, Caraguel F, Lalanne A, et al. Combination of monalizumab and durvalumab as a potent immunotherapy treatment for solid human cancers. *Cancer Research*. Conference. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

765. Sparano J A, Fisher R, I, Weiss G, R, Margolin K, Aronson F, R, Hawkins M, J, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. *Journal of Immunotherapy with Emphasis on Tumor Immunology*. 1994;16(3):216-23.

배제사유 : NK 세포 활성도를 다루지 않는 연구

766. Specht H M, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl U, S, et al. Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - From preclinical studies to a clinical phase II trial. *Frontiers in Immunology*. 2015;6 (APR) (162).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

767. Spolski R LW, J. Interleukin-21: Basic biology and implications for cancer and autoimmunity. *Annual Review of Immunology*. 2008;26:57-79.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

768. Srinivasan V SD, W, Pandi-Perumal S, R, Trakht I, Cardinali D, P. Therapeutic actions of melatonin in cancer: Possible mechanisms. *Integrative Cancer Therapies*.

2008;7(3):189-203.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

769. Stangl S WA, Guertler U, Multhoff G. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. *Journal of Immunology*. 2006;176(10):6270-6.

배제사유 : 동물실험 또는 전임상시험연구

770. Stauder H KE, D. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: Current state of clinical research. *Onkologie*. 2002;25(4):374-80.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

771. Stecklum M W-GA, Paterka M, Brzezicha B, Fichtner I, Hoffmann J. Humanized immune-PDX mouse models for 10 different tumor entities in translational immuno-oncology research. *Cancer Research. Conference*. 2018;78(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

772. Steinhoff M S, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett N, W. Tachykinins and their receptors: Contributions to physiological control and the mechanisms of disease. *Physiological Reviews*. 2014;94(1):265-301.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

773. Steintraesser L KT, Jacobsen F, Daigeler A, Goertz O, Langer S, Kesting M, et al. Host defense peptides in wound healing. *Molecular Medicine*. 2008;14(7-8):528-37.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

774. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. *Nature Reviews Cancer*. 2002;2(7):514-20.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

775. Stiff A TP, Mundy-Bosse B, McMichael E, Mace T, A, Benner B, Kendra K, et al. Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. *Clinical Cancer Research*. 2018;24(8):1891-904.

배제사유 : 동물실험 또는 전임상시험연구

776. Stritzker J SA, A. Single-agent combinatorial cancer therapy. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(21):8325-6.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

777. Sugiura H IH, Omi M, Kaji M, Iwai K, Kishimoto T, Takahashi T, et al. Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell lines and vascular endothelial cells. *Pathology International*. 1994;44(9):688-96.

배제사유 : 동물실험 또는 전임상시험연구

778. Sugiura H. [LAK sensitivity of human pancreas carcinoma cell lines]. *Hokkaido Igaku Zasshi - Hokkaido Journal of Medical Science*. 1993;68(6):921-34.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

779. Sun H SK, Qi K, Kong H, Zhang J, Dai S, Ye W, et al. Corrigendum: Natural Killer

Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. *Frontiers in Immunology*. 2020;11:277.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

780. Sun H SK, Qi K, Kong H, Zhang J, Dai S, Ye W, et al. Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. *Frontiers in Immunology*. 2019;10:2819.

배제사유 : 동물실험 또는 전임상시험연구

781. Sun W LS, Li H, Cui W, Wang L. Enhancing the anticancer efficacy of immunotherapy through combination with histone modification inhibitors. *Genes*. 2018;9 (12) (633).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

782. Sunami Y KJ. Immunotherapy of pancreatic cancer. *Progress in Molecular Biology & Translational Science*. 2019;164:189-216.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

783. Sunamura M DD, G, Shimamura H, Motoi F, Yatsuoka T, Shibuya K, Takeda K, et al. Tumor dormancy therapy using genetically engineered drug delivery system. [Japanesel. *Japanese Journal of Gastroenterological Surgery*. 2001;34(4):425-30.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

784. Sunamura M SL, Lozonschi L, Duda D, G, Kodama T, Matsumoto G, Shimamura H, et al. The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice. *Pancreas*. 2000;20(3):227-33.

배제사유 : 동물실험 또는 전임상시험연구

785. Suzuki D FK, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, et al. Effects of perioperative immunonutrition on cell-mediated immunity, T helper type 1 (Th1)/Th2 differentiation, and Th17 response after pancreaticoduodenectomy. *Surgery*. 2010;148(3):573-81.

배제사유 : NK 세포 활성도를 다루지 않는 연구

786. Suzumiya J TM, Kimura N, Morioka E, Sakai T, Hisano S, Okumura M, et al. Sinonasal malignant lymphoma of natural killer cell phenotype associated with diffuse pancreatic involvement. *Leukemia & Lymphoma*. 1993;10(3):231-6.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

787. Svensson E MI, Moreno R, Alemany R, Loskog A. CD40L/4-1BBL-expressing oncolytic adenovirus (LOAd703) stimulates human dendritic cell production of Th1 cytokines and antigen-specific T cells. *Human Gene Therapy*. 2015;26 (10):A58-A9.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

788. Svensson E MI, Moreno R, Alemany R, Loskog A. Immunotherapy with a CD40L/4-1BBL double-armed oncolytic adenovirus drives Th1 immunity and control tumor progression in a pancreas cancer model. *Cancer Research*. Conference: 106th Annual Meeting of the American Association for Cancer Research, AACR. 2015;75(15 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

789. Svensson E MR, Milenova L, Christiansson L, Alemany R, Loskog A. Immunotherapy



using LOAd700 armed with CD40 ligand controls experimental pancreatic cancer and activates immune responses. *Cancer Immunology Research*. Conference: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter. United States. 2015;3(10 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

790. Svensson E WJ, Milenova I, Moreno R, Alemany R, Loskog A. CD40L and 4-1BBL immunostimulating gene therapy reduces myeloid-derived suppressor cells (MDSCs) while promoting T and NK cell activation. *Human Gene Therapy*. 2015;26 (10):A53.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

791. Swaminathan S HA, S, Heftdal L, D, Dhanasekaran R, Deutzmann A, Fernandez W, D, M, Liefwalker D, F, et al. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. *Nature Communications*. 2020;11 (1) (2860).

배제사유 : 동물실험 또는 전임상시험연구

792. Sznol M CL. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. *Clinical Cancer Research*. 2013;19(5):1021-34.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

793. Tai C J, Wang H, Wang C, K, Tai C, J, Huang M, T, Wu C, H, et al. Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. *Clinical & Experimental Medicine*. 2017;17(2):141-50.

배제사유 : 동물실험 또는 전임상시험연구

794. Tajima H MI, Ohbatake Y, Nakanuma S, Hayashi H, Nakagawara H, Miyashita T, et al. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. *Oncology Letters*. 2017;13(6):3975-81.

배제사유 : NK 세포 활성도를 다루지 않는 연구

795. Takahashi K SS, Yanagimoto H, Terakawa N, Toyokawa H, Yamamoto T, Matsui Y, et al. Circulating dendritic cells and development of septic complications after pancreatectomy for pancreatic cancer. *Archives of Surgery*. 2007;142(12):1151-7; discussion 7.

배제사유 : NK 세포 활성도를 다루지 않는 연구

796. Takahashi K TH, Takai S, Satoi S, Yanagimoto H, Terakawa N, Araki H, et al. Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. *Cancer Immunology, Immunotherapy*. 2006;55(7):775-84.

배제사유 : NK 세포 활성도를 다루지 않는 연구

797. Takahashi T IH, Iwai K, Takahashi C, Kato H, Tanabe T, Yoshiki T. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro. *Cancer Immunology, Immunotherapy*. 1993;36(2):76-82.

배제사유 : 동물실험 또는 전임상시험연구

798. Takahashi T MY, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. *Journal of Immunology*. 1994;153(5):2102-9.

배제사유 : 동물실험 또는 전임상시험연구

799. Tal Y YS, Horovitz-Fried M, Safyon E, Rosental B, Porgador A, Cohen C, J. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. *Oncotarget*. 2014;5(21):10949-58.

배제사유 : 동물실험 또는 전임상시험연구

800. Tamura H OK, Mori S, An E, Tajika K, Sugisaki Y, Dan K. Lymphoblastic lymphoma of natural killer cell origin, presenting as pancreatic tumour. *Histopathology*. 1998;32(6):508-11.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

801. Tebbutt N PM, W, Johns T, G. Targeting the ERBB family in cancer: Couples therapy. *Nature Reviews Cancer*. 2013;13(9):663-73.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

802. Tempero M A, Haga Y, Sivinski C, Stepwski Z, Kay H, D, Pour P. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma. *International Journal of Pancreatology*. 1991;9:125-34.

배제사유 : 동물실험 또는 전임상시험연구

803. Teplow D B. Preface. *Progress in Molecular Biology and Translational Science*. 2019;164:xiii-xvi.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

804. Teraoka Y IK, Morimoto H, Ohdan H. Genetic induction of recipient CD47 on xenografts prevents macrophage-mediated rejection through CD47-sirpalph inhibitory signaling: Evidence from an in vivo xenograft model. *American Journal of Transplantation*. 2012;3):149.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

805. Teraoka Y IK, Morimoto H, Ohdan H. Necessity for genetic induction of recipient CD47 to prevent macrophage-mediated xenograft rejection through CD47-sirpalph inhibitory signaling. *Transplantation*. 2012;10S):98.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

806. Teraoka Y IK, Morimoto H, Ohdan H. Necessity for genetic induction of recipient CD47 to prevents macrophage-mediated xenograft rejection through CD47-sirpalph inhibitory signaling. *Transplantation*. 2012;10S):777.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

807. Teraoka Y IK, Morimoto H, Tahara H, Ohdan H. Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPa inhibitory signaling in mice. *Xenotransplantation*. 2013;20 (5):363.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

808. Teraoka Y IK, Morimoto H, Tahara H, Ohdan H. Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPalph inhibitory signaling in mice. *PLoS ONE [Electronic Resource]*. 2013;8(3):e58359.

배제사유 : 동물실험 또는 전임상시험연구

809. Teraoka Y IK, Tahara H, Basnet N, Morimoto H, Ohdan H. Genetic induction of mouse CD47 on rat insulinoma cells prevents macrophage-mediated xenograft rejection through CD47-SIRPalpha inhibitory signaling in mice. *American Journal of Transplantation*. 2011;2):107.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
810. Terunuma H DX, Nishino N, Watanabe K. NK cell-based autologous immune enhancement therapy (AIET) for cancer. *Journal of Stem Cells & Regenerative Medicine*. 2013;9(1):9-13.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
811. Textor S BF, Henrich K, O, Gartlgruber M, Pollmann J, Fiegler N, Arnold A, et al. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. *Oncoimmunology*. 2016;5(7):e1116674.  
 배제사유 : 동물실험 또는 전임상시험연구
812. Thakur A SD, Tomaszewski E, Kondadasula S, V, Yano H, Sarkar F, H, Lum L, G. Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. *Journal of Translational Medicine*. 2013;11:35.  
 배제사유 : 동물실험 또는 전임상시험연구
813. Thiel A EM, Anlauf M, Raffel A, Stoecklein N, H, Schott M. The immune system in neuroendocrine tumors. *Hormone and Metabolic Research*. 2011;43(12):890-6.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
814. Thompson B KT, Blouw B, Clift R, Huang Y, Rosengren S, Thompson C, B, et al. Increasing tumor-infiltrating CD8+ T cell response and checkpoint inhibitor efficacy by enzymatic reduction of tumor hyaluronan in a murine syngeneic pancreatic cancer model. *Cancer Immunology Research*. Conference. 2017;6(9 Supplement).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
815. Thompson B KT, Lee J, Zhao C, Chen K, Clift R, Thompson C, B, et al. Hyaluronan (HA) accumulation restricts CD8+ T cell numbers and skews tumor-associated macrophage (TAM) phenotype in mouse syngeneic pancreatic tumors. *Cancer Research*. Conference. 2018;78(13 Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
816. Thompson B. Oncolytics Biotech◆ Inc.: REOLYSIN◆ for melanoma therapy. *Melanoma Management*. 2015;2(2):105-7.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
817. Thyphronitis G KM. Boosting the immune response: An alternative combination therapy for cancer patients. *Anticancer Research*. 2004;24(4):2443-53.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
818. Toriello H V. Policy statement on folic acid and neural tube defects. *Genetics in Medicine*. 2011;13(6):593-6.  
 배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

819. Torphy R J, Schulick R, D, Zhu Y. Newly emerging immune checkpoints: Promises for future cancer therapy. *International Journal of Molecular Sciences*. 2017;18 (12) (2642).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
820. Torsvik A BR. Mesenchymal stem cell signaling in cancer progression. *Cancer Treatment Reviews*. 2013;39(2):180-8.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
821. Trauzold A SS, Oestern S, Christgen M, Westphal S, Roederm C, Kalthoff H. Concerted deregulations of multiple apoptosis-controlling genes in pancreatic carcinoma cells. *Annals of the New York Academy of Sciences*. 2003;1010:510-3.  
배제사유 : 동물실험 또는 전임상시험연구
822. Tsang K FM, Hodge J, W, Fujii R, Fernando I, Jochems C, Heery C, et al. haNK, a cytotoxic human high affinity natural killer cell line, exerts enhanced ADCC mediated by avelumab (an anti-PD-L1 antibody) against multiple human tumor cell lines. *Journal for ImmunoTherapy of Cancer*. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC. 2016;4(Supplement 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
823. Tsang K Y, Fantini M, Fernando R, I, Palena C, David J, M, Hodge J, W, et al. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. *Vaccine*. 2017;35(19):2605-11.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
824. Tseng H C, Bui V, Man Y, G, Cacalano N, Jewett A. Induction of split energy conditions natural killer cells to promote differentiation of stem cells through cell-cell contact and secreted factors. *Frontiers in Immunology*. 2014;5 (JUN) (Article 269).  
배제사유 : 동물실험 또는 전임상시험연구
825. Turnquist H R, Lin X, Ashour A, E, Hollingsworth M, A, Singh R, K, Talmadge J, E, et al. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. *International Journal of Oncology*. 2007;30(3):631-9.  
배제사유 : 동물실험 또는 전임상시험연구
826. Turriziani M FM, Benvenuto M, Izzi V, Masuelli L, Sacchetti P, Modesti A, et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials. *Recent Patents on Anti-Cancer Drug Discovery*. 2012;7(3):265-96.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
827. Ueda J KK, Fujii T, Yamahatsu K, Suzuki T, Matsuda Y, Uchida E, et al. Establishment of novel human pancreatic cancer cell lines from liver and lung metastases in NOD/SCID/gammac null (NOG) mice. *Cancer Research*. Conference: 102nd Annual Meeting of the American Association for Cancer Research, AACR. 2011;71(8 SUPPL. 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
828. Ugai S SO, Yu L, Wang Y, Q, Kawamura K, Yamamoto H, Yamaguchi T, et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells

produces natural killer cell-dependent and -independent antitumor effects. *Cancer Gene Therapy*. 2003;10(10):771-8.

배제사유 : 동물실험 또는 전임상시험연구

829. Ullenhag G J, Mozaffari F, Broberg M, Mellstedt H, Liljefors M. Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. *PLoS ONE [Electronic Resource]*. 2017;12(1):e0169736.

배제사유 : NK 세포 활성도를 다루지 않는 연구

830. Ullrich E BM, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. *Cell Death and Differentiation*. 2008;15(1):21-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

831. Uram J N, Le D, T. Current advances in immunotherapy for pancreatic cancer. *Current Problems in Cancer*. 2013;37(5):273-9.

배제사유 : NK 세포 활성도를 다루지 않는 연구

832. Uyangaa E, Choi JY, Ryu HW, Oh SR, Eo SK. Anti-herpes Activity of Vinegar-processed *Daphne genkwa* Flos Via Enhancement of Natural Killer Cell Activity. *Immune Netw*. 2015;15(2):91-9.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

833. Vaccheli E MJ, Hadoux J, Lotz J, P. American Association for Cancer Research - AACR congress 2014. [French]. *Oncologie*. 2014;16(7-8):341-66.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

834. Vaishampayan U MJ, Velcheti V, Hoimes C, Gilbert L, McDermott D, Spreafico A, et al. ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

835. Van Audenaerde J R, M, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh J, M, J, et al. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. *Oncotarget*. 2017;8(34):56968-79.

배제사유 : 동물실험 또는 전임상시험연구

836. Van Audenaerde J R, M, Roeyen G, Darcy P, K, Kershaw M, H, Peeters M, Smits E, L, J. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. *Pharmacology & Therapeutics*. 2018;189:31-44.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

837. Van Audenaerde J VSB, Unsworth A, Marcq E, Oliver A, Slaney C, Darcy P, et al. Anti-tumoural effects of IL-15 and CD40 stimulation as a novel combination immunotherapy for pancreatic cancer. *ESMO Open*. 2018;3 (Supplement 2):A393-A4.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

838. Vance K E, Hollingsworth M, A, Grandgenett P. Identifying site-specific disparities in the

tumor microenvironment of primary and metastatic disease. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

839. Vazquez-Lombardi R RB, Christ D. Molecular engineering of therapeutic cytokines. *Antibodies*. 2013;2(3):426-51.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

840. Vemuri S GA, Sadaat N, Gowthaman P, Chrusciel M, Gupta S. Effect of oil palm phenolics (OPP) on pancreatic cancer (PC) in transgenic mouse model (KPC). *FASEB Journal*. Conference: Experimental Biology. 2013;27(Meeting Abstracts).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

841. Vendetti S CR, Piselli P, Vismara D, Cassol M, Delpino A. Induction and membrane expression of heat shock proteins in heat-treated HPC-4 cells is correlated with increased resistance to LAK-mediated lysis. *Journal of Experimental & Clinical Cancer Research*. 2000;19(3):329-34.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

842. Vendramini-Costa D B, Carvalho J, E. Molecular link mechanisms between inflammation and cancer. *Current Pharmaceutical Design*. 2012;18(26):3831-52.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

843. Venkatesulu B P, Kim B, K, Hsieh C, E, Sharma A, Regan S, N, Sanders K, L, et al. Rescues Lymphopenia and Adverse Tumor Control Outcomes Following Splenic Radiation in Murine Pancreatic Cancer Models. *International Journal of Radiation Oncology Biology Physics*. 2019;105 (1 Supplement):E248-E9.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

844. Vennin C HD, Lucas M, C, Timpson P. Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression. *F1000Research*. 2016;5 (892).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

845. Verma B AP, G, Awada A, Machiels J, P, H, Brayer J, B, Sallman D, A, Kerre T, et al. A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types. *Journal of Clinical Oncology*. Conference. 2017;35(15 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

846. Vey N KL, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, et al. A phase 1 study of lirilumab (antibody against killer immunoglobulinlike receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget*. 2018;9(25):17675-88.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

847. Vidal-Vanaclocha F ML, Telleria N, Salado C, Valcarcel M, Gallot N, Carrascal T, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. *Cancer and Metastasis Reviews*. 2006;25(3):417-34.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

848. Wachsmann M B, Pop L, Brekken R, Vitetta E. Characterization of human pancreatic cell lines for targeted therapy in a xenograft model of human pancreatic cancer. *Journal of Investigative Medicine*. 2011;59 (2):432.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

849. Wachsmann M B, Pop L, M, Vitetta E, S. Pancreatic ductal adenocarcinoma: A review of immunologic aspects. *Journal of Investigative Medicine*. 2012;60(4):643-63.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

850. Wagner K SP, Scholz A, Wiedenmann B, Menrad A. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. *Clinical Cancer Research*. 2008;14(15):4951-60.

배제사유 : NK 세포 활성도를 다루지 않는 연구

851. Wahab Z A, Metzgar R, S. Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells. *Pancreas*. 1991;6(3):307-17.

배제사유 : 동물실험 또는 전임상시험연구

852. Waidhauser J SA, Trepel M, Schmalter A, K, Rank A. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. *Cancer Immunology, Immunotherapy*. 2020;69(1):147-57.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

853. Wald N CJ, Mercier M, Nyawouame F, Brouwer M, Houthuys E, Driessens G, et al. Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer Part. 2019;7(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

854. Wald N MM, Cuende J, Nyawouame F, Prasad S, Brouwer M, Houthuys E, et al. TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity. *Cancer Research*. Conference: American Association for Cancer Research Annual Meeting. 2019;79(13 Supplement).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

855. Waldner M J, Neurath M, F. Gene therapy using IL-12 family members in infection, auto-immunity, and cancer. *Current Gene Therapy*. 2009;9(4):239-47.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

856. Walsh R J, Soo R, A. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. *Therapeutic Advances in Medical Oncology*. 2020;12.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

857. Wang C J, Wang C, Han J, Wang Y, K, Tang L, Shen D, W, et al. Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer. *Molecular Biology Reports*. 2013;40(12):6579-85.

배제사유 : 동물실험 또는 전임상시험연구

858. Wang H WC, K, Tai C, J, Huang M, T, Wu C, H, Chen R, J, Kuo L, J, et al. Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. *Clinical and Experimental Medicine*. 2017;17(2):141-50.

배제사유 : 동물실험 또는 전임상시험연구

859. Wang Q GX, Yuan Z, Wang Z, Meng Y, Cao Y, Plotnikoff N, P, et al. Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs). *Human Vaccines and Immunotherapeutics*. 2014;10(7):1836-40.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

860. Wang W J, Qin S, H, Zhang J, W, Jiang Y, Y, Zhang J, N, Zhao L. Combination doxorubicin and interferon-alpha therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2014;15(22):9667-72.

배제사유 : 동물실험 또는 전임상시험연구

861. Wang X SJ. High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. *Chinese Medical Journal*. 2002;115(9):1332-5.

배제사유 : NK 세포 활성도를 다루지 않는 연구

862. Wang Z WT, Ma M, Zhang Z, Fu Y, Liu J, Xu J, et al. Elevated interferon-gamma-induced protein 10 and its receptor CXCR3 impair NK cell function during HIV infection. *Journal of Leukocyte Biology*. 2017;102(1):163-70.

배제사유 : 동물실험 또는 전임상시험연구

863. Wang-Gillam A PV, Crocenzi T, Morse M, Zeh H, Fine R, Murphy A, et al. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study). *Journal for ImmunoTherapy of Cancer*. Conference: 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, SITC. 2014;2(SUPPL. 3).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

864. Wasser S P. Medicinal mushrooms in human clinical studies. Part I. anticancer, oncoimmunological, and immunomodulatory activities: A review. *International Journal of Medicinal Mushrooms*. 2017;19(4):279-317.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

865. Watt J KH, M. The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. *Oncoimmunology*. 2013;2(12):e26788.

배제사유 : NK 세포 활성도를 다루지 않는 연구

866. Way M AS, A. JCS editor changes. *Journal of Cell Science*. 2015;128(5):831.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

867. Wei D G, Lee H, Park S, H, Beaudoin L, Teyton L, Lehuen A, et al. Expansion and



long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. *Journal of Experimental Medicine*. 2005;202(2):239-48.

배제사유 : NK 세포 활성도를 다루지 않는 연구

868. Wei X CF, Xin K, Wang Q, Yu L, Liu B, Liu Q. Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects. *Translational Oncology*. 2019;12(5):733-8.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

869. Weidmann E BL, Hechler P, Mitrou P, S. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2. *Cancer Immunology, Immunotherapy*. 1991;33(6):398-402.

배제사유 : 동물실험 또는 전임상시험연구

870. Weiner L FA, Wang S. Fibroblast activation protein is expressed by human and murine leukocytes and nonspecific inhibition of FAP enhances anti-PD-1 therapy in murine models of PDAC. *Journal for ImmunoTherapy of Cancer*. Conference: 34th Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2019;7(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

871. Weiner L WS, O'Connell A. The potential role of fibroblast activation protein as a natural killer cell immune checkpoint in pancreatic cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

872. Wenthe J EE, Milenova I, Moreno R, Alemany R, Loskog A. A novel oncolytic adenovirus expressing tumor microenvironment stimulators to evoke and facilitate anti-tumor immune responses. *Molecular Therapy*. 2016;1):S206.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

873. Wesch D ML, Kabelitz D. Regulation of cytokine production by gammadelta T cells. *Current Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents*. 2005;4(2):153-60.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

874. Westwood J A, Berry L, J, Wang L, X, Duong C, P, Pegram H, J, Darcy P, K, et al. Enhancing adoptive immunotherapy of cancer. *Expert Opinion on Biological Therapy*. 2010;10(4):531-45.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

875. Wettersten H I, Weis S, M, Pathria P, Schalscha T, V, Minami T, Varner J, A, et al. Arming tumor-associated macrophages to reverse epithelial cancer progression. *Cancer Research*. 2019;79(19):5048-59.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

876. White P B, Dalbec K, M, True E, M, Wang S, S, Swartz-Basile D, A, Pitt H, A, et al. Does body weight influence tumor-infiltrating B cells in murine pancreatic cancer. *Cancer Research*. Conference: 101st Annual Meeting of the American Association for

Cancer Research, AACR. 2010;70(8 SUPPL. 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

877. White S B, Zhang Z, Chen J, Gogineni V, R, Larson A, C. Early Immunologic Response of Irreversible Electroporation versus Cryoablation in a Rodent Model of Pancreatic Cancer. *Journal of Vascular & Interventional Radiology*. 2018;29(12):1764-9.

배제사유 : 동물실험 또는 전임상시험연구

878. Wrobel P SH, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. *Scandinavian Journal of Immunology*. 2007;66(2-3):320-8.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

879. Wu L LW, Galustian C, Schafer P, Dalgleish A, G, Bartlett J, B. Effect of lenalidomide on the antiproliferative effect of gemcitabine against pancreatic tumor cells and on immune-mediated pancreatic cancer cell death. *Journal of Clinical Oncology*. 2009;1):e14635.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

880. Wu S Y, Guo P, Peng T, Xu J, Hou Q, Q, Sun X, et al. HSF1: A potential target for therapeutic intervention in cancer. *International Journal of Clinical and Experimental Medicine*. 2017;10(3):5637-48.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

881. Wurfel F M, Winterhalter C, Trenkwalder P, Wirtz R, M, Wurfel W. European patent in immunoncology: From immunological principles of implantation to cancer treatment. *International Journal of Molecular Sciences*. 2019;20 (8) (1830).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

882. Xia N HP, Gong J, U, Lu J, Chen Z, Zheng Y, Wang Z, et al. Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of 125 I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma. *Anticancer Research*. 2019;39(11):5919-25.

배제사유 : 동물실험 또는 전임상시험연구

883. Xie X ML, Zhou Y, Shen W, Xu D, Dou J, Shen B, et al. Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-kappaB pathway in vitro/vivo. *Carbohydrate Polymers*. 2019;225:115223.

배제사유 : 동물실험 또는 전임상시험연구

884. Xu H ZX, X, Chen J. DNT cell inhibits the growth of pancreatic carcinoma via abnormal expressions of NKG2D and MICA in vivo. *Biochemical & Biophysical Research Communications*. 2016;469(2):145-50.

배제사유 : 동물실험 또는 전임상시험연구

885. Xu T JH, Cao F, Lei J, Tai Y, Li Y, Di Q, et al. Clinical efficacy of HIFU combined with concurrent gemcitabine chemotherapy and DC-CIK in treatment of advanced pancreatic cancer. [Chinese]. *Journal of Practical Oncology*. 2018;33(5):416-20.

배제사유 : 한국어 또는 영어로 출판되지 않은 연구

886. Xu X RG, S, Groh V, Spies T, Gattuso P, Kaufman H, L, Plate J, et al. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. *BMC Cancer*. 2011;11:194.  
배제사유 : 동물실험 또는 전임상시험연구
887. Xu Y F, Lu Y, Cheng H, Shi S, Xu J, Long J, et al. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. *Pancreatology*. 2014;14(4):295-301.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
888. Xu Y F, Lu Y, Cheng H, Shi S, Xu J, Long J, et al. The prognostic roles of peripheral lymphocyte subsets obtained from pancreatic ductal adenocarcinoma patients. *Pancreas*. 2014;43 (8):1424.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
889. Xu Z Y, Zhou C, Zhang K, F, Zheng Y, P. Identification of key genes in Ankylosing spondylitis. *Immunology Letters*. 2018;204:60-6.  
배제사유 : 동물실험 또는 전임상시험연구
890. Yahara N OM. [Immunotherapy for unresectable pancreatic cancer]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 2002;29(3):390-7.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
891. Yamada S. Anti-podocalyxin cancer-specific monoclonal antibody: Preclinical study. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
892. Yamaguchi Y KY, Okawaki M, Sawaki A, Yamamura M. A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer. *Anticancer Research*. 2016;36(5):2307-13.  
배제사유 : 동물실험 또는 전임상시험연구
893. Yamamoto M KT, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, et al. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. *Oncology Reports*. 2009;22(2):337-43.  
배제사유 : 동물실험 또는 전임상시험연구
894. Yamasaki A YK, Onishi H. Hypoxia and pancreatic ductal adenocarcinoma. *Cancer Letters*. 2020;484:9-15.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
895. Yamaue H MM, Katsuda M, Kawai M, Hirono S, Okada K, I, Kitahata Y, et al. The development of therapeutic cancer vaccine for pancreatic cancer. *Journal of Clinical Oncology. Conference*. 2020;38(4 Supplement).  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

896. Yamaue H TH, Aoki Y, Tsunoda T, Iwahashi M, Tani M, Tamai M, et al. Clinical and immunological evaluation of intraoperative radiation therapy for patients with unresectable pancreatic cancer. *Journal of Surgical Oncology*. 1992;49(1):10-5.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구
897. Yamaue H TH, Tsunoda T, Iwahashi M, Tani M, Inoue M, Tamai M. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes]. *Nippon Gan Chiryō Gakkai Shi - Journal of Japan Society for Cancer Therapy*. 1990;25(5):978-89.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
898. Yamaue H TH, Tsunoda T, Iwahashi M, Tani M, Tamai M, Inoue M. Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes. *Biotherapy*. 1990;2(3):247-59.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
899. Yang C CH, Zhang Y, Fan K, Luo G, Fan Z, Huang Q, et al. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. *Cancer Immunology, Immunotherapy*. 2018;67(12):1815-23.  
 배제사유 : NK 세포 활성도 측정 시 인터페론 감마를 평가대상 검사기술로 측정하지 않은 연구
900. Yang L YH, Dong S, Zhong Y, Hu S. Recognizing and managing on toxicities in cancer immunotherapy. *Tumor Biology*. 2017;39(3).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
901. Yang M WS, Y. The advances and challenges in utilizing exosomes for delivering cancer therapeutics. *Frontiers in Pharmacology*. 2018;9 (JUL) (735).  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
902. Yang Y SA, Schweickert P, G, Lanman N, A, Paul E, N, Monia B, P, Revenko A, S, et al. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion. *Cancer Research*. 2019;79(13):3417-30.  
 배제사유 : 동물실험 또는 전임상시험연구
903. Yao Y R, Wang Y, Liu J, Q, Chen F, X, Zhou Z, H. Explore the effect and mechanism of betulinic acid on NK cells killing pancreatic cancer SW1990 cells. [Chinese]. *Chinese Journal of Cancer Prevention and Treatment*. 2015;22(1):34-8.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
904. Yokoyama Y NM, I, Ottoson N, C, Kirstein M, N, Walsh R, Michel K, S, Danielson M, E, et al. Immune cell priming and potentiation of anti-tumor effects by Imprime PGG. *Cancer Research*. 2013;1):98DUMMY.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
905. Yonemaru J TM, Nara S, Ichikawa H, Ishigamori R, Imai T, Hiraoka N. A yolk sac tumor of the pancreas and derived xenograft model effectively responded to VIP chemotherapy. *Pancreatology*. 2020;20(3):551-7.  
 배제사유 : NK 세포 활성도를 다루지 않는 연구

906. Yonezawa A DS, Chester C, Kim J, Kohrt H, E. Boosting cancer immunotherapy with anti-CD137 antibody therapy. *Clinical Cancer Research*. 2015;21(14):3113-20.  
 배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)
907. Yoshida Y TK, Miyauchi M, Narita M, Takenaga K, Yamamoto H, Yaaguchi T, et al. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene. *Cancer Gene Therapy*. 2000;7(2):324-31.  
 배제사유 : 동물실험 또는 전임상시험연구
908. Yoshino S OM, Hazama S, Suzuki T. [Effect of intrapleural and/or intraperitoneal lentinan therapy in carcinomatous pleuritis and peritonitis]. *Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]*. 1990;17(8 Pt 2):1588-91.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
909. Yoshino S OM, Hazama S, Suzuki T. [Effect of intrapleural and/or intraperitoneal lentinan therapy on carcinomatous pleuritis and peritonitis with special reference to immunological evaluation]. *Nippon Geka Hokan - Archiv fur Japanische Chirurgie*. 1989;58(3):310-9.  
 배제사유 : 한국어 또는 영어로 출판되지 않은 연구
910. Yu J RG, R, Delman D, Li J, Kolhe R, Munn D, H, Bahary N, et al. Effects of indoximod plus gemcitabine/nab-paclitaxel on tumor microenvironment of patients with metastatic pancreas cancer. *Journal for ImmunoTherapy of Cancer*. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC. 2018;6(Supplement 2).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
911. Yule M DK, Bloe M, Hodneland L, Engelsen A, Lie M, Bougnaud S, et al. Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung. *Journal of Clinical Oncology*. Conference. 2018;36(5 Supplement 1).  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
912. Zaharoff D A, Hance K, W, Rogers C, J, Schlom J, Greiner J, W. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. *Journal of Immunotherapy*. 2010;33(7):697-705.  
 배제사유 : 동물실험 또는 전임상시험연구
913. Zaharoff D A, Hance K, W, Rogers C, J, Schlom J, Greiner J, W. Intratumoral immunotherapy with chitosan/EL-12 eradicates established tumors and elicits durable, tumor-specific immune responses. *Journal of Immunotherapy*. 2009;32 (9):965-6.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
914. Zaravinos A RK, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C. Prognostic impact of immune cytolytic activity and its association with checkpoint molecules and TIL/TAN load in human malignancies. *FEBS Open Bio*. 2018;8 (Supplement 1):301.  
 배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
915. Zarkavelis G KA, Pentheroudakis G. The emerging role of Interleukin-21 as an

antineoplastic immunomodulatory treatment option. *Translational Cancer Research*. 2017;6(Supplement2):S328-S330.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

916. Zeligs K AP, M, Tsang K, Hernandez L, Fantini M, Annunziata C, M. Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies. *Cancer Research. Conference: American Association for Cancer Research Annual Meeting*. 2017;77(13 Supplement 1).

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

917. Zeligs K P, Morelli M, P, David J, M, Neuman M, Hernandez L, Hewitt S, et al. Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer. *Frontiers in Oncology*. 2020;10:805.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

918. Zeniya M DM, Arashiyama Y, Aizawa Y, Kameda H, Miyazaki H, Watanabe R. Immunological effects of oral administration of the streptococcal preparation OK-432 on gastrointestinal malignancies. *Jikeikai Medical Journal*. 1989;36(1):55-62.

배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구

919. Zgodzinski W WG, Dabrowski A. Angiogenesis inhibitors. New anticancer strategy. *Polish Journal of Pharmacology*. 1999;51(6):455-62.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

920. Zhan Y LA, M, Chopin M. The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game. *Frontiers in Immunology*. 2019;10 (2679).

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

921. Zhang L HY, Lindstrom A, R, Lin T, Y, Lam K, S, Li Y. Peptide-based materials for cancer immunotherapy. *Theranostics*. 2019;9(25):7807-25.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

922. Zhang W H, Wang W, Q, Gao H, L, Xu S, S, Li S, Li T, J, et al. Tumor-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumor. *The Journal of clinical endocrinology and metabolism*. 2020;105(7).

배제사유 : NK 세포 활성도를 다루지 않는 연구

923. Zhang X LQ, Liao Q, Zhao Y. Potential Roles of Peripheral Dopamine in Tumor Immunity. *Journal of Cancer*. 2017;8(15):2966-73.

배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사실, 의견 등)

924. Zhang Y LQ, Y. Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment. *Signal Transduction and Targeted Therapy*. 2020;5 (1) (114).

배제사유 : 동물실험 또는 전임상시험연구

925. Zhao J SH, A, Thelen M, Wang Z, Qin J, Li J, Popp F, et al. Tumor-derived exosomes inhibit natural killer cell functions in pancreatic cancer. *European Surgical Research*. 2019;60 (Supplement 1):18-9.

배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)

926. Zhao J SH, A, Wang Z, Qin J, Li J, Popp F, Popp M, C, et al. Tumor-derived exosomes inhibit natural killer (NK) cell functions in the pre-metastatic niche of pancreatic cancer. *Pancreatology*. 2019;19 (Supplement 1):S4.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
927. Zhao J SH, A, Wang Z, Qin J, Li J, Popp F, Popp M, C, et al. Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. *Cancers*. 2019;11 (6) (874).  
배제사유 : 동물실험 또는 전임상시험연구
928. Zhao J SH, A, Wang Z, Qin J, Li J, Popp F, Popp M, C, et al. Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. *Cancers*. 2019;11(6):22.  
배제사유 : 동물실험 또는 전임상시험연구
929. Zhao J SH, A, Wang Z, Qin J, Li J, Popp F, Popp M, et al. Tumor-derived exosomes inhibit natural killer cell function in the pre-metastatic niche of pancreatic cancer. *European Surgical Research*. 2019;60 (3-4):168.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
930. Zhao J. Tumor-derived exosomes inhibit natural killer (NK) cell function in the pre-metastatic niche of pancreatic cancer. *European Surgical Research*. 2018;59 (Supplement 1):30.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
931. Zhao P CD, Cheng H. Prognostic significance of soluble major histocompatibility complex class I-related chain A (sMICA) in gastric cancer. *British Journal of Biomedical Science*. 2018;75(4):203-5.  
배제사유 : 평가대상 암 환자를 대상으로 하지 않은 연구
932. Zhao S ZH, Lv C, Gong J, Zhang J, Fang W, Li J, et al. Anticancer drug R&D landscape in China. *Journal of Hematology and Oncology*. 2020;13 (1) (51).  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)
933. Zhao X AD, O, Wang Y, Tang M, Xie W, Chen Z, Wang M, et al. Efficient In Vitro Refolding and Characterization of Major Histocompatibility Complex Class I-Related Chain Molecules A (MICA) and Natural Killer Group 2 Member D (NKG2D) Expressed in *E. coli*. *Protein & Peptide Letters*. 2015;22(5):460-9.  
배제사유 : 동물실험 또는 전임상시험연구
934. Zhao Y SM, Feng Y, He R, Xu X, Xie Y, Shi X, et al. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. *Oncotarget*. 2018;9(19):14803-14.  
배제사유 : 동물실험 또는 전임상시험연구
935. Zheng L XJ, Jaffee E, M, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. *Gastroenterology*. 2013;144(6):1230-40.  
배제사유 : 원저가 아닌 연구(체계적문헌고찰, 리뷰, 가이드라인, 사설, 의견 등)

936. Zhou G NL, Z, Qiu D, W, He L, H, Zuo J, S, Xu K, C, Wang F, et al. Effect of cryosurgery on the cellular immune function of pancreatic cancer patients. [Chinese]. Chinese Journal of Cancer Prevention and Treatment. 2011;18(24):1938-41.  
배제사유 : 한국어 또는 영어로 출판되지 않은 연구
937. Zhou Y F, Xu L, X, Huang L, Y, Guo F, Zhang F, He X, Y, et al. Combined detection of serum ul16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer. Oncology Letters. 2014;8(5):2096-102.  
배제사유 : NK 세포 활성도를 다루지 않는 연구
938. Zhou Y HL, Xu L, Zhang F, Guo F, Yao W, Yuan Y. The diagnostic value of combined detection of serum ULBP-2, MIC-1 in pancreatic cancer patients. Journal of Gastroenterology and Hepatology. 2013;3):450-1.  
배제사유 : 회색문헌 (초록만 발표된 연구, 학위논문 등)
939. Ziske C MA, Schottker B, Buttgereit P, Schakowski F, Gorschluter M, von Rucker A, et al. Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2001;3(1):54-60.  
배제사유 : 동물실험 또는 전임상시험연구